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General introduction 
 
Acute respiratory tract infections are responsible for considerable morbidity and mortality 
and costs attributable to acute respiratory tract illnesses (ARI) are an important burden on 
national health care budgets13,165. A variety of viruses, bacteria and fungi are associated with 
ARI174. This thesis only focuses on viral causes of ARI  
Diagnosis of respiratory tract infections is important for adequate treatment of patients and 
community surveillance studying the spread of respiratory viruses forms the basis for 
preventive strategies. Despite the use of a variety of diagnostic assays, 15-50% of the 
samples obtained from persons suffering from ARI do not yield positive diagnoses, which is 
at least in part due to limitations of diagnostic procedures. However, a proportion of ARI 
may be caused by still unknown pathogens, providing an additional explanation for the 
relatively high proportion of negative laboratory diagnoses. This thesis describes the 
identification and characterisation of a hitherto unknown virus as the causative agent of ARI, 
which was subsequently found to be responsible for a high portion of the unexplained ARI. 
In this introduction background information on characteristics, diagnostics and epidemiology 
of known respiratory viruses will be provided. 
 
 
Viruses associated with ARI 
 
A large number of viral pathogens, belonging to a variety of virus families, have been 
associated with ARI in humans. Viruses detected most frequently in association with ARI 
belong to the families Paramyxoviridae, Orthomyxoviridae, Picornaviridae, Adenoviridae, 
and Coronaviridae, although other viruses such as members of the family Herpesviridae, and 
Hantavirus (Bunyaviridae) have also been associated with respiratory tract disease in humans 
(Table 1). Furthermore many viral pathogens, most of them related to human viral 
pathogens, are associated with respiratory disease in animals. In the next paragraphs only the 
most important respiratory viruses of humans will be described in detail. 
 
Members of the family Paramyxoviridae 
The Paramyxoviridae family is among the most costly in terms of disease burden and 
economic impact caused by its members in humans and animals142,155,272. Moreover, a large 
number of new candidate members have been identified in humans and animals over the past 
decade. The family is divided into two subfamilies, the Paramyxovirinae, with five genera, 
and the Pneumovirinae, with two genera (Figure 1). The classification of these viruses is 
based on morphological criteria, genome organisation, the biological activities of the 
proteins, the sequence relationship of the encoded proteins and finally on overall biological 
criteria. The pneumoviruses can be distinguished from the Paramyxovirinae members 
morphologically because they contain narrower nucleocapsids. In addition, pneumoviruses 
have differences in genome organisation, the number of encoded proteins and an attachment 
protein that is different from that of members of the subfamily Paramyxovirinae142. 
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Subfamily Paramyxovirinae 
Two of the genera (Respirovirus and Rubulavirus) within this subfamily include major 
causes of human ARI: the parainfluenza viruses (PIV), genetically and antigenically divided 
into serotypes 1 to 4112,142. As a group PIV 1, 2 and 3 are second to respiratory syncytial virus 
(RSV) as important causes of lower respiratory tract (LRT) infections in young 
children41,56,112. Most children have been infected by PIV-3 by the age of two years and by 
PIV 1 and 2 by the age of five years. Pneumonia and bronchiolitis resulting from PIV-3 
infection occur primarily in the first six months of life, as is the case for RSV infection, but 
with lower frequency. Croup is the most presented clinical manifestation of infection with 
PIV, especially type 1, and is the main cause of hospitalisation from PIV infections in 
children two to six years of age112. Although little is known about infections in adults, 
immunity to PIV appears to be incomplete and repeated infections occur throughout life. 
Infection with PIV 4 is relatively rare and it is therefore often not included in 
epidemiological studies (reviewed in 112,105). 
 
Figure 1:  
Schematic diagram of 
known members of the 
Paramyxoviridae family 
based on phylogenetic 
analysis of the nucleotide 
sequences for the 
polymerase gene of these 
viruses. 
Abbreviations: NiV: Nipah 
virus; HeV: Hendra virus; 
TuV: Tupaia virus; CDV: 
Canine distemper virus; PDV: 
Phocine distemper virus; MV: 
Measles virus; MuV: Mumps 
virus; SV5: Simian virus 5; 
SV41: Simian virus 41; APV: 
Avian pneumovirus; PVM: 
Pneumonia virus of mice; 
RSV: Respiratory syncytial 
virus; b: bovine; h: human. 
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The genus Rubulavirus includes mumps virus (MuV) infections with which are characterised 
by salivary gland swelling. This virus infects the respiratory tract, but clinical manifestations 
usually relate to infection of the parotid gland, without respiratory tract illness276.  
The genus Morbillivirus includes one human virus: measles virus (MV). Infection with MV 
is characterised by fever, cough, and conjunctivitis followed by the appearance of 
generalised maculopapular rash. LRT illnesses have been reported, but through the wide 
application of a live attenuated vaccine, measles virus is no longer a major pathogen of ARI 
in the developed world102.  
The Avulavirus genus contains only avian viruses. The genus Henipahvirus, with the human 
viruses Nipah and Hendra, has recently been established (see below). 
 
Newly identified members of the subfamily Paramyxovirinae 
In the last decade a large number of hitherto unknown paramyxoviruses have been identified 
in animals and humans. Most of these were identified in animals such as snakes88,210, 
salmon140, horses (Salem virus)209, tree shews (Tupaia virus)247,  and pigs and bats (Mapuera, 
Menangle and Tioman virus)35,111,193. Not all of these viruses have been associated with 
illness, several of them were detected in the hunt for the reservoir for two of the newly 
emerging human viruses, Hendra virus (isolated from horses and humans) and Nipah virus 
(isolated from pigs and humans)34,178. These two viruses are associated with severe ARI 
and/or encephalitis in humans with a high mortality rate. They are genetically related and 
have recently been classified in a new genus: the Henipahvirus genus. Both viruses caused 
relatively small outbreaks, with high case fatality rates, restricted to Australia, Malaysia and 
Singapore in 1995-1999. 
 
Subfamily Pneumovirinae 
The subfamily Pneumovirinae contains two genera: the pneumoviruses and the 
metapneumoviruses. RSV is the type species of the genus Pneumovirus and was until 
recently the only human pathogen identified in the subfamily Pneumovirinae. RSV is a 
ubiquitous pathogen circulating in humans of all ages around the globe. Two subgroups (A 
and B) have been identified based on differences in nucleotide sequences, reactivity patterns 
with monoclonal antibodies and in vitro neutralisation assays with subgroup-specific 
antisera7,37,95,176. Some studies have suggested that viruses belonging to the two subgroups 
differ in pathogenicity, although this has not been found by other groups116,164,246,263. 
RSV infects approximately 90% of all children under the age of 2. Almost 1% of these 
children develop bronchiolitis and/or pneumonia severe enough to require hospital 
admission, and of these about 1% die, particularly those with congenital heart defects, 
bronchopulmonary dysplasia, very low birth weight, prematurity or immunodeficiency234,272. 
Re-infections with both homologous and heterologous viruses during life are common. 
However, the severity of disease generally decreases with subsequent re-infections, and the 
frequency of re-infections decreases with age46. Unlike the severe infections seen in infants, 
RSV infections in healthy adults are usually self-limiting and induce only mild to moderate 
symptoms55,78. The virus is however an important pathogen among elderly and 
immunocompromised patients (see later sections). 
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Newly identified members of the subfamily Pneumovirinae  
In 1976 a respiratory tract disease was observed in turkeys, which was demonstrated to be 
caused by a virus tentatively named turkey rhinotracheitis virus (TRTV)26,27,96,129,163,274,278. 
Examination of the proteins and genes revealed similarities with pneumoviruses which 
established the classification in the Pneumovirinae subfamily and resulted in the name avian 
pneumovirus (APV)31,40,118,150,281. Additional genomic sequencing of APV revealed a distinct 
genomic order and content of genes as compared to RSV: APV does not encode NS1 and 
NS2 genes, and has a different order between the matrix and polymerase genes151,204,282. 
These differences formed the basis for subdivision of the subfamily Pneumovirinae into two 
genera: the pneumoviruses with RSV as type species and the metapneumoviruses with APV 
as the sole member118,200. Further comparison of nucleotide and amino acid sequences of the 
attachment protein G, and differences in antigenicity, led to classification of the different 
APV isolates into two distinct subgroups: A and B39,130. New subgroups or subtypes of APV 
have been recently identified, such as APV C in the United States222,224 and APV D in 
France11 and this subdivision is again based on sequence differences, in particular for the 
attachment protein G, and on differences in antigenicity. Although there is only limited 
information on APV D, it has become clear from genetics, serology and protection studies 
that APV A and B are more closely related to each other than any of them to APV C51, 109. It 
has been suggested that APV C constitutes a separate serotype of APV51,223. 
In 1986, sero-epidemiological studies reported that adult human sera exhibited moderate to 
high neutralising activity against pneumonia virus of mice (PVM). This virus, a member of 
the genus Pneumovirus within the subfamily Pneumovirinae, causes respiratory tract disease 
mostly in laboratory mice and rats. The suggestion that PVM or an antigenically related virus 
circulates in the human population has so far not lead to the identification of such a virus201. 
 
Members of other virus-families  
The family Ortomyxoviridae includes the three influenza virus types A, B and C, divided on 
basis of antigenic properties of internal proteins of influenza viruses.  Influenza virus type A 
is associated with annual influenza epidemics and intermittent pandemics. Influenza virus 
type B is associated with influenza epidemics only and influenza virus type C is clinically 
irrelevant. Type A influenza virus can be further divided into antigenic subtypes based on 
differences of the haemagglutinin (HA) and the neuraminidase (NA) glycoproteins, so far 15 
subtypes of HA and 9 of NA have been described in birds and some are found in various 
combinations in humans and other mammals143. Influenza pandemics occur when new 
influenza A subtypes, carrying antigenically distinct HA and/or NA, are introduced into the 
human population (antigenic shift). After the introduction of such a new subtype, it causes 
recurrent annual epidemics, during which the HA and NA reveal gradual antigenic changes 
(antigenic drift), supposedly as the result of herd immunity. In temperate climates, influenza 
epidemics occur annually in the winter months and usually last 6 to 10 weeks. The severity 
of an epidemic depends on the circulating virus and the pre-existing immunity to the virus in 
the community. During an outbreak of influenza type A, up to 5-10% of the general 
population may become infected100,174.  Influenza associated severe disease is most often 
seen in young children, elderly, and those with underlying illnesses. ARI caused by influenza 
can develop into pneumonia, often accompanied by bacterial infections, and may result in 
death114. Despite the availability of vaccines and antiviral drugs, influenza continues to be a 
significant cause of illness in all age groups. 
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Members of the family Adenoviridae have a typical icosahedral shell with fibre-like 
projections228. Today there are 51 known serotypes, divided into the six species A-F, 
recognised to infect humans. The incidence of adenovirus infection peaks between the ages 
of 6 months and 5 years, where they account for approximately 5-10% of the LRT 
infections53,71. Certain serotypes such as 1,2,3,5,7 and 21, can cause severe LRT disease in 
children135. The respiratory symptoms caused by adenovirus infection include common cold 
like syndromes, but sporadic cases might be indistinguishable from other viral ARI, such as 
infections with influenza virus, PIV, and RSV. Adenovirus infections can result in 
pneumonia requiring hospitalisation, but they are usually not of great concern in older 
individuals170. Of great concern are the 5-20% of adenovirus infections occurring in patients 
undergoing stem cell transplantation, where they are associated with mortality rates of up to 
50%262.  
 
The major groups within the family Picornaviridae causing ARI are the rhinoviruses, 
consisting of more than 110 serotypes, and the enteroviruses, comprising 68 serotypes216. 
Whereas human enteroviruses (Coxsackieviruses and ECHOviruses) cause 5-15% of viral 
ARI, rhinoviruses have been associated with 25-50% of common colds. The general 
mildness of human picornavirus-associated illness is reflected by the low percentage of 
patients seeking medical care213. However, rhinovirus infections have been reported to 
account for 22% of patients of all age groups with influenza-like symptoms consulting their 
general physician14 and may also cause complications involving the URT and LRT, such as 
exacerbations of asthma93,206. Re-infections with antigenically different rhinoviruses are 
common since there is no cross-immunity among rhinovirus serotypes213. Due to incomplete 
and short-lived immunity after infection, homologous re-infection with rhinoviruses is 
common too. Enterovirus infections are often accompanied by mild ARI, although they are 
also detected in patients suffering from croup, bronchiolitis or pneumonia155.  
 
The Coronaviridae family comprises the genera Coronavirus and Torovirus, and within the 
genus Coronavirus three groups have been recognised based on genetic data and serological 
assays. The majority of human coronaviruses are serologically related to one of two 
reference strains, 229E and OC43 (group I and group II, respectively). Although 
coronaviruses infect people of all age groups, they may cause severe LRT illnesses in frail 
patients, such as young children and elderly individuals72,79,97,254. The symptoms associated 
with human coronavirus infections are similar to those associated with rhinovirus infections, 
accounting for approximately 35% of common colds in adults79. Coronaviruses have been 
reported to account for 2% of patients of all age groups with influenza-like symptoms 
consulting their general physician14,254. In 2003, a worldwide outbreak occurred of a life 
threatening febrile respiratory illness that has been named severe acute respiratory syndrome 
(SARS). A causal association between SARS and a newly identified coronavirus has been 
demonstrated by a number of research groups working together to identify the cause of 
SARS66,67, 86, 138, 139, 189. Where the classical coronaviruses usually cause mild symptoms in 
healthy persons, individuals infected with SARS coronavirus may experience severe 
respiratory illness and sometimes require mechanical ventilation. In particular, patients with 
underlying disease and elderly are susceptible to severe disease, whereas children less than 
15 years of age do not seem to be particular vulnerable to severe disease caused by this 
newly discovered virus138. 
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Table 1: Characteristics of selected human viral respiratory pathogens 
 
 
General features of respiratory viruses 
 
Seasonality  
The seasonal fluctuation of the prevalence of numerous respiratory viruses has been 
established in many epidemiological studies. Worldwide, the seasonality of respiratory 
agents varies geographically, largely according to climate zones. The reasons for seasonality 
are not fully understood. Indoor crowding, relative humidity and temperature, overall 
immunological status and a variety of other factors may all account for this phenomenon. 
RSV and influenza viruses cause epidemics mainly in the winter to early spring in temperate 
regions and in the late spring-summer season in the (sub) tropics266. The start of the influenza 
season typically follows that of the RSV season. Rhinoviruses circulate in all months of the 
year with peaks of illness in the fall and in the spring, where fall-outbreaks are a result of 
children returning to school213,214. Parainfluenza-viruses are most prevalent in the summer 
months but also may be present during the spring and fall. Spring and summer infections 
most often are associated with outbreaks of PIV- 3 infections, whereas PIV-1 and 2 more 
Virus family virus Serotypes/
subgroups 
(n=) 
genome virion 
structure  
seasonality 
Paramyxoviridae Parainfluenza 
virus 
4 negative sense 
RNA 
 
Enveloped 
150-350 nm 
Type 1 and 2: autumn-
winter, type 3: spring-
summer 
 Respiratory 
syncytial virus 
 
2(a) negative sense 
RNA 
Enveloped 
150-350 nm 
Late fall to early spring 
Orthomyxoviridae Influenza virus 3(b) negative sense 
RNA 
(segmented) 
Enveloped 
80-120 nm  
 
Winter–early spring 
Adenoviridae Adenovirus 51 (c) 
 
double-
stranded DNA   
 
Non-
enveloped 
65-80 nm 
  
All year, time of 
epidemics depends on 
the serotype 
 
Coronaviridae Coronavirus  4 (d) positive sense 
RNA 
  
Enveloped 
60-200 nm 
  
Late fall to early spring  
Picornaviridae Rhinovirus >110 positive sense 
RNA 
  
Non-
enveloped 
27-30 nm 
Early fall and spring, 
rarely in summer 
 Enterovirus 68  positive sense 
RNA 
  
Non-
enveloped 
27-30 nm 
All year, peaks in 
summer and fall 
 Footnotes: (a) two subgroups have been defined, which have not fulfilled the criteria for serotypes (b) 
3 types of influenza have been identified, with those of type A divided in subtypes (c) 9 of the 
serotypes are associated with ARI in humans (d) 3 antigenic groups have been associated with human 
ARI. 
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frequently are isolated during fall months113. Coronaviruses cause well-defined epidemics, 
with peak incidence in the late fall to early spring in temperate climate zones148. 
 
Nosocomial spread   
Nosocomial infections are infections that spread in the hospital or instutions, such as elderly 
homes. Transmission of nosocomial respiratory viruses is usually seasonal, with the peak 
incidence occurring in the winter months, mirroring the disease activity in the community. 
Paediatric units, wards with elderly and immunosuppressed individuals, and institutions such 
as nursing homes are particularly prone to seasonal introductions and nosocomial spread of 
viral infection. RSV is one of the most common agents of nosocomial infections followed by 
influenza viruses, PIV, rhinoviruses, and adenoviruses. Cross infection with RSV within 
paediatric wards is a common problem, with over 40% of the children becoming infected if 
hospitalised during the winter months for more than 7 days, and each year approximately 
50% of paediatric staff acquire the infection. RSV outbreaks in oncology and bone marrow 
transplant wards and nursing homes have also been detected. Several studies detected RSV 
in 2 to 89% of the nursing home patients during epidemics2. For influenza numerous 
nosocomial outbreaks involving long-stay facilities for the elderly have been reported. These 
outbreaks are often but not exclusively associated with poor vaccine coverage. In addition, 
outbreaks of influenza involving medical, paediatric, and bone marrow transplant units have 
been reported250. The prevention of nosocomial spread of viral infections depends on timely 
diagnosis, and effective preventive procedures such as patient isolation, wearing of 
protective clothing, and limiting contact between patients and symptomatic staff or visitors. 
Besides vaccination of health care workers (for influenza), the prophylatic use of antiviral 
drugs is an option for some of the viruses involved (see next section)2. 
 
Prevention and intervention  
The most effective and cost-effective intervention strategy for known respiratory virus 
infections is the use of vaccines. After the eradication of smallpox and the ongoing efforts 
for poliovirus, measles virus is on the list of the world health organisation to be eradicated 
through vaccination. In developed countries, influenza vaccines are used to limit the impact 
of the disease, primarily in the elderly and other risk-groups for severe disease. The 
development of PIV and RSV vaccines has been a high priority for decades, however so far 
without satisfying results. Major complications for vaccine development are the antigenic 
variability of certain viral respiratory pathogens and the potential enhanced disease 
associated with the use of certain inactivated vaccines, such as seen for RSV132,134. 
Only for RSV and influenza viruses antiviral drugs are available for prophylactic or 
therapeutic use. For RSV hyper-immune-globulins (RSV-Ig) and humanised monoclonal 
antibodies against the F protein (palivizumab) are used in high-risk patients to protect against 
severe disease233. For influenza, a number of antiviral drugs are available. Amantadine and 
rimantadine function by blocking the M2 ion channel protein of the virus. Both drugs may be 
of substantive benefit in treating influenza A but not without side effects on the central 
nervous system, the liver and kidneys and by the rapid emergence of drug resistance. More 
recently zanamir and osteltamivir have been developed, which block the action of 
neuraminidase to prevent release of newly formed virus from the infected host cell and its 
spread within the host. These neuraminidase inhibitors, which inhibit both influenza A and B 
are associated with little side effects or emergence of resistant viruses. Both drugs have been 
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known to be effective in preventive and therapeutic use, reducing clinical disease and 
complications57,114,250. 
The antiviral drug Pleconaril appears to be a promising drug for the treatment of enteroviral 
and rhinoviral infections. Clinical studies have reported a reduction in the duration and 
intensity of symptoms in children and adults with enteroviral meningitis and in adults with 
rhinoviral respiratory tract infections treated with pleconaril. Lastly, pleconaril has 
demonstrated efficacy in the treatment of severe life-threatening enteroviral infections of the 
newborn and in immunosuppressed individuals84,212. 
Several other drugs, for instance ribavirin, which prevents replication of certain viruses, are 
used preventive and therapeutic against a wide variety of viral respiratory viruses. However, 
clinical use of this compound is contentious, because ribavirin may cause side effects, 
treatment is expensive and there is some question about its practical utility and effectiveness 
against RSV infections65,277. 
 
 
Laboratory diagnosis of viral ARI 
 
Virus isolation   
Virus isolation from nasal washes or nasopharyngeal aspirates has long been the gold 
standard for diagnosis of viral ARI. Alternative samples (throat swabs, broncho-alveolar 
lavages, etc) are also commonly used. However, such procedures can require many days or 
even weeks for virus detection and identification, providing diagnostic outcomes to 
clinicians in a period of time that may not be clinically useful. A variety of specific 
serological assay (such as IF, haemagglutination assays, etc) is used to characterise positive 
viral cultures. Centrifugation of the clinical specimens onto cell monolayers (shell vial 
cultures) followed by immuno-fluorescence (IF) detection to identify viral antigens allows a 
much earlier diagnosis of infection. However, depending on the virus involved, these 
techniques may still not establish a diagnosis within a clinically useful time period185,202. A 
serious problem with virus isolation is that different respiratory viral pathogens may require 
a wide range of cell substrates in which they can replicate. Potentially, some viruses may not 
replicate in commonly used in-vitro cell cultures at all. 
 
Antigen detection 
For rapid diagnosis, most laboratories use virus specific antibodies to detect the respiratory 
viral antigens directly in cells in clinical specimens. These rapid testing methods frequently 
use direct immuno-fluorescence assay (DIF) and/or membrane enzyme-linked 
immunosorbent assay techniques in various testing formats, with results obtained within 10 
to 60 minutes157,229. Nasopharyngeal, tracheal or bronchial aspirate samples are the preferred 
specimens for DIF, since throat or nose swabs usually contain a limited number of intact 
infected cells157. Not all virus infections can be detected by DIF since, either suitable 
specimens cannot be taken, or the variety of antigenic types precludes making appropriate 
reagents or reagents are not available at all157,229,244. At last, the results obtained in studies 
using DIF, depend on the balance between sensitivity and specificity of the applied test. Very 
high sensitivity may result in false positive identification, and a high specificity usually 
results in lower sensitivity. In most studies DIF resulted in 70-95% sensitivity compared with 
conventional culture techniques157,208. While rapid testing plays an important role in 
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individual diagnosis, comparative studies have shown that these procedures should be used 
in conjunction with conventional culture and serological tests or genome detection to yield 
the highest identification rate for epidemiological surveys. The culture of samples negative 
by direct assays not only increases the yield of viruses for which direct testing was attempted 
but also allows the recovery of agents not covered by direct-testing protocols, including rare 
or even unknown agents16,64,127,157,264. 
 
Genome detection 
Virus genome detection by nucleic acid amplification assays (for instance PCR, RT-PCR, 
real time PCR and NASBA) is now widely used in the modern laboratories. A major 
advantage of these assays is the possibility to screen for several respiratory viruses at the 
same time74,80,103,152. PCR methods are particularly useful for detecting viruses that are 
difficult to isolate, such as rhinoviruses and coronaviruses. Unlike cell culture techniques, 
PCR assays do not require viable pathogens. PCR assays also provide materials for storage 
and further analysis. However, PCR tests do not discriminate between “live” and non-
replicating (e.g., neutralised) virus. In addition, RNA viruses in particular have highly 
variable genomes; therefore reverse transcriptase PCR (RT-PCR) assays have to use primers 
that are designed against highly conserved regions. Monitoring genomic changes in these 
viruses is of utmost importance to keep the designed primers up to date with the circulating 
genotypes. Attempts to isolate virus from samples negative by PCR may result in the 
identification of viruses with sequence variation in the primer-binding sites and may also 
allow the detection of other agents, including rare or unknown agents16,64,127,264. Moreover, 
PCR based assays are not widely available or standardised yet and not all laboratories have 
implemented such costly techniques in their routine screening for respiratory viruses. 
 
Antibody detection  
Direct diagnosis of ARI is not always successful, since acute infection when viral load is 
usually high, may have occurred before the patient seeks care. Therefore, serological 
methods to detect virus-specific antibodies can contribute to the identification of viral 
pathogens causing ARI. Since antibodies are usually detected after the acute phase of 
disease, this technique is only useful for epidemiological studies or retrospective diagnoses. 
Enzyme-linked immunosorbent assays (ELISA), immune fluorescence assays (IFA), 
neutralisation and haemagglutination inhibition tests to detect viral antibodies are commonly 
used.  A fourfold rise in antibody titer is generally considered significant to identify acute 
infection if paired acute- and convalescent-phase serum samples are tested36,183,207. Although, 
not used standard for respiratory viruses, a rapid diagnosis can be made on the basis of a 
single acute-phase serum by demonstrating virus-specific antibody of the IgM class, as for 
instance used for the diagnosis of measles virus infection271. 
However, serologic tests in infants are less usefull, particularly in those younger than 4-8 
months22. Moreover, one must be aware of serological cross-reactions between different 
viruses, even when the same serological assays do not detect such cross-reactivity using 
animal antisera. For instance, although the three parainfluenza virus types belong to two 
different genera of the Paramyxovirinae, antigenic determinants present on the H site of the 
HN proteins of the PIV 1, 2 and 3 cross react in complement-fixation, haemagglutination-
inhibition or virus neutralisation assays41,145. 
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Epidemiological studies  
Epidemiological studies are crucial for our understanding of the behaviour of the different 
pathogens involved and their impact on the burden of disease. Such studies can detect 
changes in spread or virulence of respiratory viruses and are the basis for preventive 
strategies such as vaccination. 
Most of the studies have been hampered by incomplete study approaches. First, the number 
of aetiologic agents tested for are often limited. The majority of studies are restricted to 
either virology or bacteriology, although studies focussing on bacteria sometimes include 
major viral pathogens such as influenza virus and RSV, and virology-based studies 
sometimes include a small number of non-viral pathogens. Secondly, criteria for patient 
inclusion are usually restricted, based on illness manifestation and age. In studies restricted 
to patients visiting their physician with only influenza-like or febrile illnesses (not general 
ARI) RSV and influenza viruses and rhinoviruses – if tested for - account for the highest 
percentages of illnesses, but this underestimates the circulation of other respiratory viruses 
(not causing fever) in the population. In addition, studies limited to adults describe relatively 
low percentages of RSV and PIV infections and relatively high percentages of influenza 
virus compared to studies among children. The majority of hospital-based studies are limited 
to patients suffering from pneumonia, excluding those patients who are hospitalised with 
other severe ARI131,147,148,251,279.Third, diagnostic methods used might underestimate the true 
incidence of the particular pathogen. As mentioned above, virus isolation is used as the gold 
standard, but in combination with IF, antibody detection and PCR techniques detection rates 
of viral pathogens can be increased131. 
There are few reports describing the detection of all known aetiological agents of ARI in the 
same set of patients, and even fewer studies have combined different diagnostic techniques 
to identify the maximum number of pathogens. One of the most comprehensive studies on 
the causative pathogens (both viral and non-viral) of community-acquired pneumonia 
identified a causative agent in 85% of the patients131. This hospital-based study used a 
combination of conventional culture with IF, PCR assays and serological tests and detected 
62% of the patients with a viral, 53% with a bacterial and 30% with a mixed infection 
(Figure 2) In another study among patients attending their physician for ARI, a causative 
agent was identified in 60% of the cases, using conventional culture, IF and PCR techniques 
(Figure 2)109. Despite the use of combinations of diagnostic assays and targeting at both 
bacteria and viruses, 15-50% of the patients thus remain undiagnosed. This may be due to 
reasons such as inappropriate sample collection, transport, storage and processing, or to poor 
sensitivities of the diagnostic tests. However, unidentified aetiological agents may account 
for a substantial percentage of the undiagnosed cases of ARI. 
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ARI in the general community. 
The most prevalent acute respiratory tract illnesses in the general community are generally 
benign, self-limiting events following primarily infections of the URT169. These illnesses, 
often referred to as common colds, are the leading cause of patient visits to physicians, as 
well as work and school absenteeism. Primary pathogens associated with common colds are 
the rhinoviruses and coronaviruses160,171. URT infection may precede LRT illnesses of which 
bronchitis, bronchiolitis and pneumonia are the most common clinical manifestations. These 
manifestations are usually mild and self-limiting, but can be severe enough to require the 
attention of a physician or admission to hospital.   
Viral ARI affect persons of all ages, but their incidence is higher among children than among 
adults. The incidence in adults is 2 to 4 colds per year and in children 6 to 8 per year173,253. In 
1998, about 3.5 million deaths occurred worldwide from ARI, of which 55% were children 
under the age of five years old (WHO 1999, http://www.who.int/infectious-disease-
report/pages/graph5). Bronchiolitis, one of the main clinical syndromes in hospitalised 
children, accounts for up to 60% of all LRT illnesses during the first year of life and for up to 
32% of hospitalisations for LRT illnesses in this age group144. The main causative agents of 
severe LRT in children were, until recently, RSV, followed by PIV, influenza viruses and 
adenoviruses. 
ARI in adults are responsible for a large percentage of physician office visits, days lost from 
work, and for a smaller percentage of the utilisation of emergency centre facilities, and 
hospitalisations. Adults with ARI usually suffer from common cold like symptoms and are 
rarely in need of medical attention. Epidemiological studies among patients who are visiting 
their physician, have shown that rhinoviruses and influenza virus are detected most 
frequently109,147,148,171.  
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Figure 2:  
Percentages of viruses and other agents detected in A) 540 patients visiting their physician for ARI109 
and B) 254 hospitalised patients with pneumonia131 
  
ARI in the elderly 
Respiratory viral infections have been recognised as important contributors to death and 
disability in older adults in the community or in long-term care facilities.  Waning immunity 
and decreasing immunocompetence may play a crucial role, but the specific reasons for the 
enhanced disease associated with ARI in the elderly is still subject of research. Influenza has 
received the greatest attention and remains a significant problem in the elderly. Although 
only about one-fourth of hospitalisations for influenza occur in individuals over the age of 
65, 75% of influenza-associated deaths occur in this age group. RSV and PIV have also been 
recognised as cause of serious illness in these individuals, especially among institutionalised 
elderly. The severity of RSV infection in these patients is variable; serious complications are 
well-recognised with rates of pneumonia ranging from 5 to 67%, and mortality from 0-
53%78,250. 
 
ARI in hospitalised patients 
Severe LRT illnesses such as bronchiolitis, bronchitis and pneumonia are the most prevalent 
clinical manifestations for ARI-associated hospitalisation. Children constitute the largest 
group of such hospitalised patients, followed by elderly and adults with underlying disease. 
In North America each year approximately 3% of all children under the age of 1 are admitted 
to the hospital with moderate to severe LRT infections21,227. RSV is detected in 50-80% of 
these children, with the high percentages detected during the winter months227. 
Epidemiological studies among hospitalised patients suffering from ARI demonstrated that 
RSV and occasionally influenza viruses are the leading cause of viral ARI, followed by PIV 
and adenoviruses, although these numbers depend on the study population and clinical 
illnesses studied131,235,251. In a substantial proportion of these patients however, no 
aetiological agent is identified.  
  
ARI in high risk patients 
Next to frail elderly, patients with weakened immunity due to for instance intensive 
chemotherapy, corticosteroid use, or iatrogenic immunosuppression for bone marrow or solid 
organ transplantation have been identified as being at the highest risk for developing severe 
ARI. In addition, patients with chronic lung conditions such as asthma or chronic obstructive 
pulmonary disease and patients with congenital heart disease are a well-defined risk groups 
for severe ARI. Viral respiratory infections among immunocompromised patients are 
characterised by persistence of infection and viral shedding beyond the time period reported 
for immunocompetent patients, and high frequencies of pneumonia and death in association 
with the infection55,83,113. The types of viral respiratory infections in these patients often 
correspond with those circulating in the community at that particular time point97. The 
clinical illnesses range from self-limited upper respiratory illness to fatal pneumonia, 
depending on the type of virus and the nature of immunosuppression. The direct cause of 
pneumonia may be viral, bacterial/fungal, or mixed. The highest frequency of progression to 
fatal viral pneumonia has been reported for RSV infections in recently transplanted bone 
marrow transplant recipients and immunosuppressed patients with leukaemia269. Next to 
RSV, and PIV, influenza virus infections can be especially severe in immunocompromised 
patients, with progression to pneumonia observed in over 50% of patients and mortality rates 
of 28-75% 20,78,153,270. 
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ARI and asthma 
Acute respiratory, wheezing illnesses (bronchiolitis, wheezy bronchitis and asthma) are the 
major causes of hospitalisation of children. Asthma is defined as recurrent episodes of 
airway obstruction caused by inflammation of the airway and increased susceptibility to 
bronchoconstriction in response to irritants or allergens (airway hyperresponsiveness) 94. 
Many respiratory viruses may provoke acute asthma symptoms, but rhinoviruses are most 
often implicated, especially during spring and fall93,206. In fact, peaks in hospitalisations for 
asthma closely coincide with patterns of rhinovirus isolation within the community126. A 
possible link between RSV-induced wheezing in infancy and later development of persistent 
asthma is still the subject of discussion in the RSV field115,232,238. ARI may produce dual 
effects pertaining to asthma. First, it has been suggested that vigorous stimulation of the 
immune system by a severe viral or bacterial infection can affect the development of the 
immune system and modify the subsequent risk of allergy or asthma. Secondly, in children 
and adults with established asthma, viruses such as rhinovirus and RSV may trigger acute 
symptoms of asthma. The precise direct and indirect mechanisms of viral contribution to 
inception and exacerbation of asthma remain to be elucidated92,252.  
 
 
Scope of the present thesis 
 
Over the last 20 years, the virus diagnostic laboratory of Erasmus Medical Centre collected 
specimens from patients suffering from ARI, in which no pathogen could be detected. These 
samples were obtained primarily in the winter months and the majority of the samples were 
collected from young children suffering from clinical illnesses resembling those caused by 
RSV. Upon inoculation of in-vitro cell cultures with a number of these clinical specimens, 
cytopathic effects (CPE) were observed resembling the CPE caused by RSV. A variety of 
diagnostic assays failed to detect any known respiratory virus. Examination of these viral 
cultures under the electron microscope revealed virus particles with a paramyxovirus-like 
structure, and classical virological techniques revealed that the virus contained an envelope, 
and did not agglutinate erythrocytes. 
We identified this virus as a new paramyxovirus within the genus Metapneumovirus of the 
subfamily Pneumovirinae (chapters 2 and 3). Based on this proposed classification we 
named the virus human metapneumovirus (hMPV). Chapter 4 describes the genetic and 
antigenic variation of hMPV, revealing the presence of two serotypes of hMPV. To collect 
evidence that this virus is an aetiologic agent of ARI, we studied hMPV infections in 
cynomolgus macaques (chapter 5). After identification and characterisation of the virus, 
studies were undertaken to investigate the prevalence and clinical impact of the virus in 
patients suffering from ARI (Chapters 6, 7, 8). In chapter 9 the findings presented in this 
thesis, and results from other groups that followed-up on our initial discovery, are discussed. 
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  Discovery of hMPV 
  
Abstract 
 
From 28 young children in The Netherlands, we isolated a paramyxovirus that was identified 
as a tentative new member of the Metapneumovirus genus based on virological data, 
sequence homology and gene constellation. Previously, avian pneumovirus was the sole 
member of this recently assigned genus, hence the provisional name for the newly 
discovered virus: human metapneumovirus. The clinical signs of the children from whom the 
virus was isolated were similar to those caused by human respiratory syncytial virus 
infection, ranging from upper respiratory tract disease to severe bronchiolitis and pneumonia. 
Serological studies showed that by the age of five years, virtually all children in The 
Netherlands have been exposed to human metapneumovirus and that the virus has been 
circulating in humans for at least 50 years. 
 
Introduction 
 
The Paramyxovirinae and the Pneumovirinae subfamilies of the Paramyxoviridae family 
include several major pathogens of man and animals. The Pneumovirinae are taxonomically 
divided in the Pneumovirus and the Metapneumovirus genera118. Human respiratory 
syncytial virus (hRSV), the type species of the Pneumovirus genus, is the single most 
important cause of lower respiratory tract infections (RTIs) during infancy and early 
childhood worldwide65,226. Other members of the Pneumovirus genus include bovine 
respiratory syncytial virus (bRSV), ovine respiratory syncytial virus (oRSV) and pneumonia 
virus of mice (PVM). Avian pneumovirus (APV), previously known as turkey rhinotracheitis 
virus (TRTV), is the aetiologic agent of an upper RTI of turkeys50,96 and the sole member of 
the recently assigned Metapneumovirus genus118. Until now, metapneumoviruses have not 
been associated with infections or disease in mammals. The classification of the two genera 
is based primarily on their gene constellation: metapneumoviruses lack non-structural 
proteins NS1 and NS2 and the gene order is different from that of pneumoviruses (RSV: '3-
NS1-NS2-N-P-M-SH-G-F-M2-L-5'; APV: '3-N-P-M-F-M2-SH-G-L-5')151,204,282. 
In the past decades, many aetiologic agents of respiratory tract illnesses (RTI) have been 
identified76,142. However, a proportion of these illnesses can still not be attributed to known 
pathogens. We have now isolated a previously undiscovered paramyxovirus from 
nasopharyngeal aspirate samples taken from 28 epidemiologically unrelated children in The 
Netherlands suffering from RTI during the past 20 years. Of the patients, 27 were below the 
age of five years and 13 of these were infants between the ages 0 and 12 months old. The 
clinical symptoms of these children were largely similar to the RTI caused by hRSV, ranging 
from mild respiratory problems to severe cough, bronchiolitis and pneumonia, often 
accompanied by high fever, myalgia and vomiting. Some of these patients were hospitalised 
and needed mechanical ventilation. The virus isolates exhibited a paramyxovirus-like 
morphology in negative contrast electron microscopy and were closely related both 
antigenically and genetically. Based on sequence homology and gene constellation, the 
viruses seemed to be a tentative new member of the Metapneumovirus genus that we have 
provisionally named human metapneumovirus (hMPV). Serological surveys showed that by 
the age of five years virtually all children in The Netherlands have been exposed to hMPV 
and that the virus has been circulating in humans for at least half a century.  
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Results 
 
Virus isolation and characterisation 
Within our diagnostic virology setting, we isolated 28 unidentifiable viruses from patients in 
The Netherlands with RTI over the past 20 years. Of the 26 patients for whom personal 
information was available, eight (31%) were females, 13 (50%) were between the age of 0 
and 12 months old, and 12 (46 %) were between 1 and 5 years. All viruses were isolated 
from samples collected in the winter months. The unidentified virus isolates replicated 
slowly in tertiary monkey kidney (tMK) cells, very poorly in Vero cells and A549 cells and 
could not be propagated in Madin Darby kidney (MDCK) cells or chicken embryo 
fibroblasts (CEF). The cytopathic effects induced by these virus isolates were virtually 
indistinguishable from those caused by hRSV, with characteristic syncytia formation 
followed by rapid internal disruption of the cells and subsequent detachment from the culture 
plate. The cells usually displayed cytopathic effects at day 10-14 post inoculation, slightly 
later than the cytopathic effects induced by hRSV-containing specimens (data not shown). 
After 14 days of virus propagation, the viral titers in the cultures were on average 10,000 
TCID50 (50% tissue culture infectious doses) per ml. Supernatants of infected tMK cells were 
used for electron microscopy analysis, which revealed the presence of paramyxovirus-like 
pleiomorphic particles in the range of 150-600 nm, with short envelope projections in the 
range of 13-17 nm (Figure 1). Similar to some other paramyxoviruses such as selected hRSV 
and parainfluenza virus 
isolates, nucleocapsids 
were rarely observed.  
Consistent with the 
biochemical properties 
of enveloped viruses 
such as the 
Paramyxoviridae, 
standard chloroform 
treatment187 resulted in 
10,000-fold reduction of 
the TCID50 for tMK 
cells. Virus-infected 
tMK cell-culture 
supernatants did not display haemagglutinating activity with turkey, chicken or guinea pig 
erythrocytes. In tMK cell cultures, virus replication was found to be dependent on trypsin. 
These combined virological data indicated that the newly identified virus is a member of the 
Paramyxoviridae family. 
We isolated RNA from the supernatant of tMK cells infected with 15 of the unidentified 
virus isolates for reverse transcription (RT)-PCR analyses using primer sets specific for 
known paramyxoviruses (human parainfluenza virus (hPIV) types 1-4, mumps virus, measles 
virus, hRSV, simian virus type 5 (SV-5), Sendai virus and Newcastle disease virus (NDV)). 
We carried out RT-PCR assays at low stringency in order to detect potentially related viruses 
and used RNA isolated from homologous virus stocks as positive controls. Whereas the 
controls all reacted positive with the respective virus-specific primers, the newly identified 
Figure 1:  
Electron micrograph of 
hMPV particles. Virus 
concentrated from infected 
tMK-cell culture supernatants 
were visualised by negative 
contrast electron microscopy 
after PTA staining. 
Magnification, x 92,000. 
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virus isolates did not (data not shown), indicating the virus was not closely related to the 
viruses for which primer sets had been selected. 
We next inoculated ferrets and guinea pigs intranasally with two of the virus isolates 
(without prior purification) to raise virus-specific antisera. The animals did not display any 
clinical symptoms. The antisera did not react in immune fluorescence assays (IFA) with cells 
infected with a panel of paramyxoviruses and orthomyxoviruses (hPIV types 1-4, hRSV, 
influenza virus type A and B). All animals seroconverted as shown in virus neutralisation 
assays and IFA against the homologous viruses. We next tested the 28 unidentified virus 
isolates with the guinea pig and ferret pre- and post-infection sera. tMK cell cultures infected 
with each of the 28 virus isolates reacted positive in IFA with the post-infection animal sera, 
indicating that they were serologically related or identical.  
  
RAP-PCR 
To obtain sequence information on the unknown virus isolates, we used a random PCR 
amplification strategy known as RAP-PCR203,267. To this end, we infected tMK cells with one 
of the virus isolates (isolate 00-1) or with hPIV-1 that served as a control. We sequenced 20 
differentially displayed bands specific for the unidentified virus. When we used the deduced 
amino acid sequences to search for homologies against sequences in the Genbank database 
using the BLAST software (www.ncbi.nlm.nih.gov/BLAST), 10 out of 20 fragments 
displayed resemblance to APV/TRTV sequences. These 10 fragments were located in the 
genes coding for the nucleoprotein (N; fragments 1 and 2), the matrix protein (M; fragment 
3), the fusion protein (F; fragments 4, 5, 6, 7,) and the polymerase protein (L; fragments 8, 9 
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Figure 2:   
Schematic representation of genomic fragments obtained from hMPV. A schematic diagram of APV 
(3’to 5’end, left to right) is shown above the fragments obtained with RAP-PCR and RT-PCR on 
virus isolate 00-1. Fragments 1-10 were obtained using RAP-PCR. Fragment A was obtained with a 
primer in RAP-PCR fragment 1 and 2 and a primer designed on basis of alignment of leader and 
trailer sequences of APV and RSV204. Fragment B was obtained with primers designed in RAP-PCR 
fragments 1 and 2 and RAP-PCR fragment 3. Fragment C was obtained with primers designed in 
RAP-PCR fragment 3 and RAP-PCR fragments 4-7. 
  
  
and 10) (Figure 2). We can exclude the possibility of contamination of the human samples 
with APV/TRTV as we do not have this virus in our laboratories. We next designed PCR 
primers to complete the sequence information for the 3' end of the viral genome based on our 
RAP-PCR fragments as well as published leader and trailer sequences for the 
Pneumovirinae204 (Figure 2). 
In total, we have generated 
5.7 kilobases of sequence 
information of the viral 
genome. Analyses of the 
sequences of these fragments 
revealed the absence of NS1 
and NS2 open reading frames 
(ORFs) at the extreme 3' end 
of the viral genome (Figure 
3A) and positioning of the 
putative F ORF immediately 
adjacent to the putative M 
ORF (Figure 3B). This 
genomic organisation 
resembles that of the 
metapneumovirus APV, 
which is consistent with the 
sequence homology. It should 
be noted however that the 
genomic organisation of 
hMPV cannot be simply 
deduced from that of APV, 
and requires further analysis. 
The translated sequences for 
the N, P, M and F ORFs were 
aligned with the amino-acid 
sequences of hRSV and APV 
(Figure 3 C-F). For N, these 
alignments revealed a 20% 
homology with hRSV and 
52% homology with APV. 
The amino-acid sequences for 
P revealed 25% homology 
with hRSV and 67% with 
APV; for M, 37% with hRSV 
and 87% with APV; and for F, 
32% with hRSV and 80% 
homology with APV.  
 
 
 
Figure 3 : 
Nucleotide and deduced amino-acid sequences for selected 
regions of the hMPV genome. A and B, The nucleotide sequences 
for the 3’end of the viral genome and the intergenic region 
between M and F ORFs. Note that the underlined sequence in A 
refers to the primer used for PCR amplification, and therefore 
does not necessarily reflect the actual hMPV leader squence. C-
F, Comparison of the amino acid sequences of the putative N 
(panel C), P (panel D), M (panel E) and F (panel F) ORFs of 
hMPV, aligned with those of APV and RSV. Residues that differ 
between isolate 00-1 and the other viruses are shown, identical 
amino acids are represented by periods, gaps are represented by 
dashes. 
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Phylogeny 
As an indication for the relationship between the newly identified virus isolates and members 
of the Pneumovirinae, phylogenetic trees were constructed based on the N, P, M and F ORFs 
of these viruses. In all four phylogenetic trees, the newly identified virus isolate was most 
closely related to APV (Figure 4). From the four serotypes of APV that have been described 
11,51, APV serotype C, the metapneumovirus found primarily in birds of the United States, 
showed the closest resemblance to the newly identified virus; however, only limited 
sequence information for APV serotype D is available.  
 
 
Experimental infection of birds and cynomolgus macaques 
Since hMPV appeared to be closely related to APV, we wished to test whether hMPV is a 
primary human pathogen or an avian pathogen that can also infect humans. We inoculated 
four juvenile turkeys, four juvenile chickens and four juvenile cynomolgus macaques with 
50,000 TCID50 of hMPV on their conjunctivae and in their respiratory tracts. We collected 
cloaca and/or throat samples and tested them for the presence of hMPV by RT-PCR. During 
the 3 weeks follow-up, none of the birds showed clinical signs or virus replication as 
determined by RT-PCR using RNA isolated from the throat and cloaca swabs. In contrast, 
the virus replicated efficiently in the respiratory tract of all four monkeys as shown by RT-
PCR of RNA isolated from the throat swabs. Whereas vial RNA was not detectable in 
samples taken at day 1, virus replication peaked between days 2 and 8 after inoculation. Two 
of the monkeys presented with mild upper respiratory tract signs that upon histological 
analysis proved to be associated with suppurative rhinitis (data not shown). Although the 
detailed pathological, virological and immunological analyses are incomplete at present, 
these preliminary data indicate that hMPV is a primate pathogen associated with respiratory 
disease.  
 
Genetic heterogeneity of hMPV isolates 
We next amplified small parts of the N, M, F and L ORFs (71, 143, 142 and 102 nucleotides 
respectively) for 9 of the 28 virus isolates by RT-PCR, then sequenced these fragments 
directly to minimize the possibility of errors introduced by the amplification procedure. 
Phylogenetic analyses revealed significant sequence variation and the existence of two 
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Figure 4:  
Phylogenetic analysis of ORFs of hMPV 
and selected pneumoviruses. A-D, The F 
(panel A), N (panel B), M (panel C), and P 
(panel D) ORFs of hMPV isolate 00-1 were 
aligned with those of other members of the 
genus Pneumovirinae, and phylogenetic 
trees were generated by maximum 
likelihood analyses using 100 bootstraps 
and 3 jumbles. The scale representing the 
number of nucleotide changes is shown for 
each tree. Bootstrap values are based on the 
consensus trees. 
  
  
potential genetic clusters of hMPV isolates obtained in The Netherlands (Figure 5). The 
nucleotide sequence identity between isolates within a cluster was 90-100 % for all four 
fragments, whereas the sequence identity for isolates between the two clusters was 81-88 %. 
Variation was similar for the N, M, F and L fragments and did not seem to correlate with the 
year of virus isolation (indicated by the first to numbers in the name of the isolates). The 
genetic clusters might represent subgroups of the newly identified virus in analogy to other 
pneumoviruses such as RSV.  
 
Seroprevalence  
To study the prevalence of this virus in the human population, we tested sera from humans in 
different age categories by indirect IFA using tMK cells infected with one of the unidentified 
virus isolates. This analysis revealed that 25% of the children between 6 and 12 months had 
antibodies to the virus, and towards the age of 5 virtually all of the children had become 
seropositive (Table 1). In addition, 56 serum samples tested by indirect IFA were tested by 
virus neutralisation assays. For 51 (91%) of the samples, the results of the virus 
neutralisation assay (titer >8) correlated with the results obtained with indirect IFA 
(titer>32). Four samples that were positive in IFA (titer >32) were negative by virus 
neutralisation tests (titer <8), and one serum sample that reacted negative in IFA (titer<32) 
was positive in the virus neutralisation test (titer >16). Indirect IFA conducted with 72 sera 
taken from humans in 1958 (ages 8-99 years)162,177 revealed a 100% seroprevalence, 
indicating that the virus has been circulating in the human population for more than 43 years. 
In addition, testing of a number of these sera in virus neutralisation assays confirmed the IFA 
data (Table 1).  
The range of antibody titers appeared higher for individuals older than 2 years as compared 
to children between 6 and 24 months. This observation could be related to boosting of 
antibody responses as a consequence of reinfection with the same or a closely related virus. 
However, more detailed serological and virological analyses will be required to substantiate 
this speculation. 
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Figure 5: 
Phylogenetic analysis of 9 hMPV isolates. 
A-D, Parts of the F (panel A),  N (panel 
B), M (panel C) and L (panel D) ORFs of 
the indicated hMPV isolates were 
amplified by PCR and sequenced directly 
(fragments of 142, 71, 143, and 102 
nucleotides, respectively). Phylogenetic 
trees were generated as described in 
Figure 4. The first 2 numbers in the 
isolate names refer to the year from which 
the isolate originated. We were unable to 
amplify the F fragent for isolate 93-4. 
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Discussion 
 
Here, we describe the characterisation of a new member in the Paramyxoviridae family, 
isolated from 28 children with RTI in The Netherlands. The children presented with clinical 
symptoms reminiscent of those caused by hRSV infection, ranging form mild upper 
respiratory tract disease to severe bronchiolitis and pneumonia. As is seen with hRSV-
infected children, very young hMPV-infected children appeared to require hospitalisation 
and mechanical ventilation. Whether hMPV infection causes RTI cannot be formally 
concluded from the present data. Most importantly, acute and convalescent paired sera were 
not available for the children from whom hMPV was isolated. However, considering that no 
other virus was identified in any of the 28 hMPV-infected children and that hMPV was not 
isolated from 400 samples taken from children under two years of age without respiratory 
symptoms (not shown), a causal relationship seems likely. The experimental infection of 
cynomolgus macaques supports this conclusion. 
Based on the data here we propose the name human metapneumovirus (hMPV). hMPV 
proved to have a paramyxovirus-like morphology in electron microscopy, to be chloroform-
sensitive and to replicate optimally in a trypsin-dependent manner in tMK cells. The clinical 
symptoms of the hMPV- infected children, the characteristic cytopathic effects and the lack 
of haemagglutinating activity further suggested that this virus might be related to hRSV; 
although most paramyxoviruses have haemagglutinating activity, most of the pneumoviruses 
do not199. Genetic analyses of the putative N, M, P and F genes revealed that hMPV showed 
a higher sequence homology to the recently proposed genus Metapneumovirus (average of 
66%) as compared to the genus Pneumovirus (average of 30%) and a genomic organisation 
that is most similar to APV/TRTV. In contrast to the genomic organisation of the 
pneumoviruses ('3-NS1-NS2-N-P-M-SH-G-F-M2-L-5'), metapneumoviruses lack NS1 and 
*, Sero-archeological analysis using sera collected in 1958 (Mulder, J. et al., 1958; Masurel, N. et al., 
1969) 
Table 1: Seroprevalence of hMPV antibodies in humans categorised by age group. 
 Immunofluorescence assays Virus neutralisation assays 
Age (Years) n tested n positive (%) n tested n positive (%) Titer range 
0.5-1 20 5 (25) 12 3 (25) 16-32 
1-2 20 11 (55) 13 4 (31) 16-32 
2-5 20 14 (70) 8 3 (38) 16-512 
5-10 20 20 (100) 4   4 (100) 32-256 
10-20 20 20 (100) 4 3 (75) 32-128 
> 20 20 20 (100) 4 3 (75) 32-128 
8-99* 72 72 (100) 11 11 (100) 16-128 
C
hapter 2
 33
  
  
NS2 genes and have a different positioning of the genes between M and L ('3-N-P-M-F-M2-
SH-G-L-5'). The absence of ORFs between the M and F genes in this virus and the lack of 
NS1 and NS2 genes adjacent to N is in agreement with it being the first identified non-avian 
member of the Metapneumovirus genus. However, until sequence information becomes 
available for the entire genomic organisation of hMPV, a definitive classification of this 
virus is not possible.  
Of the four serotypes of APV that have been described, serotype C was most closely related 
to hMPV based on the N, P, M and F genes. However, for serotype D only limited sequence 
information for the F gene is available from Genbank and for serotype B, only M, N and F 
sequences are available. For both hRSV and APV, different genetic and serological subtypes 
have been described. We also found evidence for genetic variation between hMPV isolates. 
Although it is tempting to speculate that these subgroups of hMPV isolates represent 
different serotypes of hMPV, sequence analyses of other parts of the hMPV genome and of 
isolates obtained from different geographical locations as well as detailed serological studies 
will be needed to support this hypothesis.  
Our serological survey revealed that hMPV commonly infects children. The repeated 
isolation of this virus from clinical samples from children with RTI indicates that hMPV 
infection may have considerable clinical and economical impact. New diagnostic assays 
based on virus detection and serology should allow a more detailed analysis of the incidence 
and both clinical and economical impact of this newly identified human virus. To get an idea 
of the potential impact of this virus for RTI we have tested nasopharyngeal aspirate sample 
collected during the 2000 winter season from children presenting with RTI, at Erasmus 
University Medical Center that were negative for RSV, influenza A and B viruses, 
parainfluenza virus types 1-3, human rhinovirus and corona virus (HCV-229E and HCV-
OC43). Seven of the 68 samples tested proved to be positive for hMPV by RT-PCR, 
indicating that for the 2000 winter season approximately 10% of the unexplained RTI may 
be associated with hMPV. 
The minor differences between our IFA and virus neutralisation results (5 samples) may be 
due to several factors: only IgG serum antibodies are detected in IFA, virus neutralisation 
antibodies are generally directed against surface glycoproteins, the sensitivities of the two 
assays may differ and different serotypes of hMPV may exist. The latter suggestion is of 
particular interest, since only one isolate (00-1) was used for IFA and virus neutralisation, 
potentially giving rise to false negative results using sera raised against genetically distinct 
hMPV isolates such as those shown in Figure 5.  
As hMPV seems most closely related to APV, we speculate that the human virus has 
originated from birds. Analysis of serum samples taken from humans in 1958 revealed that 
hMPV has been widespread in the human population for at least half a century, indicating 
that a possible zoonotic event must have taken place before 1958.  
The question than arises: Why has this virus remained unidentified for so many years? First 
of all, many virology laboratories use continuous cell lines for virus isolation, in which 
hMPV does not seem to replicate efficiently. Second, hMPV displays very slow replication 
kinetics in vitro, and may therefore have remained undetected. Third, replication of hMPV 
in-vitro appeared to be trypsin dependent and many of the earlier studies to find respiratory 
pathogens did not use trypsin. Finally, the apparent lack of cross-reactivity in the serologic 
assays we performed and the low nucleotide sequence homology to known human viral 
pathogens make the detection of hMPV unlikely with standard serological or molecular 
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techniques. Pringle and Eglin have described serological evidence for an unidentified "PVM-
like" pneumovirus that frequently infects humans201. We feel it is unlikely that hMPV is the 
PVM-like-virus described by Pringle and Eglin for a number of reasons. First, high titer sera 
specific for several paramyxoviruses, including PVM and RSV, failed to react in 
immunofluorescence studies with hMPV-infected tMK cells as targets (data not shown). 
Second, most of our hMPV-positive human serum samples did not have PVM-specific 
antibodies as measured by ELISA. Furthermore, PVM (and supposedly a PVM-like virus) 
has haemagglutinating activity, whereas we have no evidence that hMPV does. Finally, the 
genomic organisation of PVM is similar to that of RSV and thus different from that of 
hMPV.  
The identification of this tentative new member of the Metapneumovirus genus may aid in 
the development of diagnostic assays, vaccines and antiviral agents for viral RTIs.  
 
 
Methods 
 
Virus isolation 
Over the past decades our virus diagnostic hospital-based laboratory has collected 
nasopharyngeal aspirates from children suffering from RTI. These samples were routinely 
tested for the presence of viruses by direct immune fluorescence assays (DIF) using 
antibodies against viruses known to cause RTI (hPIV types 1-3, hRSV, influenza virus type 
A and B) and by virus isolation using rapid shell-vial techniques on tMK cells and CEF, as 
well as various cell lines such as Vero, A549 and MDCK cells23,215. Samples showing 
cytopathic effects after two or three passages that were negative in DIF were tested by 
indirect IFA using virus-specific antibodies against influenza virus types A, B and C, hRSV, 
hPIV types 1-4, measles virus, mumps virus, Sendai virus, SV-5, and NDV. Although for 
many cases the aetiologic agent could be identified, some specimens yielded cytopathic 
effects in cell cultures but were negative for all viruses tested.  
  
Animal immunisation 
To raise virus-specific antisera, 1.0 ml volumes of virus-infected tMK cell- culture 
supernatants of two different virus isolates containing approximately 1 x 104 TCID50/ ml 
were used to inoculate guinea pigs and ferrets intranasally without prior purification. 
Samples were taken at day 0 and at day 14 or 28 post infection the animals were bled by 
cardiac puncture, and their pre-and post-infection sera were used as negative and positive 
reference sera respectively. The sera were tested for reactivity against all previously 
described viruses with DIF and IFA as described above.  
 
Virus characterisation 
We cultured the virus isolates in tMK cells in Eagle’s MEM with Hanks’s salt, supplemented 
with 0.02% trypsin and without serum. After inoculation, the plates were incubated at 37 °C 
for a maximum of 14 days during which time the medium was changed once a week and 
cultures were checked daily for cytopathic effects. Because the degree of cytopathic effects 
differed slightly for each isolate, all cultures were tested at days 10-14 with indirect IFA 
using ferret antisera raised against one of the isolates.  For electron microscopy analyses, 
virus was concentrated from infected cell-culture supernatants in a micro-centrifuge at 4 °C 
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at 17,000g, after which the pellet was resuspended in PBS and after potassium tungstat acid 
(PTA) staining, inspected by negative contrast electron microscopy156. Standard 
haemagglutination assays, chloroform sensitivity tests, DIF and IFA were performed as 
described23,145,187,215. Virus neutralisation assays were performed on tMK cells with serial 2-
fold dilutions of human or animal sera (starting at 1:8) and with 100 TCID50 of hMPV, 
following procedures as described145. Since cytopathic effects were not always easy to detect, 
IFA was used to determine the virus neutralisation titer. The virus neutralisation titer was 
defined as the reciprocal of the highest dilution of the serum sample resulting in negative 
IFA and inhibition of cytopathic effects in cell cultures.  
 
RAP-PCR and RT-PCR 
RNA was isolated from the supernatant of infected cell cultures or sucrose gradient fractions 
using a High Pure RNA Isolating kit according to instructions from the manufacturer (Roche 
Diagnostics, Almere, The Netherlands). RT-PCR assays were performed according to 
established techniques. Primers specific for the panel of paramyxoviruses tested and 
conditions are available upon request. For RAP-PCR, virus was concentrated from infected 
tMK-cell supernatants by ultracentrifugation on a 20-60% sucrose gradient. Gradient 
fractions were inspected for the presence of virus-like particles by electron microscopy and 
poly-acrylamide gel electrophoresis followed by silver staining. The approximately 50% 
sucrose fractions that appeared to contain nucleocapsids were used for RNA isolation and 
RAP-PCR. RAP-PCR was performed essentially as described203,267 and primer sequences 
used are available upon request. Differentially displayed fragments specific for hMPV were 
purified from the gel with a Qiaquick Gel Extraction kit (Qiagen, Leusden, The Netherlands) 
and cloned in vector pCR2.1 (Invitrogen, Groningen, The Netherlands) according to 
instructions from the manufacturer. 
 
Sequence analysis 
RAP-PCR products cloned in vector pCR2.1 were sequenced with M13-specific 
oligonucleotides. DNA fragments obtained by RT-PCR were purified from agarose gels 
using a Qiaquick Gel Extraction kit (Qiagen, Leusden, The Netherlands) and sequenced 
directly with the same oligonucleotides used for RT-PCR assays. Sequence analyses were 
performed using a Dyenamic ET terminator sequencing kit (Amersham Pharmacia Biotech, 
Roosendaal, The Netherlands) and an ABI 373 automatic DNA sequencer (PE Applied 
Biosystem, Nieuwerkerk aan den IJssel, The Netherlands), according to the instructions of 
the manufacturer.  
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Phylogenetic analyses 
For all phylogenetic trees, DNA sequences were aligned using the ClustalW software 
package and maximum likelihood trees were generated using the DNA-ML software package 
of the Phylip 3.5 program using 100 bootstraps and 3 jumbles. Bootstrap values were 
computed for consensus trees created with the consense package82. hMPV sequences are 
available from Genbank under accession numbers AF371330 through AF371367. All other 
sequences used here are available from Genbank under accession numbers NC001781 
(hRSV all ORFs); NC001989 (bRSV all ORFs); D10331 (PVM N); U39295 (APV-A N); 
U39296 (APV-B N); AF176590 (APV-C N); U09649 (PVM P); U22110 (APV-A P); 
AF176591 (APV-C P); U66893 (PVM M); X58639 (APV-A M); U37586 (APV-B M); 
AF262571 (APV-C M); D11128 (PVM F); D00850 (APV-A F); Y14292 (APV-B F); 
AF187152 (APV-C F). 
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Abstract 
 
We recently described the isolation of a novel paramyxovirus from children with respiratory 
tract disease in The Netherlands. Based on biological properties and limited sequence 
information the virus was provisionally classified as the first non-avian member of the 
Metapneumovirus genus and named human metapneumovirus (hMPV). This report describes 
the analysis of the sequences of all hMPV open reading frames (ORFs) and intergenic 
sequences as well as partial sequences of the genomic termini. The overall percentage amino 
acid sequence identity between APV and hMPV N, P, M, F, M2-1, M2-2 and L ORFs was 
56 to 88%. Some nucleotide sequence identity was also found between the noncoding 
regions of the APV and hMPV genomes. Although no discernable amino acid sequence 
identity was found between two of the ORFs of hMPV and ORFs of other paramyxoviruses, 
the amino acid content, hydrophilicity profiles and location of these ORFs in the viral 
genome suggest that they represent SH and G proteins. The high percentage sequence 
identity between APV and hMPV, their similar genomic organisation (3’-N-P-M-F-M2-SH-
G-L-5’), and phylogenetic analyses provide evidence for the proposed classification of 
hMPV as the first mammalian metapneumovirus. 
 
 
Introduction 
  
Recently we reported the isolation of human metapneumovirus (hMPV) from 
nasopharyngeal aspirate samples taken from young children in The Netherlands256. The 
clinical symptoms of these children were largely similar to the respiratory tract illnesses 
caused by the human respiratory syncytial virus (hRSV), ranging from mild respiratory 
problems to severe cough, bronchiolitis and pneumonia. The newly discovered virus 
displayed high percentage sequence identity with and probably a genomic organisation 
similar to avian pneumovirus (APV), the aetiologic agent of an upper respiratory tract 
disease in turkeys50,96. APV, also known as turkey rhinotracheitis virus (TRTV) belongs to 
the Metapneumovirus genus, which together with the Pneumovirus genus constitutes the 
Pneumovirinae subfamily within the Paramyxoviridae family118. The Pneumovirus genus 
contains the mammalian respiratory syncytial viruses (human, ovine, bovine RSV) and 
pneumonia virus of mice (PVM). Until the discovery of hMPV, APV was the sole member 
of the Metapneumovirus genus. The classification of the two genera is based primarily on the 
gene constellation; metapneumoviruses lack nonstructural proteins NS1 and NS2 and the 
gene order is different from that of pneumoviruses (RSV, 3’-NS1-NS2-N-P-M-SH-G-F-M2-
L-5’; APV, 3’-N-P-M-F-M2-SH-G-L-5’)42,151,204,282. 
Sequence analyses of the nucleoprotein (N), phosphoprotein (P), matrix protein (M) and 
fusion protein (F) genes of hMPV revealed the highest percentage of sequence identity with 
APV serotype C, the avian pneumovirus found primarily in birds in the United States. These 
analyses also revealed the absence of NS1 and NS2 at the 3' end of the viral genome and 
positioning of F immediately adjacent to M. Here we present the sequences of the putative 
22K protein (M2), the small hydrophobic protein (SH), the attachment glycoprotein (G) and 
the large polymerase protein (L) genes, the intergenic regions, and the trailer sequence. In 
combination with the sequences described previously the sequences presented here complete 
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the genomic sequence of hMPV with the exception of the extreme 12-15 nt of the genomic 
termini and establish the genomic organisation of hMPV. Side by side comparisons of the 
sequences of the hMPV genome with those of APV subtype A, B and C, hRSV subgroup A 
and B, bRSV, PVM and other paramyxoviruses provides strong evidence for the 
classification of hMPV in the Metapneumovirus genus.  
 
 
Results 
 
Sequence strategy 
hMPV isolate 00-1256 was propagated in tertiary monkey kidney (tMK) cells and RNA 
isolated from the supernatant 3 weeks after inoculation was used as template for RT-PCR 
analyses. Primers were designed on the basis of the partial sequence information available 
for hMPV 00-1256 as well as the leader and trailer sequences of APV and RSV167,204. Initially, 
fragments between the previously obtained products, ranging in size from 500 to 4000 bp in 
length, were generated by RT-PCR amplification and sequenced directly. The genomic 
sequence was subsequently confirmed by generating a series of overlapping RT-PCR 
fragments ranging in size from 500 to 800 bp that represented the entire hMPV genome. For 
all PCR fragments, both strands were sequenced directly to minimize amplification and 
sequencing errors. The nucleotide and amino acid sequences were used to search for related 
sequences in the Genbank database using the BLAST software 
(http://www.ncbi.nlm.nih.gov/BLAST). Putative protein names were assigned to open 
reading frames (ORFs) based on sequence identity with known viral genes as well as their 
location in the genome. Based on this information, a genomic map for hMPV was 
constructed (Figure 1). The hMPV genome was found to be 13,378 nt in length and its 
organisation was found to be similar to the genomic organisation of APV. It should be noted 
that the sequence of the genomic termini reflect primer sequences and therefore these parts 
of the genome are still uncertain with respect to size and sequence. Below, we present a 
comparison between the ORFs and noncoding sequences of hMPV and those of other 
paramyxoviruses and discuss the important similarities and differences. 
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Figure 1:  
Genomic map of hMPV isolate 00-1. Putative ORFs and the nt positions of the start and stop codons 
are indicated. The double lines crossing the L ORF indicate the shortened representation of the L gene. 
Note that the length of the genome is still uncertain since the sequence of the genomic termini reflects 
primer sequences. The three reading frames below the map indicate the primary G ORF (nt 6262-6972) 
and overlapping potential secondary ORFs. 
  Molecular characterisation of hMPV 
  
 
The nucleoprotein (N) ORF 
As shown previously256 the first gene in the genomic map of hMPV codes for a 394-aa 
protein, which resembles the N protein of other pneumoviruses. The length of the N ORF is 
identical to the length of the N ORF of APV-C (Table 1) and is smaller than those of other 
paramyxoviruses8. Analysis of the aa sequence revealed the highest percentage of sequence 
identity with APV-C (88%), and only 7-11% with other paramyxoviruses (Table 2). 
 
Table 2: Amino acid sequence identity between the putative ORFs of hMPV and those of other 
paramyxovirusesa 
a.  Percentage  sequence identity could not be determined for the G and SH proteins 
because these proteins could not be properly aligned with known G and SH proteins. 
b. Sequence not available. c. Human parainfluenza virus types 2 and 3, Sendai virus, 
measles virus, Nipah virus, phocine distemper virus, and Newcastle disease virus. 
d. ORF absent in viral genome. 
Table 1: Lengths of the putative ORFs of hMPV and other paramyxoviruses 
a. Lengths in amino acid reidues. b. Sequences not available. c. Human parainfluenza virus types 2 
and 3, Sendai virus, Measles virus, Nipah virus, phocine distemper virus, and Newcastle disease 
virus. d. ORF absent in viral genome 
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P   M F M2-1 M2-2 SH G   L   
hMPV   394   294   254 539 187 71 183 236   2005   
APV A   391   278   254 538 186 73 174 391   2004   
APV B   391   279   254 538 186 73 -b 414   - b   
APV C   394   294   254 537 184 71 -b - b   - b   
APV D   -b   - b   -b -b -b -b -b 389   - b   
hRSV A   391   241   256 574 194 90 64 298   2165   
hRSV B   391   241   256 574 195 90 65 299   2166   
bRSV   391   241   256 574 186 90 81 257   2162   
PVM   393   295   257 537 176 98 92 396   - b   
Others C   418- 542   225 - 709   335-393 539-565 -d -d -d - d   2183 - 2262   
  
  
  
  N  P  M  F M 2-1 M 2-2 L
A P V  A    6 9 55   7 8   6 7 7 2 2 6 6 4A P V  B  6 9 51   7 6   6 7 7 1 2 7 -bA P V  C  8 8 68   8 7   8 1 8 4 5 6 -bh R S V  A  4 1 24   3 8   3 3 3 6 1 8 4 4h R S V  B   4 1 23   3 7   3 3 3 5 1 9 4 4b R S V  7 - 1 1 22   3 8   3 4 3 5 1 3 4 4P V M  4 1 26   3 7   3 8 3 4 1 2 -bO thers c  4 5 4  - 9   7  - 1 0   1 0-1 8 -d -d 1 3-1
  
  
Barr et al. (1991)8 identified 3 regions of 
similarity between viruses belonging to the 
order Mononegavirales: A, B and C (Figure 
2). Here, aa residues are regarded as similar 
when they are replaced by aa residues from 
a group sharing some physical or chemical 
properties: hydrophobic/aliphatic (I, L, V, M 
and A); small/neutral (G, P, S, T and A); 
acidic/polar (D, E, Q and N); aromatic (F, 
Y, W and H); basic (K and R); thiol (C). 
Although similarities are highest within a 
virus family, these regions are highly 
conserved between virus families. In all 
three regions hMPV revealed 99,3% aa 
sequence similarity with APV-C, 98,6% 
with APV-A, 95,3% with APV-B, and 78-
92% with RSV and PVM.  
The region between aa residues 160 and 340 
appears to be highly conserved among 
metapneumoviruses and to a somewhat 
lesser extent the Pneumovirinae8,146,168.  
This is in agreement with hMPV being a 
metapneumovirus, showing 99% similarity 
with APV-C.  
 
The phosphoprotein (P) ORF  
The second ORF in the genome map codes 
for a 294-aa protein which shares 68% aa 
sequence identity with the P protein of 
APV-C, and only 22-24% with the P protein 
of RSV (Table 2). The putative P gene of 
hMPV contains one substantial ORF and in 
that respect is similar to P from many other 
paramyxoviruses (Reviewed in142,225). 
In contrast to APV-A and -B and PVM and 
similar to RSV and APV-C the hMPV P 
ORF lacks cysteine residues. The C-
terminus of the hMPV P protein is rich in 
glutamate residues as has been described for 
APVs149. Ling et al. (1995)146 suggested that 
a region of high similarity between all 
pneumoviruses (aa 185-241) plays a role 
either in the RNA synthesis process or in 
maintaining the structural integrity of the 
nucleocapsid complex. This conserved 
region may represent the domain that 
interacts with the polymerase protein. This 
Figure 2:  
Amino acid sequence comparison of the putative 
nucleoprotein ORF of hMPV and other 
pneumoviruses. The conserved regions (Barr et 
al., 1991)8 are represented by boxes and are 
labeled A, B, and C. The conserved region 
among pneumoviruses (Li et al., 1996)146 is 
shown shaded in gray. Gaps are represented by 
dashes and periods indicate the positions of 
identical aa residued compared to hMPV. 
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region of high similarity is also found in 
hMPV (Figure 3), showing 100% similarity 
with APV-C, 93% with APV-A and -B, and 
approximately 81% with RSV (see the 
section on the N ORF for the definition of 
similarity).  
 
The matrix protein (M) ORF  
The third ORF of the hMPV genome 
encodes a 254-aa protein, which resembles 
the M ORFs of other pneumoviruses. The 
putative M ORF of hMPV has exactly the 
same size as the M ORFs of other 
metapneumoviruses (Table 1) and shows 
high aa sequence identity with the matrix 
proteins of APV (76-87%), lower identity 
with those of RSV and PVM (37-38%) and 
10% or less identity with those of other 
paramyxoviruses (Table 2). 
Easton and Chambers (1997)33 compared 
the sequences of matrix proteins of all 
pneumoviruses and found a conserved 
hexapeptide at residue 14 to 19 that is also 
conserved in hMPV (Figure 4). For RSV, 
PVM and APV small secondary ORFs 
within or overlapping with the major ORF 
of M have been identified (52 aa and 51 aa 
in bRSV, 75 aa in hRSV, 46 aa in PVM and 
51 aa in APV)69,220,282. We noticed two 
small secondary ORFs in the M ORF of 
hMPV. One small ORF of 54 aa residues 
was found within the major M ORF, 
starting at nt 2281, and one small ORF of 
33 aa residues was found overlapping with 
the major ORF of M, starting at nt 2893 
(data not shown). Similar to the secondary 
ORFs of RSV and APV there is no 
significant sequence identity between these 
secondary ORFs and secondary ORFs of the 
other pneumoviruses, and apparent start and 
stop signals are lacking. Evidence for the 
synthesis of proteins corresponding to these 
secondary ORFs of APV and RSV has not 
been reported. 
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Figure 3:   
Amino acid sequence comparison of the putative 
phosphoprotein ORF of hMPV and other 
pneumoviruses. The region of high similarity 
(Ling et al., 1995)149 is boxed, and the glutamine-
rich region is shaded in gray. Gaps are 
represented by dashes and periods indicate the 
position of identical aa residues compared to 
hMPV 
  
  
The fusion protein (F) ORF  
The putative F ORF of hMPV is located 
adjacent to the putative M ORF, which is 
characteristic for members of the 
Metapneumovirus genus. The F gene of 
hMPV encodes a 539-aa protein, which is 2 
aa residues longer than F of APV-C (Table 
1). Analysis of the aa sequence revealed 
81% sequence identity with APV-C, 67% 
with APV-A and -B, 33-38% with other 
pneumovirus F proteins, and only 10-18% 
with other paramyxoviruses (Table 2). One 
of the conserved features among F proteins 
of paramyxoviruses and also seen in hMPV 
is the distribution of cysteine residues175,280. 
The metapneumoviruses share 12 cysteine 
residues in F1 (7 are conserved among all 
paramyxoviruses), and two in F2 (1 is 
conserved among all paramyxoviruses). Of 
the three potential N-linked glycosylation 
sites present in the F ORF of hMPV, none 
are shared with RSV and two (position 66 
and 389) are shared with APV. The third, 
unique, potential N-linked glycosylation site 
for hMPV is located at position 206 (Figure 
5).  
Despite the relatively low percentage 
sequence identity with other 
paramyxoviruses, the F protein of hMPV 
revealed typical fusion protein 
characteristics consistent with those 
described for the F proteins of other 
Paramyxoviridae family members175. F 
proteins of Paramyxoviridae members are 
synthesised as inactive precursors (F0) that 
are cleaved by host cell proteases, which 
generate N-terminal F2 subunits and large 
C-terminal F1 subunits. The cleavage site is conserved among all members of the 
Paramyxoviridae family46. The cleavage site of hMPV contains the residues RQSR. Both 
arginine residues are shared with APV and RSV, but the glutamine and serine residues are 
shared with other paramyxoviruses such as human parainfluenza virus type 1, Sendai virus 
and morbilliviruses (data not shown). In RSV a second cleavage site (RARR) was found 
which is separated from the first cleavage site immediately upstream of the fusion peptide by 
a stretch of 27 aa. Cleavage at both sites is required for the acquisition of membrane fusion 
potential of the F protein.  
 
C
ha
pt
er
 3
 
  46 
Figure 4:  
Amino acid sequence comparison of the putative 
matrix protein ORF of hMPV and other 
pneumoviruses. The conserved hexapeptide 
sequence (Easton and Chambers, 1997)69 is 
shaded in gray. Gaps are represented by dashes 
and periods indicate the position of identical aa 
residues relative to hMPV. 
  Molecular characterisation of hMPV 
  
 
 
The F proteins of other pneumoviruses such as APV and PVM as well as other 
paramyxoviruses lack the sequence between the two cleavage sites99,286. As can be seen in 
Figure 5, this second cleavage site and the connecting peptide are absent in the hMPV F 
protein. The hydrophobic region at the N-terminus of F1 functions as the membrane fusion 
domain and displays a high degree of sequence similarity among paramyxoviruses and 
Figure 5:  
Amino acid sequence comparison of the putative fusion protein ORF of hMPV and other 
pneumoviruses. The cleavage sites are shown shaded in gray and three hydrophobic domains (the 
putative signal peptide, fusion domain, and membrane anchor domain) are shown italicalised in 
boldface type. The conserved cysteine residues are boxed, putative N-linked glycosylation sites are 
underlined, and domains HRA and HRB are indicated with a line above the sequence. Gaps are 
represented by dashes and periods indicate the position of identical aa residues relative to hMPV. 
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morbilliviruses and to a lesser extend the 
pneumoviruses117,175. This hydrophobic 
region (position 137-159, Figure 5) are 
conserved between hMPV and APV-C, 
which is in agreement with this region being 
highly conserved among the 
metapneumoviruses179,224. Adjacent to the 
fusion peptide and transmembrane segment 
are two regions that contain heptad repeats 
(HRA and HRB) which are relatively poor in 
glycines, contain no helix-breaking prolines, 
and contain charged aa side chains in all 
heptad positions except a and d. These 
heptad regions that are necessary for viral 
fusion25,33,141,217 are also found in the hMPV 
F gene. Whereas a high percentage sequence 
identity is found between HRA of hMPV and 
all other pneumoviruses (especially in 
positions a and d of the repeats), a high level 
of sequence identity in HRB is restricted to 
the metapneumoviruses (Figure 5). 
Furthermore, for RSV and APV, the signal 
peptide and anchor domain were found to be 
conserved within subtypes and displayed 
high variability between subtypes179,195. At 
the N-terminus of F2 of hMPV, 11 out of 18 
aa residues are identical to those of APV-C 
and lower sequence identity is observed with 
the signal peptides of other APV or RSV F 
ORFs. Much more variability is seen in the 
membrane anchor domain at the C-terminus 
of F1, although some sequence identity is 
still seen with APV-C. 
 
The 22K protein (M2) ORF  
The M2 gene is unique to the members of 
the Pneumovirinae subfamily and two 
overlapping ORFs have been observed in 
all pneumoviruses. The first major ORF 
represents the M2-1 protein which enhances 
the processivity of the viral polymerase43,46 
and its readthrough of intergenic 
regions81,108. The putative M2-1 gene for 
hMPV, located adjacent to the F gene, 
encodes a 187-aa protein (Table 1) and 
reveals the highest percentage of sequence 
Figure 6:  
Amino acid sequence comparison of the putative 
M2 ORFs of hMPV and other pneumoviruses. 
(A) Alignment of M2-1 ORFs, with the 
conserved N-terminus (Collins et al., 1990; 
Zamora and Samal, 1992)45,248 shown shaded in 
gray. The conserved cysteine residue are printed 
in boldface type and are indicated by pound 
signs. (B) Alignment of M2-2 ORFs. Gaps are 
represented by dashes and periods indicate the 
position of identical aa residues relative to 
hMPV. 
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identity with M2-1 of APV-C (84%, Table 2). Comparison of all pneumovirus M2-1 proteins 
revealed the highest level of conservation in the N-terminal half of the protein1,45,284, which is 
in agreement with the observation that hMPV displays 100% similarity with APV-C in the 
first 80 aa residues of the protein (Figure 6A). The hMPV M2-1 protein contains 3 cysteine 
residues located within the first 30 aa residues that are conserved among all pneumoviruses. 
Such a concentration of cysteines is frequently found in zinc-binding proteins1,61. 
The secondary ORFs (M2-2) that overlap with the M2-1 ORFs of pneumoviruses are 
conserved in location but not in sequence and are thought to be involved in the control of the 
switch between virus RNA replication and transcription1,3,10,12,45,49,73,151,284. For hMPV, the 
putative M2-2 ORF starts at nt 512 in the 
M2-1 ORF (Figure 1), which is exactly the 
same start position as for APV-C. The 
length of the M2-2 ORFs are the same for 
APV-C and hMPV, 71 aa residues (Table 
1). Sequence comparison of the M2-2 ORF 
(Figure 6B) revealed 56% aa sequence 
identity between hMPV and APV-C and 
only 26-27% aa sequence identity between 
hMPV and APV-A and B (Table 2).  
 
The small hydrophobic protein (SH) 
ORF  
The gene located adjacent to M2 of hMPV 
probably encodes a 183-aa SH protein 
(Figures 1 and 7). There is no discernible 
sequence identity between this ORF and 
other RNA virus genes or gene products. 
This is not surprising since sequence 
similarity between pneumovirus SH 
proteins is generally low. The putative SH 
ORF of hMPV is the longest SH ORF 
known to date (Table 1). The aa 
composition of the SH ORF is relatively 
similar to that of APV, RSV and PVM, 
with a high percentage of threonine and 
serine residues (22, 18, 19, 20, 21 and 28% 
for hMPV, APV, RSV A, RSV B, bRSV 
and PVM respectively). The SH ORF of 
hMPV contains 10 cysteine residues, 
whereas APV SH contains 16 cysteine 
residues. The SH ORF of hMPV contains 
two potential N-linked glycosylation sites 
(aa 76 and 121), whereas APV has one, 
RSV has two or three and PVM has four. 
The hydrophilicity profiles for the putative 
hMPV SH protein and SH of APV and 
Figure 7:  
Amino acid sequence analysis of the putative SH 
ORF of hMPV. (A) Amino acid sequence of the 
putative SH ORF of hMPV, with cysteine 
residues in boldface type, potential N-lined 
glycosylation sites underlined, and the most 
hydrophobic region represented by a line above 
the sequence. (B) Alignment of the hydrophilicity 
plots of the SH proteins of hMPV, APV-A, and 
hRSV-B. The procedure of Kyte and Doolittle 
(1982) was used with a window size of 17 aa 
residues. Arrows indicate strong hydrophobic 
domains. 
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RSV revealed similar characteristics (Figure 7B). The SH ORFs of APV and hMPV have a 
hydrophilic N-terminus, a central hydrophobic domain which can serve as a potential 
membrane-spanning domain (aa 30-53 for hMPV), a second hydrophobic domain (aa 155-
170), and a hydrophilic C-terminus. In contrast, RSV SH appears to lack the C-terminal part 
of the APV and hMPV ORFs. In all pneumovirus SH proteins the hydrophobic domain is 
flanked by basic aa residues, which are also found in the SH ORF for hMPV (aa 29 and 54). 
 
The attachment glycoprotein (G) ORF 
The putative G ORF of hMPV is located 
adjacent to the putative SH gene and 
encodes a 236-aa protein (nt 6262-6972, 
Figure 1). A secondary small ORF is 
found immediately following this ORF, 
potentially coding for 68 aa residues (nt 
6973-7179) but lacking a start codon. A 
third potential ORF in the second 
reading frame of 194 aa residues is 
overlapping with both of these ORFs but 
also lacks a start codon (nt 6416-7000). 
This ORF is followed by a potential 
fourth ORF of 65 aa residues in the same 
reading frame (nt 7001-7198), again 
lacking a start codon. Finally, a potential 
ORF of 97 aa residues (but lacking a 
start codon) is found in the third reading 
frame (nt 6444-6737, Figure 1).  
Unlike the first ORF, the other ORFs do 
not have apparent gene start or gene end 
sequences (see below). Although the 236 
aa G ORF probably represents at least a 
part of the hMPV attachment protein it 
can not be excluded that the additional 
coding sequences are expressed as 
separate proteins or as part of the 
attachment protein through some RNA 
editing event. It should be noted that for 
APV and RSV no secondary ORFs after 
the primary G ORF have been identified 
but that both APV and RSV have 
secondary ORFs within the major ORF of 
G. However, evidence for expression of 
these ORFs is lacking and there is no 
sequence identity between the predicted 
aa sequences for different viruses151.  
Figure 8:  
Amino acid sequence analysis of the putative G 
ORF of hMPV. (A) Amino acid sequence of the 
putative G ORF of hMPV, with the cysteine 
residue in boldface type, potential N-linked 
glycosylation sites underlined, and the 
hydrophobic region represented by a line above 
the sequence. (B) Alignment of the hydrophilicity 
plots of the G proteins of hMPV, APV-A, and 
hRSV-B. The procedure of Kyte and Doolittle 
(1982) was used with a window size of 17 aa 
residues. Arrows indicate hydrophobic domains. 
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The secondary ORFs in hMPV G do not 
reveal characteristics of other G proteins and 
whether the additional ORFs are expressed 
requires further investigation.  
BLAST analyses with all ORFs revealed no 
discernible sequence identity at the 
nucleotide or aa sequence level with other 
known virus genes or gene products. This is 
in agreement with the low percentage 
sequence identity found for other G proteins 
such as those of hRSV A and B (53%)125 
and APV-A and- B (38%)130.  
Whereas most of the hMPV ORFs resemble 
those of APV in both length and sequence, 
the putative G ORF of 236 aa residues of 
hMPV is considerably smaller than the G 
ORF of APV (Table 1). The aa sequence 
revealed a serine and threonine content of 
34%, which is even higher than the 32% for 
RSV and 24% for APV. The putative G 
ORF also contains 8.5% proline residues, 
which is higher than the 8% for RSV and 
7% for APV. The unusual abundance of 
proline residues in the G proteins of APV, 
RSV and hMPV has also been observed in 
glycoproteins of mucinous origin where it is 
a major determinant of the proteins three-
dimensional structure48,121,268. The G ORF of 
hMPV contains five potential N-linked 
glycosylation sites, whereas hRSV has 
seven, bRSV has five and APV has three to 
five. 
The predicted hydrophilicity profile of 
hMPV G revealed characteristics similar to 
the other pneumoviruses. The N-terminus 
contains a hydrophilic region followed by a 
short hydrophobic area (aa 33-53 for 
hMPV) and a mainly hydrophilic C-
terminus (Figure 8B). This overall 
organisation is consistent with that of an 
anchored type II transmembrane protein and 
corresponds well with these regions in the 
G protein of APV and RSV. The putative G 
ORF of hMPV contains only 1 cysteine 
residue in contrast to RSV and APV (5 and 
20 respectively). Of note, only two of the 
Figure 9: 
Amino acid sequence comparison of a conserved 
domain of the putative polymerase ORF of 
hMPV and other paramyxoviruses. Domain III is 
shown with the four conserved polymerase motifs 
(A, B, C, and D) boxed (Poch et al., 1989, 1990). 
Gaps are represented by dashes and periods 
indicate the position of identical aa residues 
relative to hMPV. HPIV2 and HPIV3, human 
parainfluenza virus types 2 and 3; SV, Sendai 
virus; NDV, Newcastle disease virus; MV, 
measles virus; NIPAH, Nipah virus. 
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four secondary ORFs in the G gene contained one additional cysteine residue and these four 
potential ORFs revealed 12-20% serine and threonine residues and 6-11% proline residues. 
 
The polymerase protein (L) ORF 
In analogy to other negative-strand viruses, the last ORF of the hMPV genome is the RNA-
dependent RNA polymerase component of the replication and transcription complexes. The 
L gene of hMPV encodes a 2005-aa protein, which is one residue longer than the APV-A L 
protein (Table 1). The L protein of hMPV shares 64% aa sequence identity with APV-A, 
44% with RSV, and 13-15% with other paramyxoviruses (Table 2). Poch et al.196,197 
identified six conserved domains within the L proteins of non-segmented negative strand 
RNA viruses, from which domain III contained the four core polymerase motifs that are 
thought to be essential for polymerase function. These motifs (A, B, C and D) are well 
conserved in the hMPV L protein: hMPV shares nearly 100% aa sequence similarity with 
other pneumoviruses. For the entire domain III (aa 625- 847 in the hMPV L ORF), hMPV 
shares 83% aa sequence identity with APV, 67-68% with RSV and 26-30% with other 
paramyxoviruses (Figure 9). In addition to these polymerase motifs the pneumovirus L 
proteins contain a sequence which conforms to a consensus ATP-binding motif 
K(X)21GEGAGN(X)20K237.The hMPV L ORF contains a similar motif as APV, in which the 
spacing of the intermediate residues is off by one: K(X)22GEGAGN(X)19 K. 
 
Phylogenetic analyses  
As an indicator for the relationship between hMPV and members of the Pneumovirinae, 
phylogenetic trees based on the N, P, M, and F ORFs have been constructed previously256 
and revealed a close relationship between hMPV and APV-C. Because of the low sequence 
identity of the hMPV SH and G genes with those of other paramyxoviruses, reliable 
phylogenetic trees for these genes could not be constructed. In addition, the distinct genomic 
organisation between members of the Pneumovirus and Metapneumovirus genera make it 
difficult to generate phylogenetic trees based on the entire genomic sequence. We therefore 
only constructed phylogenetic trees for the M2-1 and L genes in addition to those previously 
published. Both these trees confirmed the close relation between APV and hMPV within the 
Pneumovirinae subfamily (Figure 10). 
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Figure 10: 
Phylogenetic analyses of the M2-1 and L 
ORFs of hMPV and selected paramyxoviruses. 
The putative M2-1 (A) and L (B) ORFs of 
hMPV were aligned with those from selected 
paramyxoviruses (see legend Figure 9) and 
phylogenetic trees were generated by 
maximum-likelihood analyses using 100 
bootstraps and three jumbles. The most 
probable trees are shown with numbers 
representing the boostrap values calculated 
from the consensus trees. The scale bars 
roughly represent 10% of nucleotide changes 
between close relatives. 
  Molecular characterisation of hMPV 
  
hMPV noncoding sequences 
The noncoding regions between the ORFs of pneumoviruses contain gene end signals, 
intergenic regions and gene start signals, and they vary in size and sequence17,48,62. The 
noncoding sequences between the hMPV ORFs range in size from 23 to 209 nt (Figure 11A) 
and do not reveal significant sequence identity with those of APV and RSV.  
The region between the M and F ORFs of hMPV contains part of a potential secondary ORF, 
which starts in the primary M ORF (see above). 
Figure 11: 
Noncoding sequences of hMPV isolate 00-1. (A) The noncoding sequences between the putative 
ORFs ant at the genomic termini are shown in the positive sense. From left to right, stop codons of 
indicated ORFs are shown, followed by the noncoding sequences, the gene start signals, and start 
codons of the indicated subsequent ORFs. Numbers indicate the first position of start and stop codons 
in the hMPV map. Sequences that display similarity to published gene end signals are underlined and 
sequences that display similarity to UAAAAAU/A/C are indicated with a line above the sequence. 
(B) Nucleotide sequences of the genomic termini of hMPV. The genomic termini of hMPV are 
aligned with each other and with those of APV. Underlined regions represent the primer sequences 
used in RT-PCR assays, which are based on the 3’and 5’end sequences of APV and RSV (Randhawa 
et al., 1997; Mink et al., 1991). Boldface italicalised nucleotides are part of the gene start signal of the 
N gene. Le, leader; Tr, trailer. 
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The region between SH and G ORFs of 201 nt does not appear to have coding potential 
based on the presence of numerous stop codons in all three reading frames.  
The region between G and L of 209 nt may encode additional ORFs in two reading frames 
(see above). Interestingly, the start of the L ORF is located in these secondary ORFs. 
Whereas the L gene of APV does not start in the preceding G ORF, the L ORF of RSV starts 
in the preceding M2 gene. Comparison of the noncoding sequences between the ORFs of 
hMPV revealed a consensus sequence for the gene start signal of the N, P, M, F, M2 and G 
genes: GGGACAA A/G U (Figure 11A), which is similar to the consensus gene start signal 
of the APV11,146,151,282. The gene start signals for the SH and L genes of hMPV were found to 
be slightly different from this consensus (SH: GGGAUAAAU, L: GAGACAAAU). For 
APV the gene start signal of L was also found to be different from the consensus: 
AGGACCAAT (APV-A)205 and GGGACCAGT(APV-D)11. In contrast to the similar gene 
start sequences of hMPV and APV, the consensus gene end sequence of APV, 
UAGUUAAUU33,205, could be found only in the F and L genes of hMPV. Variants of this 
motif, with 1 to 3 nt substitutions were found in the N, P, M, M2 and SH genes, but no 
homologue was found in G. Another repeated sequence (UAAAAA U/A/C) was found 
downstream each of the hMPV ORFs except G. The gene end signal described for G of APV 
Fr/85/111 was found also at the end of the G ORF of hMPV (Figure 11A).Although these 
sequences may represent (part of) the gene end signal, sequence analyses of viral mRNA is 
required to formally delineate the hMPV gene end signals.  
Short extragenic regions at the 3’ and 5’ extremities of the genome of paramyxoviruses are 
referred to as the leader and trailer sequences, and approximately the first 12 nt of the leader 
and last 12 nt of the trailer are complementary, probably because each of them contain basic 
elements of the viral promoter17,62,167. The 3’ leader of hMPV and APV are both 41 nt in 
length, and some sequence identity is seen in the region between nt 16 and 41 of both viruses 
(18 out of 26 nt) (Figure 11B). As mentioned before, the first 15 nt of the hMPV genomic 
map are based on a primer sequence derived from the APV genome. At the 5’ end of the 
viral genome of hMPV after the stop codon of the L ORF 179 nt of noncoding sequence is 
found, including the trailer sequence. Alignment of the APV trailer sequence with the 
extreme 45 nt of the hMPV genome revealed 24 out of 33 nt to be identical, excluding the 
extreme 12 nt which represent primer sequences based on the genomic sequence of APV 
(Figure 11B).  
  
 
Discussion 
 
Previously we proposed the classification of hMPV in the Metapneumovirus genus based on 
limited sequence information for this virus. The sequence information described here is in 
agreement with this classification. Our sequence analyses revealed the absence of NS1 and 
NS2 genes at the 3’ end of the genome and a genomic organisation resembling the 
organisation of metapneumoviruses (3’-N-P-M-F-M2-SH-G-L-5’). The high percentage 
sequence identity found between hMPV and APV ORFs further emphasises the close 
relationship between these two viruses. For the N, P, M, F, M2-1 and M2-2 ORFs of hMPV 
an overall aa identity of 80% is found with APV-C. In fact, for these genes APV-C and 
hMPV revealed percentages sequence identity which are in the same range as those found 
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between subgroups of other genera, such as RSV- A and -B or APV-A and -B. This close 
relationship between APV-C and hMPV is also seen in the phylogenetic analyses, which 
revealed hMPV and APV-C to be always in the same branch, separate from the branch 
containing APV-A and B. The identical genomic organisation, the high percentage sequence 
identity, and phylogenetic analyses are all in favor of the classification of hMPV as the first 
mammalian member in the Metapneumovirus genus.  
It should be noted that previously found sequence variation between different virus isolates 
of hMPV in the N, M, F and L genes revealed the possible existence of different 
genotypes256. Here we describe the genomic sequence of virus isolate 00-1, the prototype of 
one of the subgroups. Sequence analyses of the genome of a member of the other subgroup is 
in progress to further investigate the relationship between distinct hMPV isolates and APV.  
The close relationship between hMPV and APV-C is not reflected in the host range, since 
APV infects birds in contrast to hMPV256. This difference in host range may be determined 
by the differences between the SH and G proteins of both viruses. The SH and G proteins of 
hMPV did not reveal significant aa sequence identity with SH and G proteins of any other 
virus. Although the aa content and hydrophilicity plots are in favor of defining these ORFs as 
SH and G, experimental data are required to formally prove this. Such analyses will also 
shed light on the role of the additional overlapping ORFs in the putative G gene. Sequence 
analysis of a second hMPV isolate that belongs to a distinct genetic lineage256 revealed the 
presence of a similar primary G ORF and the presence of secondary ORFs (data not shown). 
However, the positions and sizes of the secondary ORFs were not identical to those of isolate 
00-1. Sequence analyses of the SH and G genes of APV-C might provide more insight in the 
function of the putative SH and G proteins of hMPV and their relationship with those of 
APV-C. 
Some of the noncoding regions of hMPV were found to be similar to those of APV. The 
3’leader and 5' trailer sequences of APV and hMPV displayed a high percentage of sequence 
identity. Although the lengths of the intergenic regions were not always the same for APV 
and hMPV, the consensus gene start signals of most of the genes were found to be identical 
and some similarity may exist between potential gene end signals of APV and hMPV. 
Sequence analysis of viral mRNAs is required to formally delineate the gene end sequences 
of hMPV. It should also be noted that sequence information for 15 nt at the extreme 3' end 
and 12 nt at the extreme 5' end are still missing. This information will be of crucial 
importance for the development of reverse genetics systems for hMPV, as was shown 
recently for RSV and APV 161. Nevertheless, the sequence information provided here will be 
of importance for the generation of diagnostic tests, vaccines, and antivirals for hMPV.  
 
 
Materials and Methods 
 
Sequence analysis 
Virus isolate 00-1 was propagated to high titers (approximately 10,000 TCID50/ml) on 
tertiary monkey kidney cells as described previously256. Viral RNA was isolated from 
supernatants from infected cells using a High Pure RNA Isolating Kit according to 
instructions from the manufacturer (Roche Diagnostics, Almere, The Netherlands). Primers 
were designed based on sequences published previously256 in addition to sequences 
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published for the leader and trailer of APV/RSV167,204 and are available upon request. RT-
PCR assays were conducted with viral RNA, using a one-tube assay in a total volume of 
50µl with 50 mM Tris pH 8.5, 50 mM NaCl, 4.5 mM MgCl2, 2 mM DTT, 1 µM forward 
primer, 1µM reverse primer, 0.6 mM dNTP’s, 20 units RNAsin (Promega, Leiden, The 
Netherlands), 10 U AMV reverse transcriptase (Promega, Leiden, The Netherlands), and 5 
units Taq Polymerase (PE Applied Biosystems, Nieuwerkerk aan den IJssel, The 
Netherlands). Reverse transcription was conducted at 42°C for 30 min, followed by 8 min 
inactivation at 95°C. The cDNA was amplified during 40 cycles of 95°C for 1 min, 42°C for 
2 min, 72°C for 3 min, with a final extension at 72°C for 10 min. After examination on a 1% 
agarose gel, the RT-PCR products were purified from the gel using a Qiaquick Gel 
Extraction kit (Qiagen, Leusden, The Netherlands) and sequenced directly using a Dyenamic 
ET terminator sequencing kit (Amersham Pharmacia Biotech, Roosendaal, The Netherlands) 
and an ABI 373 automatic DNA sequencer (PE Applied Biosystems, Nieuwerkerk aan den 
IJssel, The Netherlands), according to the instructions of the manufacturer. 
Sequence alignments were made using the Clustal software package available in the software 
package of BioEdit version 5.0.6.107 (http://jwbrown.mbio.ncsu.edu/Bioedit/bioedit.html).  
 
Phylogenetic analysis 
To construct phylogenetic trees, DNA sequences were aligned using the ClustalW software 
package and maximum likelihood trees were generated using the DNA-ML software package 
of the Phylip 3.5 program using 100 bootstraps and three jumbles. Bootstrapping is a method 
for deriving confidence values for the groupings in a tree, which involves making random 
samples of sites from the alignment, drawing trees from each sample, and counting how 
many times each grouping from the original tree occurs in the sample trees. Bootstrap values 
were computed for consensus trees created with the consense package82. 
The hMPV genomic sequence is available from Genbank under accession No. AF371337. 
All other sequences used here are available from Genbank under accession Nos. AB046218 
(measles virus, all ORFs), NC001796 (human parainfluenza virus type 3, all ORFs), 
NC001552 (Sendai virus, all ORFs), X57559 (human parainfluenza virus type 2, all ORFs), 
NC002617 (Newcastle Disease virus, all ORFs), NC002728 (Nipah virus, all ORFs), 
NC001989 (bRSV, all ORFs), M11486 (hRSV A, all ORFs except L), NC001803 (hRSV, L 
ORF), NC001781 (hRSV B, all ORFs), D10331 (PVM, N ORF), U09649 (PVM, P ORF), 
U66893 (PVM, M ORF), U66893 (PVM, SH ORF), D11130 (PVM, G ORF), D11128 (F 
ORF), AF176590 (APV-C, N ORF), U39295 (APV-A, N ORF), U39296 (APV-B, N ORF), 
AF262571 (APV-C, M ORF), U37586 (APV-B, M ORF), X58639 (APV-A, M ORF), 
AF176591 (APV-C, P ORF), AF325443 (APV-B, P ORF), U22110 (APV-A, P ORF), 
AF187152 (APV-C, F ORF), Y14292 (APV-B, F ORF), D00850 (APV-A, F ORF), 
AF176592 (APV-C, M2 ORF), AF356650 (APV-B, M2 ORF), X63408 (APV-A, M2 ORF), 
U65312 (APV-A, L ORF), S40185 (APV-A, SH ORF). The PVM M2 ORF was taken from 
Ahmadian et al. (1999)1.  
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   Genetic and antigenic variability of hMPV 
  
Abstract 
  
Human metapneumovirus (hMPV) is a member of the subfamily Pneumovirinae within the 
family Paramyxoviridae. Other members of this subfamily, respiratory syncytial virus and 
avian pneumovirus, can be divided in subgroups based on genetic and/or antigenic 
differences. For hMPV the existence of different genetic lineages has been described based 
on variation in a limited set of available sequences. In the present study we addressed the 
antigenic relationship between the different genetic lineages in virus neutralisation assays. In 
addition, we analysed the genetic diversity of hMPV by phylogenetic analysis of sequences 
obtained for part of the fusion protein (n=84) and the complete attachment protein open 
reading frames (n=35). On the basis of sequence diversity between attachment protein genes 
and the differences in virus neutralisation titers, two hMPV serotypes were defined. Each 
serotype could be divided in two genetic lineages, but these did not reflect significant 
antigenic differences. 
 
Introduction 
 
The human metapneumovirus (hMPV) has recently been identified as a causative agent of 
respiratory tract illnesses (RTI) in humans world-wide77,90,186, and is a member of the 
Pneumovirinae subfamily within the Paramyxoviridae family259. The Pneumovirinae 
subfamily consists of two genera: the pneumoviruses and the metapneumoviruses. Human 
respiratory syncytial virus (hRSV) the major viral cause of severe RTI in children, is the type 
species of the pneumoviruses46. Avian pneumovirus (APV), the causative agent of RTI in 
turkeys and chickens96 was the sole member of the Metapneumovirus genus until the 
discovery of hMPV118. 
For most pneumoviruses different subgroups or subtypes have been identified. For hRSV, 
two subgroups have been identified based on differences in nucleotide sequences, reactivity 
patterns with monoclonal antibodies and in vitro neutralisation assays with subgroup-specific 
antisera7,37,95,176. Additional genotypes have been identified within subgroups, largely based 
on the high variability of the attachment protein gene29,241. The fusion (F) and the attachment 
(G) proteins are the main targets for the neutralising and protective antibody response6,125,184, 
with F being one of the most conserved proteins and G the most variable123,124,130,179. For 
APV two different subgroups (A and B) have been defined on the basis of nucleotide 
sequences of the G protein and neutralisation tests using monoclonal antibodies that also 
recognise the G protein, but these subgroups belonged to one serotype52. APV type C, a 
possible second serotype, was identified based on the lack of cross reactivity with antisera 
specific for groups A and B and the nucleotide sequences also proved to be significantly 
different from strains belonging to group A or B222,224. In addition, there is evidence for a 
subgroup D containing isolates from France that are not neutralised by monoclonal 
antibodies raised against viruses belonging to either subgroup A, B or C11. 
For hMPV two major genetic lineages have been identified world-wide based on analysis of 
a limited set of sequences192,192,239,256. One of the features of hMPV that poses a challenge to 
future vaccine development is that infections may occur in the presence of pre-existing 
immunity. Very young children (<1 year) were shown to be infected by the virus, and re-
infections have also been demonstrated191. hMPV might cause repeated infections throughout 
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life similar to RSV, which could be due either to incomplete immunity or to genetic 
heterogeneity of the virus.  For the development of vaccines it is important to develop a 
thorough understanding of the extent of genetic and antigenic variability of the different 
hMPV transmembrane glycoproteins. In the present study we analysed the genetic diversity 
of hMPV by phylogenetic analyses of sequences obtained for part of the F (n=84) and the 
complete G open reading frames (ORFs) (n=35). In addition, we addressed the antigenic 
relationship between the different lineages with virus neutralisation (VN) assays using 
lineage-specific antisera raised in ferrets. Classical virology studies have used a definition of 
a homologous-to-heterologous VN titer ratio of more than 16 as a definition for serotypes87. 
Based on the results shown in the present work, and based on the described definition, we 
now define the two major lineages of hMPV as serotype A and B. In accordance with the 
definition and the obtained results the sublineages within each serotype are not identified as 
different serotypes. The presence of at least two serotypes of hMPV in the human population 
has implications for the development of intervention strategies, such as immunisation and 
vaccination. 
 
 
Materials and Methods 
Sample collection, RNA isolation, RT-PCR assays and sequencing 
HMPV positive nasopharyngeal aspirate samples were obtained from different cohort 
studies: 61 samples from The Netherlands, 11 samples from Finland, 8 samples from 
England, one from Hong-Kong and two from Brazil. Clinical samples had been obtained 
between 1981 and 2002. Samples were obtained from young children, infants, adults, elderly 
and immune compromised individuals and these patients suffered from mild RTI to severe 
RTI. Epidemiological and clinical data for most isolates have been described 
elsewhere30,120,258. 
Similar to the influenza nomenclature, sequences are identified by the country of origin, an 
identification number and the year of isolation. RNA isolation was performed as described 
previously256. cDNA was synthesised at 42°C for 60 minutes with random hexamer primers 
(Promega, Leiden, The Netherlands) and superscript II RNase H-reverse transcriptase 
(Invitrogen, Merelbeke, Belgium). An aliquot of cDNA was used in a PCR assay to amplify 
the full-length G ORF or a fragment of the F ORF. Primers: SH7: 5’- 
TACAAAACAAGAACATGGGACAAG-3’ and SH-8 5’-GAGATAGACATTAACAGTG-
GATT-3’ (G ORF), BF100 5’-CAATGCAGGTAT AACACCAGCAATATC-3’ and BF101 
5’-GCAACAATTGAACTGATCTTCAGGAAAC-3’ (F ORF). Thermocycling conditions: 
94 °C for 1 min., 40 °C for 2 min., 72 °C 3 min. (40 cycles). When necessary a nested PCR 
was performed using 5 µl of PCR product with primers SH7 and SH8 for the G ORF or 
primers BF 103 5’-ACATGCCAACATCTGCAGGACAAA TAAAAC-3’ and BF104 5’-
ACATGCTGTTCACCTTCAACTTTGC-3’ for the F ORF. PCR products were sequenced 
directly on both strands with multiple primers as described before256. When identical 
sequences were obtained (suspicious of laboratory contamination), and to confirm sequence 
uncertainties such as frame shifts, we repeated the RNA isolation, RT-PCR and subsequent 
sequencing using the original materials. 
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Phylogenetic analysis  
Nucleotide sequences were aligned using the Clustal W program running within the Bioedit 
software package, version 5.0.9. Maximum likelihood trees were generated with the Seqboot 
and Dnaml packages of Phylip version 3.6 using 100 bootstraps and 3 jumbles. The 
consensus tree was calculated using the Consense package of Phylip 3.6 and was 
subsequently used as usertree in Dnaml to recalculate the branch lengths from the nucleotide 
sequences. Finally, the trees were rerooted at midpoint using the Retree software of Phylip 
3.6. Trees were visualised with the Treeview 1.6.6 program distributed with Bioedit version 
5.0.982.  Sequences are available from Genbank under accession numbers AY295930 to 
AY296012 (F partial) and AY304360 to AY304362 (complete F for NL/17/00, NL/1/99 and 
NL/1/94 respectively), AF371337 (complete genome NL/1/00) and AY296014 to AY296047 
(complete G regions). 
 
Virus preparations and titration’s 
Viruses were isolated on tertiary monkey kidney (tMK) cells as described before256. For each 
genetic lineage a prototype virus isolate was chosen on the basis of its ability to grow to high 
titers on tMK cells, and to reflect the specific genotype for the lineage. Virus titrations were 
cultured for 7 days and infected wells were identified by immune fluorescence assays (IFA) 
with hMPV specific polyclonal antiserum raised in guinea pigs. Titers were expressed in 
50% tissue culture infectious dose (TCID50 ). 
  
Antisera  
Lineage-specific polyclonal hMPV antisera were raised by inoculating ferrets with 1 ml of 
virus-infected tMK supernatants containing approximately 104-105 TCID50 virus. All 
inoculations were performed in duplo, and the animals with the highest antibody responses 
are shown. Sera were collected at days 0 and 28 post infection (ferret I and II) or at days 0 
and 21 (ferret III to VI). Inoculations were performed as follows: ferrets I and III: hMPV 
NL/1/00, prototype virus for lineage A1. Ferrets II and V: hMPV NL/1/99, prototype virus 
for lineage B1. Ferret IV: hMPV NL/17/00, prototype virus for lineage A2 and ferret VI: 
hMPV UK/5/01 a virus from lineage B2. Ferrets were housed in isolator cages to avoid 
cross-infections.  
HMPV-specific polyclonal antisera were raised in guinea pigs as described before256. 
Antisera raised in separate guinea pigs against viruses from the two main genetic lineages (A 
and B) were mixed 1:1, and this mixture tested positive against all hMPV isolates in IFA. 
 
Virus neutralisation assays 
VN assays of heat-inactivated (30 min. 56 °C) ferret sera were performed as described 
before256. Briefly, twofold serial serum dilutions starting at 1:8 were incubated with 
approximately 30 TCID50 virus. Seven days after infection of tMK cells with the 
antibody/virus mixture, IFA with the guinea pig antiserum was performed. The VN titer was 
defined as the reciprocal of the highest serum dilution at which no positive IFA signal was 
obtained (depicted as means of duplicate measurements). Each experiment included virus 
titrations of the working solution of the virus, using two-fold dilutions, and a range of 10 to 
100 TCID50/well was considered acceptable. 
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Results 
 
Variation in the fusion protein gene 
Partial F gene sequences (nucleotide (nt) 780-1221 in the F ORF) were obtained from 
clinical samples collected from 84 hMPV-infected patients. Phylogenetic analysis of these 
sequences confirmed the presence of two main genetic lineages, A and B. Each of these 
lineages appeared to consist of two sublineages, which were tentatively named A1, A2, B1 
and B2 (Figure 1A). Comparison of the sequences revealed high percentage identities 
between members of the same sublineage (nt: 97-100%, aa: 99 to 100%), members of the 
two different sublineages within each main lineage (nt: 94 –96%, aa: 97-99%) and even 
between members of the two different main lineages A and B (nt: 84 –86%, aa: 94-97%). 
Whereas no specific amino acid (aa) residue substitutions could be found between sequences 
from subgroups A1 and A2, there were 5 specific aa substitutions between sequences from 
genotypes A and B, and one substitution between B1 and B2 (Table 1). The low variability 
was also observed when complete F protein genes from prototype viruses for each sublineage 
were sequenced (Figure 2). 
 
Variation in the attachment protein gene 
Nucleotide sequences of the region between the start codons of the G and the polymerase (L) 
open reading frame (ORF) were obtained for 35 samples. Phylogenetic analysis revealed the 
same clustering of the sequences over the four sublineages as seen for the F protein gene 
(Figure 1B). The G region showed some variation in length, ranging from 860-908 nt. The 
first 657-708 nt have been described as the putative primary G ORF259. Alignment of the 
primary G ORFs revealed a variation in length of these ORFs even for members of the same 
sublineage, due to single nt substitutions that resulted in premature termination codons 
(Figure 3). For two samples a change in reading frame was observed as a result of an 
addition (BR/2/01: G pos. 519) or a deletion (NL/2/93: C at position 243) of a single nt. 
These mutations resulted in relatively short G ORFs (NL/2/93 110 aa; BR/2/01: 193 aa) 
because of premature termination and in drastic changes in the deduced amino acid 
sequences of the carboxy-terminus of the G proteins. 
Table 1: Lineage-specific amino acid substitutions between the four sublineages in the fusion open 
reading frame between position 260 and 407. 
 
 
Sublineage AA286 AA296 AA312 AA348 AA404 
A1 V K Q K N 
A2 V K Q K N 
B1 I N K R P 
B2 I D K R P 
 
C
ha
pt
er
 4
 
  62 
   Genetic and antigenic variability of hMPV 
  
Figure 1: 
Phylogenetic trees constructed 
based on the (A) partial F gene 
(ORF position 780-1221, n=84) 
or (B) the complete G coding 
region (start G ORF to start L 
ORF, n=35). Trees were 
generated by maximum 
likelihood analysis using 100 
bootstraps and 3 jumbles. The 
scale representing the percentage 
of nucleotide changes is shown 
for each tree. Bootstrap values 
are based on the consensus trees, 
and relevant numbers are shown 
in the tree. The four prototype 
viruses are shown in boldface, 
with ovals drawn around them. 
NL = viruses from the 
Netherlands; FN= viruses 
obtained from Finland; UK= 
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Comparison of the primary G ORF sequences, excluding sequences of NL/2/93 and BR/2/01 
because of the putative frameshifts, revealed a relatively high percentage identity between 
members of the same sublineage (nt: 93-100%, aa: 75 to 99.5%), less identity between 
members of the two different sublineages within each main lineage (nt: 76-83%; aa: 60-75%) 
and low sequence identity between members of the two different main lineages A and B (nt: 
50-57%, aa: 30-37%).  
The position of the hydrophobic domain, a high percentage of proline, serine and threonine 
residues and a cysteine residue at position 27 are features shared by all hMPVs. Whereas the 
cytoplasmic tail was conserved among all members (58-70% aa identity), the proposed 
ectodomains (start aa 51) were quite variable (18 –25% aa identity between lineage A and 
B). The number and position of potential sites for N-linked glycosylation sites varied even 
within each sublineage, ranging from 2 to 6 potential sites, with one located at the proposed 
cytoplasmic tail conserved among all lineages. 
 
 
Figure 2: 
Amino acid sequence comparison for the fusion genes of prototype hMPV isolates of each 
sublineage. The predicted signal peptide, fusion domain and membrane anchor are shown in italics in 
boldface type, the cleavage sites are boxed and the region sequenced for 84 samples is underlined in 
boldface type. Periods indicate the position of identical aa residues relative to isolate NL/1/00. 
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Figure 3:  
Amino acid sequence 
comparison of the putative 
attachment (G) protein of 
hMPV strains per genetic 
lineage. For each lineage 
only representative samples 
are depicted, resulting in 24 
sequences. Representative 
sequences were chosen, so 
that form each year in 
which samples were 
obtained at least one 
sequence is depicted, and 
sequences with only a few 
amino acid substitutions 
were omitted. Potential N-
linked glycosylation sites 
are underlined, and periods 
indicate the position of 
identical aa residues 
relative to the first sequence 
in each subgroup. Numbers 
indicate the nucleotide 
position in the primary G 
ORF. 
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Geographical and temporal distribution 
Analysis of hMPV sequences obtained from samples received from different countries 
revealed that sequences from Finland, the United Kingdom, and the limited sequences from 
Asia and Southern America, were found on branches between the Dutch sequences in the F 
tree, and not as a separate lineage. The variation between sequences obtained from samples 
from a single country was found in the same range as the variation found between samples 
obtained from different countries. In agreement with the genetic lineages of hMPV observed 
world wide, which usually includes sequences similar to those of isolate NL/1/00 or 
NL/1/99, geographical clustering does not appear to apply to hMPV. The different hMPV 
samples were obtained over the last 20 years with most of them in the years 2000 until 2002 
and fourteen from the 1990’s. As indicator for possible fixation of aa variation over time, we 
analysed the G ORF aa sequence of members in sublineage A2 and B1 (containing samples 
from 1981 to 2002) in more detail. The aa sequence variation between the viruses from 1981 
and 2001 was in the same range as the variation found between viruses from 2001, and 
alignments of the sequences did not reveal fixation of aa changes between 1981 and 2002. 
Thus, antigenic drift, as observed for influenza A and B viruses, does not appear to be an 
important phenomenon for hMPV. 
 
Table 2: 
Homologous and 
 heterologous VN 
antibody titers of sera 
obtained from ferrets 
infected with hMPV 
viruses belonging to 
different genetic 
sublineages. (A) VN 
antibody titers obtained in 
three independent 
experiments for sera 
collected 28 days post 
infection from ferrets I 
and II (infected with 
NL/1/00 and NL/1/99, 
respectively). (B) VN 
antibody titers obtained 
for sera collected 21 days 
post infection from ferrets 
III to VI (infected with 
NL/1/00, NL/17/00, 
NL/1/99 and UK/5/01, 
respectively). 
A 
Experiment Virus used 
in VN 
TCID50/
well 
Ferret I 
NL/1/00  
[A1] 
Ferret II 
 NL/1/99 
 [B1] 
1 NL/1/00 12 1024 32 
 NL/1/99 9 16 512 
     
2 NL/1/00 30 1024 8 
 NL/1/99 20 8 768 
     
3 NL/1/00 40 768 24 
 NL/1/99 25 16 768 
Ratio A-B    48-128  
Ratio B-A    16-96 
 
 
B 
Virus used 
in VN 
Ferret III  
 NL/1/00 
 [A1] 
Ferret IV  
 NL/17/00 
 [A2] 
Ferret V 
 NL/1/99 
 [B1] 
Ferret VI 
 UK/5/01  
 [B2] 
 
 
NL/ 1/00  
 
256 
 
256 
 
6 
 
32 
NL/17/00  512 768 12 24 
NL/ 1/99  16 32 256 384 
UK/ 5/01  12 64 256 512 
Ratio A-B 
Ratio B-A 
16-21 12-24 
 
 
21-43 
 
16-21 
 
Homologous VN titers are underlined, values are average of duplicate measurements, 
ratio’s are given as the homologous VN titer divided by the heterologous titers. 
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Antigenic variation 
To address the antigenic variation between the genetic lineages A and B, we raised antisera 
in ferrets against isolate NL/1/00, the prototype virus for lineage A1 and against isolate 
NL/1/99, the prototype virus for lineage B1. The sera were collected 28 days post infection 
and tested in VN assays against the homologous and heterologous viruses. In three 
independent experiments, the virus titer used per well varied between 10 and 50 TCID50, 
which variation did not affect the measured VN titers (Table 2A). Ferret I, infected with the 
lineage A prototype virus (NL/1/00), showed a 48 to 128 –fold higher VN titer against the 
homologous virus NL/1/00 than to the heterologous virus NL/1/99. Similarly, ferret II, 
infected with the lineage B prototype virus NL/1/99, had a 16 to 96-fold higher homologous 
than heterologous VN titer. In a second experiment, ferret antisera were raised to viruses 
from all four sublineages, and to measure the most specific serological response, sera were 
collected 21 days post infection after which homologous and heterologous VN titers were 
measured (Table 2B).  
Within each main genetic lineage, a high degree of cross-neutralisation was observed 
between viruses from the two sublineages (e.g. A1 vs A2 and B1 vs. B2), which is reflected 
in the low ratio between homologous to heterologous VN titers: 0.5 to 3.0. Although sera 
from ferret III to VI had slightly lower homologous VN titers than those of ferrets I and II, 
sera raised against viruses from the main lineage A still showed a 12 to 24 fold higher VN 
titer against the lineage A viruses than to lineage B viruses. Similarly, sera raised against 
viruses from lineage B had a 16 to 43 fold higher VN titer against the lineage B viruses than 
to lineage A viruses. 
 
 
Discussion 
 
In the present study the genetic heterogeneity of hMPV was addressed by analysis of the 
nucleotide and predicted amino acid sequences of part of the F (n=84), complete F (n=4), 
and the complete G (n=35) protein genes. Phylogenetic analysis of these sequences revealed 
the presence of two main lineages (A and B) with each divided into two sublineages (1 and 
2). As for RSV and APV, the F protein was highly conserved, which is in agreement with F 
proteins of pneumoviruses having structural and functional constraints for amino acid 
mutations236. Based on the high percentage sequence identity for the complete F proteins of 
the prototype viruses of the four lineages, sequences for the complete F proteins of all 84 
samples would probably demonstrate similar low variability. In contrast to the F protein, the 
nucleotide and predicted amino acid sequences of the complete G coding regions revealed 
high sequence diversity (as low as 30-37% aa identity). Besides the high amino acid 
sequence variation, we observed variation in length of the different G proteins. Where most 
of the length variation was due to nucleotide substitutions, two of the samples revealed a 
change in reading frame due to deletion or addition of single nucleotides. Frameshift 
mutations and use of alternative reading frames have been described for RSV28,28,91,243,243. As 
described for isolate NL/1/00, the G coding region of the 35 samples sequenced in the 
present work revealed long alternative reading frames. However these secondary ORFs 
varied in length and position compared to the ones described259. Whether the presence of 
premature stopcodons and the incidence of frame shift mutations and possible use of 
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alternative reading frames have influence on the antigenic properties of the viruses needs to 
be examined in more detail. 
Phylogenetic analyses revealed that the hMPV samples obtained from different years and 
from different countries were randomly distributed over all four sublineages. For RSV it has 
also been reported that very similar viruses were isolated at different times and from 
geographical distant sites28. Different lineages within RSV subgroup A and B have been 
found based on the variation in the G protein. Within each subgroup progressive 
accumulation of amino acid changes was noted, suggesting that the G protein of RSV might 
be susceptible to immune pressure28. Analysis of the amino acid sequences of the hMPV 
samples described in the present study did not reveal indications of such accumulation over 
time. However the observations that I) most of the amino acid sequence variation was found 
in the extracellular domain of the G protein and II) the variation found at the amino acid 
sequence level was higher than that at the nucleotide sequence level and III) the number and 
position of potential glycosylation sites were not conserved and IV) deletions, additions and 
substitutions of single nucleotides resulted in premature stopcodons and drastic changes of 
the carboxy terminal of the protein, indicate that the variation of the hMPV G protein might 
occur as a result of immunogenic pressure in a same manner as was postulated for the RSV 
G protein28,124,124. Until a larger number of more chronologically diverse hMPV samples 
have been examined this issue remains inconclusive. 
To address the antigenic relationship between members of the different hMPV lineages, we 
tested ferret sera raised against viruses from the four sublineages in VN assays. Serological 
responses upon infections tend to broaden over time. Based on the relatively close genetic 
relationship between sublineages A1 and A2 or B1 and B2, we decided to collect sera at an 
early time point, in order to obtain large antigenic differences between the four sublineages. 
The low homologous VN titers in sera collected 21 dpi may explain the lower ratio between 
homologous and heterologous VN titers as compared to sera collected 28 dpi. The studies 
with sera collected at 21 dpi revealed that viruses within one main lineage (e.g. A1 and A2 or 
B1 and B2) were antigenically closely related. The difference in homologous and 
heterologous VN titers between members of the two different lineages A and B (12 to 128 
fold higher homologous titer than heterologous titer) indicate a difference in antigenicity 
between lineage A and B. Classical virology studies have used a definition of a homologous-
to-heterologous VN titer ratio of more than 16 for defining serotypes. This same definition 
notes that if neutralisation shows a certain degree of cross-reaction between two viruses in 
either or both directions (homologous-to-heterologous titer ratio of 8 or 16), distinctiveness 
of serotype is assumed if substantial differences in sequences are observed87. Based on the 
presented results, and based on the described definition, we here propose to define the two 
main lineages of hMPV as serotypes A and B. The hMPV samples were obtained from 
different study populations, from different countries and from patients with a wide spectrum 
of clinical signs. So far, we have no indication for an association between infection with 
either of the serotypes and a specific study group or with severity of disease. More 
epidemiological studies are needed to address this issue.  
The circulation of two serotypes of hMPV might have implications for the development of 
vaccines. Studies in cynomolgous macaques revealed that re-infection is suppressed by high 
titers of VN antibodies against the homologous virus and far less by heterologous VN 
antibodies (data not shown). So far, for humans only one –heterologous- reinfection has been 
reported191. However, it has been shown that children around the age of five have higher VN 
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antibody titers than those at the age of one or two256 suggesting that re-infections may occur 
frequently, most likely with the viruses from the heterologous serotype. For RSV, the 
significance of difference in antigenicity between the two subgroups regarding protective 
immunity and vaccine development is still subject of discussion. However, in animals and in 
humans the neutralising capacity against homologous viruses is higher than that against 
heterologous viruses and in animals high homologous VN titers protect against re- infection. 
In humans it has been shown that re-infection often occurs with a strain from the 
heterologous group, and high homologous VN antibodies titers protect against severe 
infection (reviewed in 241). The two serotypes of hMPV might resemble the two subgroups 
of hRSV in immunogenic properties, although more extensive epidemiological and 
immunological studies have to prove this. It may well be that the cross-reactive immunity 
provided by the F protein is sufficient to overcome the effects of changes in the G protein. 
For hRSV the immune response against the F protein is cross reactive between subgroup A 
and B, whereas the response against the G protein is subgroup (and sometimes even 
genotype) specific125,128,128,184,184. The prophylactic use of a VN monoclonal antibody 
preparation directed against the RSV-F protein has been shown to decrease the severity of 
lower respiratory tract diseases caused by both subgroups of RSV104,110,110,231,231. In a similar 
way, the conserved F protein of hMPV could be a target for the development of monoclonal 
antibodies for treatment of hMPV-infected individuals. 
The data presented in this work support a technical description of two serotypes of hMPV in 
experimentally infected ferrets. It will be of interest to identify the existence and relevance of 
these serotypes in other animal species, including humans.  
Our results in combination with data published by others18,192,239192,239 demonstrate that 
hMPV clusters in two globally distributed serotypes. However, the identification of two 
serotypes does not exclude the possible existence of more serotypes or sublineages. The 
described viruses were all identified by using primers against conserved regions in the 
genome of the four prototype viruses, but in order to allow identification of more diverse 
hMPV strains, virus isolation of original materials is a standard procedure in our laboratory. 
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Abstract 
 
A substantial proportion of hitherto unexplained respiratory tract illnesses is associated with 
human metapneumovirus (hMPV) infection. This virus also was found in patients with 
severe acute respiratory syndrome (SARS). To determine the dynamics and associated 
lesions of hMPV infection, six cynomolgus macaques (Macaca fascicularis) were inoculated 
with hMPV and examined by pathological and virological assays. They were euthanised at 5 
(n = 2) or 9 (n = 2) days post infection (dpi), or monitored until 14 dpi (n = 2). Viral 
excretion peaked at 4 dpi and decreased to zero by 10 dpi. Viral replication was restricted to 
the respiratory tract and associated with minimal to mild, multifocal erosive and 
inflammatory changes in conducting airways, and increased numbers of macrophages in 
alveoli. Viral expression was seen mainly at the apical surface of ciliated epithelial cells 
throughout the respiratory tract, and less frequently in type 1 pneumocytes and alveolar 
macrophages. Both cell tropism and respiratory lesions were distinct from those of SARS-
associated coronavirus infection, excluding hMPV as the primary cause of SARS. This study 
demonstrates that hMPV is a respiratory pathogen and indicates that viral replication is short-
lived, polarised to the apical surface, and occurs primarily in ciliated respiratory epithelial 
cells. 
 
 
Introduction 
 
A substantial proportion of hitherto unexplained respiratory tract illnesses in human beings is 
associated with infection by a recently discovered paramyxovirus, provisionally named 
human metapneumovirus (hMPV)256. It is most closely related to avian pneumovirus type C 
(APV), the aetiologic agent of rhinitis and sinusitis in turkeys256,259. Human 
metapneumovirus was first identified in The Netherlands, where serologic studies indicate 
that it has been circulating in the human population since at least 1958 and that most children 
are infected by 5 years of age256. Since its discovery in The Netherlands, hMPV infection 
also has been reported elsewhere in Europe90,120,239,260 and in North America75,192, Asia70,190, 
and Australia182. Respiratory tract disease associated with hMPV infection occurs both in 
children and adults, suggesting that hMPV is capable of causing clinically important 
reinfection of individuals later in life. Clinically, hMPV-associated disease includes rhinitis, 
pharyngitis, bronchitis, bronchiolitis, and pneumonia, and resembles that of human 
respiratory syncytial virus (RSV) infection255. Severity of disease varies from common cold 
to death, with very young children, the elderly, and immunocompromised patients being 
predisposed to severe lower respiratory tract disease255. In the recent epidemic of severe 
acute respiratory syndrome (SARS), the role of hMPV as a primary pathogen or co-pathogen 
was considered198,255. Although a newly discovered virus, SARS-associated coronavirus 
(SCV), proved to be the primary cause of the disease86,189, 12% (41/335) of SARS patients 
also were infected with hMPV139,  so that the role of hMPV as a copathogen cannot be ruled 
out at this time. Until now, pathologic confirmation that hMPV is a primary respiratory 
pathogen is lacking18. Diagnosis of hMPV as the aetiologic agent of respiratory illness in the 
above studies was based on virus isolation, reverse transcription-polymerase chain reaction 
(RT-PCR), seroconversion to hMPV, or a combination of these methods, combined with the 
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failure to detect other known respiratory pathogens. In order to characterise the virus 
excretion, virus distribution, and associated lesions of hMPV infection, and to determine 
whether they differ from those of SCV infection, we experimentally inoculated six 
cynomolgus macaques (Macaca fascicularis) with the prototype hMPV isolate NL/1/00. 
They were euthanised at 5 (n = 2) or 9 (n = 2) days post infection (dpi), or monitored until 14 
dpi (n = 2). Here, we report the pathological, immunohistochemical, virological, serological, 
and molecular biological findings of this experiment. 
 
 
Materials and methods 
 
Virus preparation 
The prototype hMPV isolate NL/1/00 was propagated three times on tertiary monkey kidney 
(tMK) cells and used to make a virus stock on tMK cells as previously described256. Virus 
was harvested 7 dpi and frozen in 25 % sucrose at –70 °C. The infectious virus titer of this 
stock was 104.5 median tissue culture infective dose (TCID50) per ml by titration on tMK 
cells. 
 
Experimental protocol 
Five days before infection, six juvenile, colony-bred cynomolgus macaques were placed in a 
negatively pressurised glove box in pairs of one male and one female. The macaques were 
infected with 5.0 x 104 TCID50 of hMPV, which was suspended in 5 ml of phosphate-
buffered saline (PBS). Approximately 4 ml was applied intratracheally by use of a catheter, 
0.5 ml on the tonsils, and 0.25 ml on each of the conjunctivae.The macaques were observed 
daily for the occurrence of malaise, coughing, exudate from the eyes or nose, forced 
respiration, and any other signs of illness. Macaques #1 and #2 were euthanised at 5 dpi and 
macaques #3 and #4 at 9 dpi by exsanguination under ketamine anesthesia, while macaques 
#5 and #6 were monitored until 14 dpi. The body temperatures of macaques #5 and #6 were 
measured by telemetry (IMAG, Wageningen, The Netherlands) every 3 min. To this end, a 
transponder was placed in their abdomens 30 days before inoculation. Just before infection 
and daily from 2 dpi until euthanasia or 10 dpi, the macaques were anesthetised with 
ketamine and pharyngeal swabs were collected in 1 ml transport medium 85 and stored at –70 
°C until RT-PCR and/or virus isolation. In addition, blood was collected from an inguinal 
vein just before infection in all macaques and at 14 dpi in macaques #5 and #6. Blood 
samples were collected in EDTA tubes and centrifuged at 2500g for 15 min, the plasma was 
collected and stored at –70 °C until immunofluorescence assay.  
 
Pathologic examination 
Necropsies were carried out according to a standard protocol. Samples for histological 
examination were stored in 10% neutral-buffered formalin (lungs after inflation with 
formalin), embedded in paraffin, sectioned at 4 mm, and stained with hematoxylin and eosin 
(H & E) for examination by light microscopy. The following tissues were examined by light 
microscopy: adrenal gland, brain stem, cerebellum, cerebrum, heart (left and right ventricle), 
kidney, larynx, lung (left and right; cranial, medial and caudal lobes), liver, nasal septum 
(posterior section covered by respiratory epithelium), pancreas, primary bronchus (left and 
right), small intestine, spleen, stomach, tonsil, trachea, tracheo-bronchial lymph node, upper 
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eyelid (left and right), urinary bladder. Tissue sections of a clinically healthy juvenile male 
cynomolgus macaque that had not been infected with hMPV were used as a negative control.  
  
Immunohistochemistry 
Formalin-fixed, paraffin-embedded, 4 mm-thick sections of the same tissues examined by 
light microscopy were stained using an immunoperoxidase method. Tissue sections were 
mounted on coated slides (Klinipath, Duiven, The Netherlands), deparaffinised, rehydrated 
and boiled for 15 min in citric acid buffer (10mM, pH6.0) using a microwave oven. 
Endogenous peroxidase was revealed with 4-chloro-1-naphthol (Sigma Chemical Co., St. 
Louis, MO), yielding a blue-black precipitate. Sections were subsequently washed with PBS 
containing 0.05% Tween 20 (Fluka, Chemie AG, Buchs, Switzerland) and incubated with a 
polyclonal guinea pig antiserum (dilution 1:200) to hMPV prepared as described previously 
or with a negative control guinea pig serum for 1 hr at room temperature. After washing, 
sections were incubated with a horseradish peroxidase (HRP) labeled rabbit-anti-guinea pig 
Ig (DAKO, Glostrup, Denmark) for 1 hr at room temperature. HRP activity was revealed by 
incubating the sections in 3-amino-9-ethylcarbazole (Sigma Chemical Co.) solution for 10 
min, resulting in a red precipitate. Sections were counterstained with hematoxylin. Formalin-
fixed, paraffin-embedded tMK cells infected with hMPV were included as a positive control. 
Tissue sections of a clinically healthy juvenile male cynomolgus macaque that had not been 
infected with hMPV were used as a negative control. Selected lung sections were stained 
with monoclonal antibody AE1/AE3 (Neomarkers, Fremont, California) for the identification 
of epithelial cells according to standard immunohistochemical procedures. 
 
RT-PCR 
Tissue samples of brain, heart, kidney, lung (cranial and caudal lobes), liver, nasal septum, 
primary bronchus, spleen, tonsil, trachea, and tracheo-bronchial lymph node were weighed 
and homogenised in minimal essential medium (10 ml per g tissue) by use of Potter tissue 
grinders. The homogenates were incubated with lysis buffer (2 ml per ml homogenate) 
containing proteinase K for 1 hr at room temperature, and RNA was isolated by use of a 
High Pure RNA Isolating Kit (Roche Diagnostics, Almere, The Netherlands) according to 
the manufacturer’s instructions, resulting in 50 µl RNA. RNA was isolated from 200 µl of 
transport medium from the pharyngeal swabs according to the same method. A Taqman real-
time PCR developed in-house158 was performed in triplo on 5 µl of isolated RNA from each 
sample, using serial dilutions of a titrated stock of the same virus as the calibration curve. 
The virus titer was expressed as TCID50 per mg tissue or ml transport medium from 
pharyngeal swabs. 
 
Virus isolation 
Virus isolation on pharyngeal swabs was performed on Vero cells, clone 118, in the absence 
of fetal calf serum in the presence of 0,02% trypsin and 0,3 % bovine albumin Fraction V 
(Invitrogen, Groningen, The Netherlands). The Vero-118 cell line, developed in house, has 
equal susceptibility and sensitivity to all known genetic lineages of hMPV. The Vero-118 
cells had been grown in Iscove’s Modified Dulbecco’s medium  (Biowhittaker, Verviers, 
Belgium) supplemented with 10% fetal calf serum (Biowhittaker) and 2 mM glutamine 
(Biowhittaker). The identity of the virus was confirmed by RT-PCR and automatic 
sequencing258. 
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Immune fluorescence assay 
96-Well plates coated with Vero-118 cells and infected with hMPV NL/1/00 were incubated 
with serial dilutions (up to 1:64) of plasma samples for 1 hr at 37°C. After washing with 
PBS, plates were incubated with fluorescein isothiocyanate-labelled anti-human IgG 
(DAKO, 1:60) for 1 hr at 37°C. After washing with PBS and background staining with 
eriochrome black (Sigma Chemical Co.) for 1 min, plates were read under an ultraviolet 
microscope. Non-infected Vero-118 cells were used as a negative control. Titers were 
expressed as the reciprocal of the last positive dilution. 
 
 
Results 
Clinical findings 
Rhinorrhea was seen in macaque #4 and #5 at 8 dpi. No clinical signs, including increased 
body temperatures in macaques #5 and #6, were seen in the other macaques. 
 
Gross pathology 
Inspissated purulent exudate was present in the nasal cavity of macaques #2 and #4. In the 
former, the lining mucosa was reddened. Macaque #4 had aspirated food remains 
immediately prior to euthanasia and was excluded from further laboratory examination 
because histological lesions of hMPV infection were masked and aspirated debris reacted 
non-specifically by immunohistochemistry. No other gross lesions were seen in these two 
macaques or in the other macaques. 
Figure 1→:  
Histopathology of experimental human metapneumovirus infection in cynomolgus macaques. A: 
Section of respiratory mucosa from nasal septum of negative control macaque. The pseudostratified 
epithelium consists of ciliated cells with cilia on apical surface, goblet cells with clear cytoplasm, and 
basal cells lying on the basement membrane. (H&E. Original magnification X100) B: Section of 
respiratory mucosa from nasal septum of macaque # 1. Suppurative rhinitis. There is loss of cilia, 
intercellular edema, architectural disruption, erosion, and infiltration with many neutrophils in the 
epithelium and submucosa. (H&E. Original magnification X100) C: Section of tracheal mucosa of 
negative control macaque. The pseudostratified epithelium has the same constituent cells as in panel 
A. (H&E. Original magnification X250) D: Tracheal section of macaque #1. Suppurative tracheitis. 
There is multifocal loss of cilia, intercellular edema, architectural disruption, and infiltration with a 
few neutrophils in the epithelium and submucosa. (H&E. Original magnification X250) E: Pulmonary 
section of macaque #3. Bronchiolitis. The bronchiolar lumen (arrowhead) is partly filled with 
macrophages. An increased number of macrophages also is present in alveolar lumina (arrowheads) 
adjacent to the bronchiole. (H&E. Original magnification X25) F: Pulmonary section of macaque #3. 
Erosive bronchiolitis. There is loss of bronchiolar epithelium, and the bronchiolar lumen is filled with 
macrophages. (H&E. Original magnification X100) G: Pulmonary section of macaque #3. Erosive 
bronchiolitis. Detail of panel F. Cuboidal cells (arrowheads) line the bronchiolar wall. The 
bronchiolar wall in between the arrowheads is denuded. (H&E. Original magnification X250). 
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Histopathology 
Macaques #1 to 3 had a mild rhinitis, characterised in the epithelium by loss of ciliation,  
architectural disruption, intra- and intercellular edema, and transmigration of a few 
neutrophils (Figure 1B). There was edema and infiltration with a few neutrophils in the 
underlying submucosa. All three macaques had minimal multifocal lesions in the conducting 
airways, variable in extension from larynx to bronchioles (Table 1; Figure 1, D to F). 
Epithelial lesions consisted of loss of ciliation, architectural disruption, erosion, intercellular 
edema, and transmigration of neutrophils. There was infiltration with a few neutrophils in the 
underlying submucosa. The lumen of some bronchi contained a few sloughed ciliated 
epithelial cells admixed with scant cellular debris and mucus. The lumen of some 
bronchioles contained a few alveolar macrophages, rare multinucleated giant cells and 
neutrophils, admixed with scant cellular debris and fibrin. Similar material was present in the 
alveoli around affected bronchioles. No significant histological changes were seen in 
sections of other tissues examined. Above lesions were not seen in the tissues of the negative 
control macaque.
Figure 2→: 
Immunohistochemistry of experimental human metapneumovirus (hMPV) infection in cynomolgus 
macaques. A: Section of respiratory mucosa from nasal septum of macaque #2. Expression of hMPV 
occurs in the cytoplasm of degenerate epithelial cells and in cell debris. (Immunoperoxidase stain for 
hMPV. Original magnification X100) B: Bronchial section of macaque #1. Expression of hMPV 
occurs in the cytoplasm of morphologically normal ciliated epithelial cells. (Immunoperoxidase stain 
for hMPV. Original magnification X100) C: Bronchial section of macaque #1. Detail of panel B. 
Expression of hMPV is most pronounced in the cilia and apical plasma membrane of ciliated 
epithelial cells. Mucus cells and basal cells stain negative. (Immunoperoxidase stain for hMPV. 
Original magnification X250) D, E: Pulmonary section of macaque #1. Expression of hMPV occurs 
diffusely in the cytoplasm of type 1 pneumocytes lining the alveolar walls. (Immunoperoxidase stain 
for hMPV. Original magnification X250) F: Pulmonary section of macaque #1. Expression of hMPV 
occurs in the cytoplasm of alveolar macrophages and in intraluminal cell debris. Staining of alveolar 
macrophages is multifocal and granular. (Immunoperoxidase stain for hMPV. Original magnification 
X250) 
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Immunohistochemistry 
Expression of hMPV occurred mainly in ciliated respiratory epithelium from the nasal cavity 
to the bronchioles in both macaques euthanised at 5 dpi, but not in the macaque euthanised at 
9 dpi (Table 1; Figure 2, A to C). It occurred multifocally in individual or groups of adjacent 
ciliated epithelial cells, and was seen both in morphologically normal (Figure 2B) and in 
degenerate or sloughed ciliated cells (Figure 2A). Expression of hMPV was visible as dark 
red staining of the cilia and apical plasma membrane, and diffuse lighter red staining of the 
cytoplasm. Neither goblet cells nor basal cells stained positively, even where they were 
located immediately adjacent to positively staining ciliated cells.  
Expression of hMPV occurred occasionally in alveoli of all three macaques (Figure 2, D to 
F). It occurred multifocally in type 1 pneumocytes, individual or small clusters of adjacent 
alveolar macrophages, and in intraluminal cellular debris. Expression in type 1 pneumocytes 
was visible as diffuse cytoplasmic staining (Figure 2, D and E). These cells were identified 
as type 1 pneumocytes because they lined the alveolar walls, were squamous, and expressed 
keratin in serial sections. In alveolar macrophages, it consisted of multiple distinct dark red 
granules in the cytoplasm (Figure 2F). Multinucleated giant cells did not stain positively. No 
positive staining was observed in any of the other tissues examined, nor in tissues of the 
negative control macaque. 
 
RT-PCR and virus isolation 
After an incubation period of 2 days at most, excretion of hMPV increased rapidly to a peak 
of 1.3 x 106 TCID50/ml at 4 dpi, and then decreased gradually to 0 by 10 dpi (Figure 3). The 
results of RT-PCR were confirmed by virus isolation: hMPV was re-isolated from 
pharyngeal swabs collected at the peak of virus excretion of all six macaques. 
At necropsy, hMPV was detected by RT-PCR throughout the respiratory tract, from the nasal 
cavity to the lungs, and virus titers were generally higher at 5 dpi than at 9 dpi (Table 1). The 
virus titers (mean ± standard deviation TCID50 per mg tissue) in the tonsil (26 ± 6.4 in 
macaque #1, 14 ± 3.2 in macaque #2, and 0 in macaque #3) and tracheo-bronchial lymph 
node (192 ± 42 in macaque #1, 2.1 ± 0.7 in macaque #2, and 3.2 ± 2.5 in macaque #3) 
corresponded to this temporal pattern. Human metapneumovirus was not detected by RT-
PCR in brain, heart, kidney, liver, or spleen of any of the macaques. 
Table 1:  
Microscopic lesions and presence of hMPV antigen in various tissues of the respiratory tract of 
cynomolgus macaques experimentally infected with hMPV.  
*:positive; †:mean ± standard deviation TCID50/mg tissue; -‡ negative; dpi: days post infection;  
HI: histology; IHC: immunohistochemistry; PCR: RT-PCR
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Immune fluorescence assay 
Before inoculation, anti-hMPV antibodies were not detected in plasma samples of any of the 
six macaques. At 14 dpi, both macaques #5 and #6 had seroconverted with an anti-hMPV 
antibody titer of > 64. 
 
 
Discussion 
 
This experimental infection confirms that hMPV is a primary pathogen of the upper and 
lower respiratory tract in cynomolgus macaques. Clinical signs in hMPV-infected macaques 
were limited to rhinorrhea, and corresponded with a suppurative rhinitis at pathologic 
examination. Additional histological lesions in the respiratory tract were minimal to mild 
erosive and inflammatory changes in mucosa and submucosa of conducting airways, and an 
increased number of alveolar macrophages in bronchioles and pulmonary alveoli. The close 
association between the respiratory lesions and the specific expression of hMPV antigen by 
immunohistochemistry, together with the absence of these lesions in the negative control 
tissues, support our conclusion that hMPV infection was the cause of these lesions. 
Based on expression of hMPV by immunohistochemistry, viral replication in ciliated 
epithelial cells was widespread throughout the respiratory tract and more sporadic in type 1 
pneumocytes. Viral antigen also was detected in alveolar macrophages, but the distinct 
granular character of cytoplasmic staining suggests phagocytosis of viral material rather than 
viral replication. The strong reduction in the distribution of hMPV-infected cells in the 
respiratory tract between 5 and 9 dpi (Table 1) corresponds with the reduction in viral 
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Figure 3: 
Pharyngeal excretion of human metapneumovirus by experimentally infected macaques. The 
numbers in the bars indicate the number of macaques sampled on each day. 
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excretion, as measured by RT-PCR, from the peak at 4 dpi to zero by 10 dpi (Figure 3).  The 
absence of hMPV expression by immunohistochemistry in other tissues indicates that hMPV 
replication is restricted to the respiratory tract. The above conclusions were corroborated by 
the results of virus isolation and RT-PCR. These findings substantiate the claim of van den 
Hoogen et al. that hMPV infection causes respiratory tract illness in human beings.1 The 
subclinical or mild character of the disease associated with hMPV infection in these 
macaques corresponds to that in immunocompetent middle-age adults255. Based on the ability 
of hMPV to replicate in the bronchioles and alveoli of cynomolgus macaques, one may 
expect more extensive viral replication and an associated increased severity of lesions in the 
lower respiratory tract of immunocompromised human beings, resulting in the severe 
bronchiolitis and pneumonia diagnosed clinically in such patients30,191.The predominant 
tropism of hMPV for ciliated epithelial cells in the conducting airways and the mildness of 
the associated lesions, as seen in this study, contrasts with the predilection of SCV for 
alveolar epithelial cells and the severity of the associated pneumonia in SARS 
patients89,138,181,189 and experimentally infected macaques86,139. These differences confirm that 
SCV and not hMPV is the primary aetiologic agent of SARS. 
The pathogenesis of hMPV infection in macaques is similar in many ways to that of RSV in 
human beings, as far as it has been studied. As in hMPV, incubation period and excretion 
period are short, although RSV excretion may be prolonged in infants and 
immunocompromised individuals58. Both initial infection and subsequent shedding of RSV 
are restricted to ciliated epithelial cells, based on an in vitro study using recombinant RSV 
expressing green fluorescent protein285. Similar to the localisation of RSV in that study, the 
results of immunohistochemistry in these macaques show that hMPV infection is polarised to 
the apical surface of ciliated respiratory epithelium. In immunocompetent individuals, the 
most common clinical manifestation of RSV infection is mild upper respiratory tract 
disease275. However, viral distribution and associated lesions of this mild disease have not 
been reported. In very young or immunocompromised individuals, RSV replication occurs in 
epithelial cells of bronchus, bronchiole, and in alveolar macrophages180,230, and is associated 
with severe bronchiolitis, interstitial pneumonia, or giant cell pneumonia166. Although 
clinical studies indicate that hMPV infection may cause similar lesions in this category of 
patients, confirmation of fatal bronchiolitis or pneumonia from hMPV infection awaits 
pathologic assessment of biopsy or autopsy samples18. The pathogenesis of hMPV infection 
also is similar to that of APV, its closest known relative259. As for hMPV infection in 
cynomolgus macaques, APV infection in turkeys has a short incubation and excretion period 
(2 and 8 days, respectively), occurs primarily in ciliated respiratory epithelial cells, and is 
associated with superficial erosive and inflammatory changes. In contrast to hMPV infection, 
APV antigen is not present in alveolar macrophages or alveolar walls. However, this 
difference may be explained, at least in part, by the intratracheal application of hMPV in 
macaques (this study) compared to the conjunctival and intranasal application of APV in 
experimentally infected turkeys122. The results of this study provide the first characterisation 
of the viral excretion, viral distribution and associated lesions of hMPV infection in 
cynomolgus macaques, and help to understand the pathology of this infection in human 
beings. The immunohistochemical method described above may be useful for retrospective 
analysis of respiratory tissues of human patients with respiratory disease of unknown viral 
origin, and to study the possible role of hMPV as a co-pathogen in patients with SARs. 
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       Prevalence and clinical symptoms of hMPV-infection 
  
Abstract 
 
During a 17-month period, we performed retrospective analyses of the prevalence of and 
clinical symptoms associated with human metapneumovirus (hMPV) infection, among 
patients in a university hospital in The Netherlands. All available nasal-aspirate, throat swab, 
sputum and bronchoalveolar-lavage samples (N = 1515) were tested for hMPV RNA by 
reverse-transcriptase polymerase chain reaction. HMPV RNA was detected in 7% of samples 
from patients with respiratory tract illnesses (RTIs) and was the second- most-detected viral 
pathogen in these patients during the last 2 winter seasons. hMPV was detected primarily in 
very young children and immunocompromised individuals. In young children, clinical 
symptoms associated with hMPV infection were similar to those associated with human 
respiratory syncytial virus (hRSV) infection, but dyspnea, feeding difficulties and hypoxemia 
were reported more frequently in hRSV-infected children. Treatment with antibiotics and 
corticosteroids was reported more frequently in hMPV-infected children. From these data, 
we conclude that hMPV is an important pathogen associated with RTI.  
 
  
Introduction 
 
Acute respiratory tract illnesses (RTIs) are the most common diseases experienced by people 
of all ages worldwide171. In young children, human respiratory syncytial virus (hRSV) is the 
most common cause of RTI98,133,171. Recently, a previously unknown pneumovirus was 
isolated from nasopharyngeal-aspirate samples obtained from children with RTIs in The 
Netherlands256. Those preliminary data indicated that the clinical symptoms of the children 
were similar to those of patients with RTI caused by hRSV ranging from mild respiratory 
problems to severe cough, bronchiolitis and pneumonia, often accompanied by high fever, 
myalgia and vomiting. Some of these patients were hospitalised and required mechanical 
ventilation. On the basis of the organisation of the viral genome and sequence identity to the 
Metapneumovirus avian pneumovirus, also known as turkey rhinotracheitis virus63,224, the 
virus was named human metapneumovirus (hMPV)256,259. As a result the Pneumovirus and 
Metapneumovirus genera within the subfamily Pneumovirinae (family Paramyxoviridae) 
now contain the human pathogens hRSV and hMPV, respectively. Serological surveys have 
indicated that the prevalence of hMPV in the Dutch population is high, because virtually all 
children tested were seropositive before the age of 6 years256. Recently, hMPV was also 
detected in children, adults, elderly individuals, and immunocompromised individuals with 
RTI, in Australia, North America, the United Kingdom, and Finland18,120,182,191,192,239, 
indicating that it is a common and ubiquitous human pathogen.  
In the present study, all respiratory samples obtained from patients in the university hospital 
in Rotterdam over a period of 17 months, were tested for the presence of hMPV RNA by 
reverse transcriptase polymerase chain reaction (RT-PCR). We compared the clinical 
symptoms of hMPV-infected patients with those of patients infected with other respiratory 
viruses. Our data indicate that, the prevalence and clinical severity of hMPV infections in an 
academic hospital setting are slightly lower than those of hRSV infections. Nevertheless, we 
conclude that hMPV is an important cause of RTI, primarily in infants and 
immunocompromised individuals, during the winter months. 
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Subjects, Materials and Methods 
 
Data collection  
Between 28 September 2000 and 16 February 2002, 645 throat-swab, 844 nasopharyngeal-
aspirate, 18 sputum and 297 bronchoalveolar-lavage samples were obtained at the different 
wards of the university hospital in Rotterdam and were sent to the diagnostic virology 
laboratory. For 1515 of these samples (573 throat-swab, 661 nasopharyngeal-aspirate, 12 
sputum, and 269 bronchoalveolar-lavage samples), sufficient material was available for 
hMPV testing. Of these samples, 45% were sent specifically for testing for respiratory 
viruses, including influenza A and B viruses, hRSV, human parainfluenza virus (PIV) types 
1-4, adenovirus, and rhinovirus. Routine virological testing for respiratory pathogens was 
performed using a combination of direct immunofluorescence (DIF) on cells present in the 
respiratory specimen, virus isolation in cell cultures, and immunofluorescence (IF). Cell lines 
used for virus isolation included human embryonal kidney cells, tertiairy monkey kidney 
cells, Madine Darby canine kidney cells, Vero cells, and Hep-2 cells. After diagnosis of 
enterovirus infection by virus isolation, IF, and/or DIF, a PCR was performed with 
rhinovirus-specific primers194. Of the throat-swab samples, 622 were obtained from 
transplant recipients and were submitted for testing for herpes simplex virus (HSV) types 1 
and 2, cytomegalovirus and Epstein-Barr virus and were used here as controls. Throat-swab 
samples were collected in virus transport media85, and other samples were stored without 
virus transport media. All samples were kept at 4ºC during processing, and subsequently 
stored for prolonged periods at -70ºC. 
 
Detection of hMPV RNA by RT-PCR 
RNA was isolated from 40-200 µl sample by use of a high pure RNA isolation kit (Roche 
Diagnostics), according to the manufacturer’s instructions. RT-PCRs  were performed by use 
of a 1-tube reaction with primers L6 (5' CAT GCC CAC TAT AAA AGG TCA G 3') and L7 
(5' CAC CCC AGT CTT TCT TGA AA 3'), amplifying a conserved fragment of 170 nt in 
the polymerase gene. This RT-PCR was optimised with respect to enzymes, buffer 
components and cycling parameters and was found to be 10-100-fold more sensitive than 
inoculation of tertiary monkey kidney cells with titrated virus stocks (data not shown). 
Moreover, the assay can detect the genetically diverse hMPV isolates described elsewhere256. 
The L gene was chosen as target for RT-PCR because of nucleotide-sequence conservation, 
thereby reducing the chance of missing genetic lineages of hMPV that have not been 
detected previously. PCRs were performed in a volume of 50-µl volume containing 50 
mmol/L Tris Cl (pH 8.5), 50 mmol/L NaCl, 4.5 mmol/L MgCl2, 0.2 µmol/L each primer, 0.6 
mmol/L each dNTP, 20 U RNAsin, 10 U avian myeloblastosis virus RT, and 5 U of Taq 
DNA polymerase (all enzymes from Promega). Thermocycling was performed in an MJ 
PTC-200 apparatus (MJ Research) with the following cycling parameters: 45 min at 42ºC 
and 5 min at 95ºC once; 1 min at 95ºC, 2 min at 45ºC and 3 min at 72ºC repeated 40 times; 
10 min at 72ºC once; and storage at 4ºC.  PCR products were analysed by dot-blot 
hybridisation, as described elsewhere85, by use of a biotinylated oligonucleotide (5' CTG 
TTA ATA TCC CAC ACC AGT GGC ATG C 3') 
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Clinical evaluation and statistical analysis 
The medical files of hMPV-infected children were scored by pediatricians, as described 
elsewhere136. In brief, scoring lists included demographical data (sex, age, number of 
children and parents in the family, gestational age, weight at birth, breast-feeding, and 
underlying disease of the patient or in the family, etc), clinical symptoms  (cough, rhinitis, 
body temperature, dyspnea, wheezing, feeding difficulties, retractions, respiratory rate, pulse, 
and cyanosis), laboratory testing (oxygen saturation, pCO2, hemoglobin, hematocrit, platelet 
counts, levels of C-reactive protein, and chest X-ray results), and intervention and follow-up 
(artificial respiration, administration of oxygen, use of  bronchodilators, and administration 
of antibiotics and corticosteroids). The medical files for 25 hRSV-infected children were 
scored for comparison. For each hMPV-infected child, an hRSV-infected child of the same 
sex who was hospitalised during the same time period (2-3 weeks range) and was closest in 
age to the hMPV-infected child was selected. Demographic and clinical variables were 
calculated for the hMPV and the hRSV groups, respectively, and were expressed as point 
estimates using percentages for dichotomous variables or means with 95% confidence 
interval (CI) for continuous variables, by use of SPSS for Windows (version 9.0; SPSS). For 
each variable, the difference between both point estimates with 95% CIs (hMPV vs. hRSV) 
was calculated by use of the software program Confidence Interval Analysis (version 1.0; 
BMJ Publishing Group)4. If the CI of the difference did not include zero, the corresponding 
point estimates were regarded as significantly different. C
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Figure 1: 
A. Age distribution of patients infected with human metapneumovirus (hMPV) (top) or human 
respiratory syncytial virus (hRSV) (bottom). B. Age distribution of hMPV-infected (black bars) and 
hRSV-infected (white bars) children<2 years old. The proportion of children in each age group was 
calculated relative to the no. of children <2 years old. 
  
  
Results 
 
Prevalence of hMPV 
Fifty-two samples obtained from 46 patients (28 males and 18 females) tested positive for 
hMPV by RT-PCR. For 44 of these 46 hMPV-positive patients, the samples had been 
obtained specifically because of respiratory symptoms, including fever, cough, rhinorrhoea, 
dyspnea, tachypnea, rhinitis, bronchitis, bronchiolitis, and pneumonia (see below). The 
throat-swab samples obtained from the 2 other patients were sent for HSV testing, but these 
patients may also have experienced a mild or subclinical RTI. Of the 46 hMPV-infected 
individuals, 37 were hospitalised in the wards of the children’s hospital, 4 were hospitalised 
in the nursing rooms of the cancer center, and 5 were hospitalised in other departments of 
Erasmus Medical Center (including the departments of neurology, hematology and internal 
medicine). The age distribution of the patients with RTI who tested positive for hMPV is 
depicted in Figure 1.  
Most of the hMPV-positive patients were children <2 years old who did not have illnesses 
other than RTI. Of the hMPV-positive patients who were >5 years old, most had other 
diseases (e.g. cystic fibrosis, leukemia, and non-Hodgkin lymphoma) or had recently 
received bone-marrow or kidney transplantation. These latter hMPV infections may 
therefore, have been associated with host immunosuppression. Although the overall age 
distribution of hMPV-positive patients was found to be fairly similar to that of hRSV-
positive patients in this same cohort (Figure 1A), hMPV was found significantly less 
frequently in children <2 months old than was hRSV. Of the 31 hMPV-positive children <2 
years old, only 4 (13%) were <2 months old, whereas 43 (35%) of the 122 hRSV-positive 
children <2 years old were also <2 months old (rate difference: -22.3%, 95%CI: -36.9% to -
7.8%). We obtained, from 4 hMPV-infected patients, >1 sample that tested positive for 
hMPV RNA. Three of these patients were 2-, 11-, and 16-month-old children, and virus was 
detected in nasal-aspirate samples obtained from them 6, 3 and 6 days apart, respectively. 
The fourth patient was a 36-year-old bone marrow-transplant recipient who was recovering 
from a varizella-zoster pneumonia and subsequent infection with influenza B virus infection; 
4 of this patient’s respiratory-tract specimens obtained during a 19-day period, tested positive 
for hMPV. 
 
Figure 2: 
Detection of human 
metapneumovirus 
(hMPV) (top) and 
human respiratory 
syncytial virus (hRSV) 
(bottom) per month, 
between September 
2000 and March 2002. 
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hMPV was detected predominantly in samples obtained during the winter months (Figure 2). 
The seasonal distribution of hMPV-positive samples was found to be largely similar to that 
of hRSV-positive samples, with the peak of virus detection in December and January, in both 
the 2000-2001 and 2001-2002 winter seasons. hMPV might be slightly less seasonal than 
hRSV, since the number of hRSV diagnoses in these 2 seasons was higher than the number 
of hMPV diagnoses. 
To compare the effect of hMPV to that of other respiratory viral pathogens more 
quantitatively, we compared the diagnostic outcome for 685 specimens sent to the diagnostic 
virology laboratory specifically for respiratory pathogen testing and for which sufficient 
material was available to complete all tests. The routine testing for respiratory pathogens in 
our diagnostic virology laboratory included influenza virus types A and B, hRSV, PIV types 
1-4, rhinovirus, and adenovirus. hRSV was detected most frequently, in 126 (18 %) of 685 
samples obtained from patients with RTI, and hMPV was the second-most-detected viral 
pathogen, in 48 (7%) samples  (Figure 3).  
 
 
Thus, from patients with RTI, hMPV was isolated more frequently than the PIV (9, 2, 7 and 
0 samples were positive for PIV types 1-4, respectively), adenovirus (8 samples), rhinovirus 
(28 samples), and influenza viruses types A and B (11 and 7 samples, respectively). It is 
important to note that the sensitivities of detection methods for the range of viral pathogens 
may be different, making it difficult to compare the contribution of each viral pathogen to the 
RTI quantitatively. It should also be noted that the influenza virus epidemics in these seasons 
were milder than those in previous years.  From 6 of the hMPV-positive samples, we isolated 
another respiratory virus: hRSV was isolated from 3 samples, and rhinovirus, influenza A 
virus, or adenovirus each was isolated from 1 sample. hMPV RNA was detected in only 2 of 
622 samples obtained from patients who did not have RTI, suggesting that subclinical hMPV 
infection is rare in hospitalised patients.  
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Figure 3:
Comparison of the frequency of 
detection of human metapneumovirus 
(hMPV) with those of other respiratory 
pathogens, in 685 samples obtained from 
patients with respiratory tract illness. 
Adeno, adenovirus; Entero, enterovirus; 
Flu, influenza virus; PIV, parainfluenza 
virus; Rhino, rhinovirus; RSV; 
respiratory syncytial virus. 
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76.0%
64.0%
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39.2 (15.7 to 62.7)
64.0%
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31.3%
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8.0%
64.0%
24.0%
12.0%
4.0%
6.2 (4.6 to 7.7) 
Characteristics   
  
Demographics   
  Sex , % male
  Age, months
  Patient with asthma   
  Asthma in family   
Clinical symptoms and    
laboratory tests   
  Cough   
  Rhinitis   
  Fever   
  Dyspnea   
  Wheezing   
  Feeding difficulties   
  Retractions   
  Hyperventilation   
  T achycardia
  Cyanosis   
  Hypoxemia  
  Hypercapnia
  Decreased Hemoglobin   
  Decreased Hematocrit   
  Trombocytosis   
  Illness scorec
  C - reactive protein    
  Chest x - ray performed   
    Atelectasis   
    Hyperinflation   
    Infiltrate  
    Bronchial thickening   
  Intervention and follow - up   
  Artificial respiration   
  Oxygen administration   
  Bronchodilators   
  Antibiotics   
  Corticosteroids   
  Time in hospital, days  d   
No.of   
patients  
  
25   
25   
25   
9   
  
            
25   
25   
18   
25   
25   
25   
25   
19   
17   
25   
19   
14   
22   
21   
21   
25   
18   
25   
15   
15   
15   
15   
  
       25   
25   
25   
25   
25   
15   
No. of        
patients
25
25
25
20
25
25
23
25
25
25
25
24
23
25
22
17
23
21
19
25
20
25
16
16
16
16
25
25
25
25
25
19
95% CI   
of difference b   
- 19.1 to 35.1   
- 4.8 to 12.4   
1.6 to 30.4   
- 0.1 to 73.4   
- 28.3  to 20.3   
- 15.6  to 31.6   
- 17.1  to 43.7   
- 72.3  to  – 23.7   
- 32.8  to 16.8   
- 65.2  to  – 14.8   
- 30.9  to 22.9   
- 24.9  to 34.1   
- 57.3  to 0.1   
- 30.9  to 7.0   
- 62.1  to  – 6.8   
- 33.2  to 3 6.6   
- 12.6  to 32.0   
- 12.0  to 40.5   
- 46.4  to 2.3   
- 0.20  to  – 0.03   
- 41.8  to 35.3   
- 30.9  to 22.9   
- 10.1  to 52.6   
- 44.5  to 23.6   
- 30.9  to 35.0   
- 28.7  to 3.7   
- 12.6  to 20.6   
- 54.6  to  – 1.4   
- 13.2  to 37.2   
25.0 - 71.0   
- 1.5  to 33.5   
- 1.9  to 2.8   
hMPV  RSV  
Table 1: Data from medical files of patients infected with human metapneumovirus (hMPV) and 
human respiratory syncytial virus (hRSV) 
       Prevalence and clinical symptoms of hMPV-infection 
  
Clinical symptoms 
We next examined the medical files of hMPV-infected children. Because the underlying 
disease for most hMPV-infected adults could have obscured the hMPV-related RTI, we 
limited these analyses to otherwise healthy children. Medical files were available for 25 of 
these children, and the medical files for 25 selected hRSV-infected children were used as 
controls. Demographic data were similar for the hMPV- and the hRSV-infected groups 
(Table 1). There were slightly more boys than girls in both groups. Although not statistically 
significant, the mean age was slightly higher in the hMPV-infected group than in the hRSV-
infected group. Virtually all the children in both groups who had siblings were the youngest 
children in the family, and the household compositions (numbers of children and adults) 
were similar. The pre- and perinatal data for the 2 groups (e.g. gestational age, birth weight  
and breast-feeding status) were also not significantly different. In contrast, history of asthma 
was more often associated with hMPV than with hRSV infection: 16% of the hMPV-infected 
patients had asthma and 67% of them had a family member with asthma, whereas none of the 
RSV-infected patients had asthma and only 30% of them had a family member with 
asthma.The clinical symptoms observed for the hMPV-infected children included cough 
(72%), rhinitis (80%), fever (61%), dyspnea (28%), wheezing (24%), feeding difficulties 
(36%), retractions (60%), hyperventilation (42%), tachycardia (23%) and cyanosis (8%). 
Most of these symptoms were observed with similar frequency in the group of hRSV-
infected children.  
Footnotes to table 1: 
The groups of hMPV- and hRSV-infected children both included 25 patients, but, because some of 
the files were incomplete, the no. of patients used for comparison may be lower. The following 
dichotomous variables were calculated from continuous variables by use of reference tresholds 
derived from healthy children: fever (body temperature >38.5°C), hyperventilation (respiratory rate 
>60 or >40 breaths/min for children <1 or >1 year old, respectively), tachycardia (pulse >175, 
>177, >163 and >143 for children 0-3, 3-6, 6-12 and >12 months old, respectively), hypoxemia 
(oxygen saturation <95%), hypercapnia (pCO2 >5.6 kPa), decreased hemoglobin (<8.1 or <6.6 
mmol/L for children <1 or >1 month old, respectively), decreased hematocrit (<0.42 or <0.33 L/L 
for children <1 or >1 month old, respectively), and trombocytosis (>390 x 109 or >473 x 109 
platelets/L for children <1 or >1 month old, respectively). CI, confidence interval. 
a .Point estimates are given as percentages, for dichotomous variables, or as mean  (95% CI), for 
continuous variables. 
b .If the 95% CI did not include 0, the corresponding point estimates were considered to be 
statistically significant and appear in boldface 
c .Each of the 15 clinical symptoms above was scored (1 and 0 for presence and absence, 
respectively), and the sum was divided by the no. of recorded symptoms. Thus, the illness score 
could range from 0.00 (no symptoms present) to 1.00 (all symptoms present). 
d .Three cases of hMPV infection were excluded from this comparison because of additional 
morbidity unrelated to the hMPV infection. 
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However, dyspnea, feeding difficulties (primarily, decreased intake of food), and hypoxemia  
were reported significantly more frequently in hRSV-infected children than in hMPV-
infected children. Platelet counts, relative white blood cell counts, and levels of C-reactive 
protein were similar for both groups. For 62% of the children, an X-ray of the lungs revealed 
atelectasis, hyperinflation, and infiltrates as the most common abnormalities, in both groups 
of patients. 
In agreement with the finding of a high number of hRSV- infected patients with hypoxemia, 
oxygen was administered to significantly more hRSV-infected patients than hMPV-infected 
patients (64% vs. 36%). In contrast, hMPV-infected patients were treated more often with 
bronchodilators (36% vs. 24%), antibiotics (60% vs. 12%, statistically significant), and 
corticosteroids (20% vs. 4%) than were hRSV-infected patients (Table 1). The mean duration 
of hospital stay was similar for both patient groups  (6-7 days). It should be noted that, for 
this latter analysis, 3 hMPV-infected children were excluded because of additional morbidity 
that was presumably unrelated to the hMPV infection, such as subsequent infection with 
other pathogens. 
  
 
Discussion 
 
Since the discovery of hMPV several studies have provided important information on hMPV 
epidemiology, clinical symptoms associated with hMPV infection, and the patient groups 
that are at risk for hMPV infection18,120,182,191,192,239,256. From these studies, it is now 
becoming increasingly clear that hMPV is an important human pathogen associated with RTI 
in young children, immunocompromised individuals, elderly individuals, and, to a lesser 
extent, other populations. In the present study, we analysed the relative contribution of 
hMPV to RTI, in a university hospital setting, and compared the clinical signs with those 
caused by infection with the related pathogen, hRSV. 
In the 2000-2001 and 2001-2002 winter seasons in The Netherlands, hMPV and hRSV were 
both found primarily in December and January; they were rarely detected in the summer 
months. It should be noted that, during these years, hMPV infections were temporally 
distributed somewhat more equally than were hRSV infections. The populations of patients 
most affected by the two viruses- children, immunocompromised individuals, and elderly 
individuals- were also quite similar, as was the overall age distribution of the infected 
patients. However, it is interesting to note that hRSV was detected more frequently in very 
young children than was hMPV; 35% of hRSV-infected children <2 years old were also <2 
months old, compared with only 13% of the hMPV-infected children <2 years old. Whether 
this observed difference is a true reflection of the differences in biological properties of the 
respective viruses requires further confirmation. During the 2 winter seasons under study, the 
2 genetic lineages of hMPV that were identified previously256were cocirculating in The 
Netherlands (data not shown), as has been described recently for other countries18,192,239. 
Differences in the pathogenicity of viruses belonging to the hRSV subgroups A and B have 
been described by some research teams but not by others 106,116,164,246,263. Unfortunately, at 
present, our dataset is too limited at present to compare the relative prevalence and 
pathogenicity of the distinct lineages of hMPV in a similar fashion. 
Comparison of the medical files of hMPV-infected children with those of hRSV- infected 
children revealed that the clinical symptoms associated with these viruses were quite similar. 
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Dyspnea, feeding difficulties, and hypoxemia were recorded more frequently in hRSV-
infected children than in hMPV-infected children, but all other recorded symptoms were 
found at the same frequency in both groups. For each of the children in both groups, we 
calculated an illness score, defined as the number of clinical symptoms the children had, 
divided by the total number of symptoms that were recorded for each child (Table 1). This 
analysis revealed that the hMPV-infected children had, on average, 38% of the recorded 
symptoms, whereas hRSV-infected children had 50% of the symptoms (statistically 
significant), suggesting that hRSV may be slightly more pathogenic than hMPV. The higher 
proportion of children <2 months old in the hRSV group did not have a serious effect on this 
observation; reanalysis of the data, excluding children <2 months old, still resulted in a 
statistically significant difference for the illness scores.  
It is important to note that subclinical hMPV infections appear to be rare; we detected hMPV 
RNA in only 2 of 622 samples obtained from patients who did not have RTI. This finding, as 
well as the observation that hMPV may cause mild RTI in experimentally infected 
macaques256, is indicative for hMPV being a causative agens of RTI. In agreement with these 
observations, we did not detect any other pathogens in the majority of patients with hMPV-
related RTI. Three hMPV-infected patients were also positive for hRSV, and 3 were positive 
for either influenza A virus, adenovirus or rhinovirus. On the basis of the similar seasonal 
distribution of hMPV and hRSV infections (Figure 2), dual infection with these 2 viruses is 
not unlikely.  
The statistical significance of the difference between the proportion of children with asthma 
in the hMPV group and that of children with asthma in the hRSV group requires 
confirmation in larger scale studies in the future. Numerous studies have provided evidence 
for a link between hRSV in early childhood and subsequent manifestations of asthma232,238, 
although this issue is still being studied137. The link between hMPV infection and asthma 
appears to be different from that suggested for hRSV infection. It will be of interest to further 
elucidate the underlying mechanisms for the possible association between asthma and either 
hRSV or hMPV infection, in future studies. 
It was not surprising that antibiotics and corticosteroids were administrated to hMPV-
infected children more often than to hRSV-infected children. Because hRSV diagnostics 
were performed in real time, physicians were able to choose not to give antibiotics and 
corticosteroids after a positive hRSV diagnosis. However, because, at the time of 
hospitalisation, no aetiologic agent had been identified in children with RTI associated with 
hMPV infection, physicians continued treatment with antibiotics and corticosteroids, to 
control potentially unidentified bacterial infections. This indicates that the inclusion of 
hMPV in diagnostic testing of patients with RTI may reduce unnecessary use of antibiotics 
and corticosteroids. Moreover, hMPV diagnostic testing may reduce virus transmission 
between children in hospital wards, through isolation or alternative measures currently used 
to limit the spread of hRSV. For a virus that is not easily detected by virus isolation in the 
laboratory, it will be of great importance that rapid, sensitive, and reproducible diagnostic 
tests be developed. Our RT-PCR procedure, which is based on the amplification of a 
conserved sequence in the polymerase gene, proved to be more sensitive than virus isolation 
and can detect genetically distinct hMPV strains. However, RT-PCRs based on the N gene 
may take advantage of the transcriptional gradient used by paramyxoviruses and, therefore, 
may be even more sensitive. In addition, monoclonal antibodies recognising conserved 
hMPV epitopes will be useful for rapid virus diagnostics by use of IF or DIF techniques 
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currently used for diagnosing infections with other virus pathogens, including hRSV. It will 
be important to conduct a wide range of prospective and retrospective studies to obtain a 
better estimate of the incidence, prevalence, and clinical effect of hMPV in different 
populations, the full spectrum of hMPV diseases, and risk factors that may be associated 
with severe hMPV disease. 
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                                                                                                HMPV and wheezing in children 
   
Abstract 
 
A new respiratory virus, human metapneumovirus, was recently identified. We detected this 
virus by PCR in ten (8%) of 132 consecutive children admitted to Turku Hospital, Finland, 
for acute expiratory wheezing (median age 7 months, range 4–25). The mean duration of 
hospital stay was 2.5 days (SD 1.6) and mean duration of respiratory symptoms was 19 days 
(8). The white blood cell count, C-reactive protein, and regulated upon activation, normal T-
cell-expressed and T-cell-secreted (RANTES) concentrations in nasal secretion remained 
low, whereas interleukin 8 concentrations in nasal secretion were high. Human 
metapneumovirus is a clinically important causative agent of acute wheezing in young 
children.  
 
 
Report 
 
Investigators from The Netherlands256 and North America192 have identified an earlier 
unknown virus from the Paramyxoviridae family, human metapneumovirus. Identification of 
this virus was based on virological data, sequence homology, and gene constellation. 
Clinically and cytopathologically, infection with human metapneumovirus resembles that of 
respiratory syncytial virus, ranging from mild upper respiratory tract disease to severe 
bronchiolitis and pneumonia in children. Results of a serological survey256 showed that 
human metapneumovirus usually infects young children; all 80 children in the survey in The 
Netherlands at the age of 5 years were seropositive for the virus. We investigated the 
frequency of human metapneumovirus in children admitted to the paediatric department of 
Turku University Hospital, Finland for acute expiratory airway obstruction.  
Between Sept 1, 2000, and May 31, 2001, 132 consecutive children participated in the 
continuing    study of the efficacy of systemic glucocorticoids in acute expiratory wheezing 
in the Department of Paediatrics, Turku University Hospital, Finland. We included children 
if they were aged 3 months to 16 years, had been admitted for acute expiratory wheezing, 
and if their parents had provided written informed consent. Children were excluded if they 
had a chronic disease other than asthma or allergy, had taken systemic glucocorticoids 4 
weeks or less before the start of the study, or had severe wheezing and treatment in an 
intensive care unit. The median age of the children was 2.0 years (range 4.0 months to 13.5 
years). 25 children were diagnosed with bronchiolitis, 59 with wheezy bronchitis, and 48 
with acute asthma. The study protocol was approved by the ethics committee of Turku 
University Central Hospital. 
 
On admission, we obtained nasopharyngeal aspirates and assessed them for presence of 
human metapneumovirus with a reverse transcriptase PCR assay using primers in the L gene 
that detect both genotypes of the virus256. The primers were tested for specificity against 
members of the respective paramyxovirus genera and the assay detected 0.01 tissue culture 
infective dose 50/mL virus. We cultured the aspirates and assessed the presence of antigens 
of influenza A, influenza B, adenovirus, respiratory synctial virus, and parainfluenza types 1, 
2, and 3, and did PCR for coronavirus, rhinovirus, and enterovirus160. Primer sequences and 
experimental methods are available from the authors. Symptoms were recorded by the 
parents using a home diary for 2 weeks after discharge. 
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We identified a potential causative viral agent in 116 (88%) of the 132 children; 31 (27%) 
had rhinovirus, 26 (22%) had enterovirus, 19 (16%) had non-typable picornavirus, 16 (14%) 
had respiratory syncytial virus, and ten (9%) had human metapneumovirus. Seven of these 
ten children had human mettapneumovirus alone; the other three children also had other 
respiratory viruses. Human metapneumovirus was detected in children only from from 
January to April 2001. The median age of the children with human metapneumovirus was 7 
months (range 4–25). Five children had bronchiolitis, four wheezy bronchitis, and one newly 
detected asthma. No child had previously used glucocorticoids.  
On admission, in children with human metapneumovirus, cough had lasted for a mean of 9 
days (SD 10), rhinitis for 4 days (5), expiratory wheezing for 3 days (2), and fever for 3 days 
(2). Two of the seven children with human metapneumovirus alone were diagnosed with 
acute otitis media. The mean axillary temperature was 37.8°C (1.0) and the mean oxygen 
saturation was 96% (2). Children had a mean of 9.5×109 white blood cells/L (3.0×109) and a 
mean serum C-reactive protein concentration of 9 mg/L (11). The mean interleukin 8 
concentration in nasopharyngeal aspirates obtained from six children was 480 ng/L (360) and 
the mean concentration of regulated by activation, normal T-cell expressed and secreted 
(RANTES) was 50 ng/L (31). All patients were given nebulised salbutamol. The patients 
were randomly allocated to receive 2 mg/kg oral prednisolone per day for 3 days or placebo. 
The study code has not yet been opened. The mean duration of hospital stay was 69 h (45). 
After hospital stay, the cough had lasted for a mean of 7 days (4), dyspnea for 6 days (5), and 
low fever for 0.4 days (0.9). One of the seven patients was readmitted to hospital within 2 
weeks because of recurrent breathing difficulties.  
 
In our study, the clinical diagnosis and age of the patients was closely similar to those seen in 
studies of infection with respiratory syncytial virus218,256. However, human metapneumovirus 
arose at a different time from respiratory syncytial virus infections. Human 
metapneumovirus was identified from the middle of winter to spring––a time when a limited 
spring epidemic of respiratory syncytial virus had just started in Finland. From January to 
April, 2001, we identified human metapneumovirus in ten (32%) of the 31 children with 
wheezing. 
The chemokine profile of interleukin 8 (mainly a chemotactic factor for neutrophils) and 
RANTES (chemotactic factor for eosinophils) in nasal secretions was different to that 
reported in infections with respiratory syncytial virus219. Patients with respiratory syncytial 
virus had high concentrations of RANTES and varying concentrations of interleukin 8219, 
whereas in our study, children with human metapneumovirus had low concentrations of 
RANTES and high concentrations of interleukin 8. The cytokine concentrations and blood 
samples were not confounded by use of prednisolone because the samples were taken before 
treatment. Clinically, the efficacy of systemic glucocorticoids in bronchiolitis remains 
unknown.  
 
Our results suggest that human metapneumovirus is a causative agent of acute wheezing in 
young children. During the study period, this virus was identified in childen at a time when 
other common causative agents, rhinovirus and respiratory syncytial virus, were not 
epidemic. Although the white blood cell counts and concentrations of C-reactive protein 
remained low, as usually found in viral infection218, the inflammatory response to human 
metapneumovirus was different from that seen in respiratory syncytial virus infection. 
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                                                                  HMPV in an immunocompromised patient 
   
Abstract 
 
Respiratory viruses are increasingly recognised as a cause of pneumonitis following 
haematopoietic stem cell transplantation (HSCT). However, frequently, no pathogen is 
identified in cases of suspected viral pneumonia. Recently, a previously undescribed 
paramyxovirus, designated 'human metapneumovirus' (hMPV), was isolated from children 
with respiratory illness. We have detected hMPV as the sole pathogen in the nasopharyngeal 
aspirate of an HSCT recipient who succumbed to progressive respiratory failure following an 
upper respiratory prodrome. This report highlights the importance of further studies to 
elucidate the role of hMPV in causing respiratory illnesses in the HSCT population. 
 
 
Introduction 
 
Interstitial pneumonia remains an important cause of mortality following haematopoietic 
stem cell transplantation (HSCT). With better understanding and management of 
cytomegalovirus infections, community respiratory viruses account for most of these cases. 
The most common viruses detected are human respiratory syncytial virus (RSV) and 
parainfluenza viruses. They account for about 30% of the acute respiratory illnesses post 
transplant and 50% of them progress to pneumonia with 30-100% mortality, depending on 
the clinical setting20,32,270. However, a significant minority of HSCT recipients present with a 
clinical condition indistinguishable from respiratory illness caused by respiratory viruses, 
which cannot be attributed to a known pathogen. We have an ongoing surveillance 
programme for post-transplant respiratory virus infection and no aetiologic agent is identified 
in 40% of upper respiratory illnesses and 30% of cases of suspected viral pneumonia32. 
Recently, a previously undescribed virus was isolated from children with RSV-like disease in 
The Netherlands256. This has been designated human metapneumovirus (hMPV) as it 
resembles avian pneumovirus (also known as turkey rhinotracheitis virus), in both gene order 
and sequence259. Preliminary data indicate that this newly described virus is found in about 
10% of childhood lower respiratory disease cases in which no other virus was identified. 
HMPV has now also been identified in respiratory samples from individuals aged 2 months 
to 87 years with acute respiratory tract illness in Canada192. Little is known about the 
significance of this newly described pathogen in immunocompromised patients. Recently, 
fatal pneumonia owing to hMPV was described in a child on treatment for acute 
lymphoblastic leukaemia (ALL)191. We describe the detection of hMPV for the first time in a 
fatal case of pneumonitis in an allogeneic HSCT patient and discuss the possible 
implications. 
 
 
Case report 
 
 A 33-year-old lady with ALL received a T-cell-depleted peripheral blood stem cell graft (6 
x106/kg of CD 34+ cells) in August 2000, from her HLA-matched sibling, following 
conditioning with cyclophosphamide and total body irradiation. Cyclosporine A alone was 
used as graft-versus-host disease (GVHD) prophylaxis. She had engraftment with donor cells 
by 14 days post transplant. She had a secondary graft failure 80 days after the transplant and 
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received a second transplant (2.6x106/kg of CD 34+ cells) conditioned with ATG. However, 
she remained pancytopenic 21 days following this and received a further dose of donor cells 
(5.6x106/kg of CD 34+ cells) after conditioning with fludarabine and melphalan.  Seven days 
after her third transplant she developed pyrexia with cough and coryzal symptoms with 
negative microbial culture from blood, sputum, stool, and urine. She was initially treated 
with broad-spectrum antibiotics. Amphotericin and clarithromycin were introduced 5 days 
later. The respiratory symptoms progressively worsened and the chest X-ray and CT scan 
showed both interstitial and alveolar opacities. A nasopharyngeal aspirate carried out at that 
stage (12 January 2001) was negative for RSV, influenza A and B, adenovirus and 
parainfluenza virus by direct immunoflorescence and culture. PCR assays for CMV were 
carried out on peripheral blood twice weekly and remained negative. She deteriorated 
progressively with worsening hypoxia and lung infiltrates coincident with recovery of the 
white cell count and was treated with a combination of imipenem, clarithromycin and 
ambisone. The patient refused any further intervention in the form of broncho-alveolar 
lavage (BAL) and ventilation. She succumbed to progressive respiratory failure on 17 
January 2001. The family did not consent to a post-mortem examination.  
 
Detection of hMPV 
The stored nasopharyngeal aspirate taken 5 days before the demise of the patient was 
retrospectively examined for hMPV using RT-PCR and sequencing of PCR product 
undertaken as previously described256,259. This was found to be positive for hMPV. 
Nucleotide sequence analysis of part of the fusion (F) gene of the virus from this patient 
showed that it was most closely related to the ned/00/01 strain previously described256,259. 
 
 
Discussion 
 
This patient presented with an upper respiratory prodrome and progressed to develop 
pneumonia and respiratory failure. Microbiological investigations for bacteria and viruses 
were consistently negative. Although the clinical features were compatible with a respiratory 
virus illness, the NPA sample was negative for the known viruses. Worsening of the 
respiratory illness in this patient was coincident with white cell recovery, compatible with 
the pattern noted with other respiratory viruses. The detection of this newly identified 
respiratory virus, hMPV, in this patient is significant in that light and in the given clinical 
situation, hMPV can be considered as a possible aetiology for the respiratory illness. 
Whether or not hMPV was the cause of the respiratory symptoms cannot be definitively 
determined without demonstrating viral replication in the lung tissue and it is possible that 
the virus was simply an innocent bystander or a copathogen. A recent report implicated this 
virus in the causation of recurrent lower respiratory tract infections in a child with ALL191. In 
this case, hMPV was identified retrospectively and it was not demonstrable in the BAL 
specimen. However, the demonstration of hMPV in the NPA samples from both episodes in 
the absence of other isolates suggests that hMPV was probably the pathogen responsible for 
the fatal pneumonia in this child. Although this child was on intensive treatment and 
immunosuppressed, the immunodeficiency in allograft recipients is more severe and global. 
The similarities between this case191 and our findings would warrant further investigation 
into the role of hMPV in respiratory illnesses following HSCT. 
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The implications of such a finding could be quite profound in the setting of HSCT. If hMPV 
is indeed a cause of lower respiratory infection in transplant recipients, further understanding 
of the epidemiology of this virus would be essential for the prevention of its spread within 
this vulnerable population, particularly within BMT units. Moreover, there might be a case 
for exploring the susceptibility of hMPV to antiviral agents such as ribavirin, both in vitro 
and in vivo. 
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Prevalence of hMPV infections 
 
After the discovery of hMPV as an aetiologic agent of respiratory tract illnesses (RTI)256 
several retrospective studies randomly surveyed specimens collected during the past 10 years 
from patients with RTIs of unknown aetiology18,182,192. HMPV was detected primarily in 
samples collected during the winter months. Samples were generally obtained from young 
children, but also from adults. Most of the hMPV-positive samples were obtained from 
children younger than 5 years of age with mild to severe RTI. Serological studies showed the 
presence of antibodies to the virus in virtually all children age 5 years or older, and the virus 
has been circulating at least 43 years in the human population256. Since the discovery of 
hMPV in The Netherlands, the virus has been detected worldwide.   
 
hMPV in hospitalised children 
Several studies have confirmed the original observation that children younger than 5 years of 
age are most susceptible to hMPV infection (Table 1). A recent study by Peiris, et al. 
evaluated the impact of hMPV infection in hospitalised children younger than 18 years with 
RTI within a 13-month period190. They demonstrated the presence of hMPV in 5.5% of the 
children. These hMPV-positive patients ranged from 3 months to 5 years of age, with a mean 
age of 32 months. Our study on samples collected during a 17-month period from 
hospitalised patients in all age categories demonstrated the presence of hMPV in 6.5% of the 
patients suffering from RTI258. Most of the hMPV infections were found in children younger 
than 5 years, with a peak in children between 4 and 6 months of age. As found by Peiris, et 
al., hMPV-infected patients proved to be slightly older than respiratory syncytial virus 
(RSV)-infected children: 35% of RSV-infected children <2 years of age were <2 months old, 
compared to only 13% of the hMPV-infected children <2 years of age190,258. Because these 
studies demonstrated that children <2 years of age are at the greatest risk, it is not surprising 
to find 17.5%260 or 25%159 of samples from hospitalised children younger than 2 years with 
RTI to be hMPV-positive (Table 1). If slightly older children are included, lower percentages 
of patients are hMPV-positive. Among hospitalised children younger than 3 years19,261 5.5% 
and 4.1% were hMPV-positive , and in two studies of children younger yhan 5 years of 
age75,90, 6.4% and 6.6% were positive. Again, however, most of the hMPV-positive patients 
in these studies were under the age of 2 years. 
 
The similar seasonality of several respiratory virus infections may result in frequent co-
infection of hMPV with other respiratory viruses such as RSV and influenza 
virus9,18,19,75,77,159,190,258,260. This might lead to underestimates of the percentage of hMPV-
positive samples identified in studies in which only samples negative for other respiratory 
viruses were tested75,90. The data thus far illustrate that hMPV accounts for roughly 5 to 7% 
of the RTI in hospitalised young children, with children <2 years of age being most at risk 
for serious hMPV infections (Figure 1). 
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hMPV in the elderly and immunocompromised individuals 
Like RSV and influenza virus infections hMPV infections also account for RTIs in the 
elderly population and in patients with underlying disease57,78,113. In our study most of the 
hMPV-positive patients between the ages of 5 and 65 years (n = 13) either had an underlying 
disease, such as cystic fibrosis, or received immunotherapy258. In other studies19,18,75 25 to 
50% of the hMPV- positive patients had an underlying disease. One study among the elderly 
indicated that hMPV caused more severe disease in frail elderly patients, such as nursing 
home residents, than in elderly or younger adults who are “fit”77. This same study included 
309 hospitalised elderly patients or patients with underlying disease; 6.5% of these patients 
were positive for hMPV. Although comprehensive surveys for hMPV infections among 
immunocompromised and elderly individuals have not yet been performed, these combined 
data indicate that hMPV infection, just like RSV and influenza virus infections119,234 may be 
responsible for mild to severe RTI in the elderly and immunocompromised (Figure 1). 
 
hMPV in the general community 
Although hMPV has also been detected among individuals suffering from respiratory 
illnesses in the community, the incidence varied by study group. In the UK, 1.3% of patients 
presenting to family physicians with influenza-like illnesses (ILI) were hMPV-positive239. 
This is likely an underestimate, because the study did not include all RTI but was limited to 
samples from ILI patients who were negative for other viruses. In studies in which all 
respiratory viruses were assayed in samples obtained from patients suffering from acute RTI 
(ARTI), samples from 3% of the patients tested positive19,273. In fact, in the study conducted 
in The Netherlands, fewer hMPV-positive samples were observed among patients with ILI 
than among patients with ARTI273. A study evaluating 167 adult volunteers younger than 40 
years of age during home visits for respiratory disease detected hMPV in 6.6% of the 
patients using a combination of reverse transcriptase (RT)-PCR and serological testing 
during a 2- to 4-month period77. Samples from 50% of the seroconverters were shown to be 
positive by RT-PCR. These serological tests also detected seroconversion during a 5- to 6-
month period in samples obtained from healthy adult volunteers in the community. When 
samples obtained from patients hospitalised for other diseases or from patients attending a 
physician for complaints other than RTI were tested, only two of 1282 samples were found 
positive for hMPV19,258,273, indicating that asymptomatic or subclinical infections are rare. 
The failure to detect hMPV in healthy individuals in combination with the described 
observations in patients suffering from RTI give strong indications for the causal relationship 
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Figure 1: 
Prevalence of hMPV in 
different populations. 
Percentages are probably 
underestimates, because of the 
choice of inclusion criteria and 
diagnostic tests (see text for 
details). 
  General discussion 
  
between hMPV infection and RTI, according to Koch's postulates, as modified by Rivers for 
viral diseases211: isolation of the virus from diseased hosts, cultivations of the virus in host 
cells, and seroconversion upon infections. Additional criteria, such as production of 
comparable disease in the original host species or a related one, re-isolation of the virus, and 
detection of a specific immune response to the virus, were obtained by studies in 
experimentally infected cynomolgus macaques (chapter 4). These macaques demonstrated 
viral shedding as measured by RT-PCR and virus culture, and seroconverted upon infection 
as measured by IFA and ELISA. The criterion to produce a comparable disease in the 
original host species or a related one has not been completely fulfilled. Pathologic 
examination of the respiratory tract of these infected monkeys revealed virus replication in 
epithelium cells in both the upper and lower respiratory tract, however these results cannot 
be compared with pathological examinations of respiratory tracts of hMPV infected humans, 
since these have not (yet) been conducted. In addition, the subclinical or mild character of 
the disease associated with hMPV infection in these macaques corresponds to that in 
immunocompetent middle-age adults, while hMPV causes primarily severe disease in young 
infants. Where the obtained results established hMPV as an aetiologic agent of RTI, 
additional experiments have to reveal whether cynomolgus macaques (or other animals) are 
suitable as animal model to mimic severe disease caused by hMPV in young infants. 
Studies for such animal models have been undertaken, and have demonstrated that Syrian 
golden hamsters, ferrets, and African Green Monkeys are suitable animals to study hMPV 
infections, candidate vaccines and intervention strategies (M. MacPhail, et al, submitted). 
 
Seasonality of hMPV infections 
Whereas some of the respiratory viruses, such as parainfluenza viruses and rhinoviruses, may 
circulate throughout the year, others, such as RSV and influenza viruses, circulate mainly 
during the winter season in temperate regions and in the late spring-summer season, also 
called the respiratory season, in the subtropical areas172. Most of the initial hMPV-positive 
samples18,182,192,256 were collected in the respiratory season. Studies focusing on specimens 
collected in this season, often within a 2-month period, found high percentages of hMPV-
positive specimens (Table 1). Year round surveillance studies159,190,258 confirmed that hMPV 
circulates primarily during the respiratory season in the temperate regions, peaking between 
December and February in the winters of 2000 and 2001 (Table 1). The virus was primarily 
found in the spring and summer months in Hong Kong, where RSV and sometimes influenza 
virus infections may have the same seasonality190. However, in the temperate regions, patient 
samples have tested positive for hMPV from October until May, with an occasional virus 
isolated in August19,258. In addition, as observed for RSV and influenza virus infections, the 
incidence of hMPV infections may vary by year or location. In a North American study 
among adults in the general community, hMPV was detected more frequently in 2001 than in 
2000 (7% vs. 1.5%)77. In an Italian study, hMPV was detected considerably less frequently in 
hospitalised children younger than 2 years of age with RTI in 2001 than in 2000 and 2002 
(7% vs. 37% and 43%)159. More comprehensive and long-term studies are needed to 
determine the seasonality of hMPV infections around the world.  
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A wide spectrum of clinical symptoms associated with hMPV infection has been reported in 
patients of all ages, ranging from mild upper RTI to severe disease requiring hospitalisation 
(Table 2). In the general community, hMPV-infected adults usually suffer from relatively 
mild common cold-like respiratory symptoms such as cough, rhinorrhea, hoarseness, sore 
throat and sometimes fever77,239,273. In hospitalised children, patients with underlying disease, 
immunocompromised individuals, and fragile elderly, hMPV disease tends to be more 
severe. A spectrum of symptoms involving both the lower and upper respiratory tract has 
been reported from this group of patients, including cough, rhinorrhea, wheeze and dyspnea. 
Resulting diagnoses may range from rhinopharyngitis to bronchitis and pneumonia, and 
some patients may be admitted to intensive care units. In addition, diarrhea, vomiting, rash, 
febrile seizures, feeding difficulties, conjunctivitis and otitis media have been 
reported18,19,75,190,258 (Table 2). The wide spectrum of hMPV-induced illnesses reported thus 
far are similar to those caused by RSV and influenza virus infections.  
 
Comparison of hMPV and RSV infections 
A number of studies have compared the clinical symptoms associated with hMPV infection 
in hospitalised patients with those associated with RSV and influenza virus 
infections19,75,182,190,192,258,260. Although hMPV infections tend to be slightly milder than RSV 
infections, in many studies a statistically significant difference was not observed. When we 
compared the clinical symptoms of 25 hMPV-infected children with age-matched RSV-
infected children, we could not discriminate between clinical symptoms caused by RSV or 
hMPV, although dyspnea, hypoxemia and feeding difficulties were found more often in 
RSV-infected individuals than in hMPV-infected patients258. In addition, hMPV patients had 
38% of all recorded symptoms compared to 50% for the RSV-infected children, indicating 
that hMPV infections are slightly milder than RSV infections. Two studies in hospitalised 
patients showed that hMPV patients did not need intensive care, in contrast to some of the 
RSV- and influenza infected patients. The study also showed that pneumonia was more often 
associated with RSV than with hMPV19,260. Another study comparing hMPV-infected 
children to age-matched RSV or influenza virus–infected children revealed that hMPV 
infection was more frequently associated with lower respiratory tract involvement, thus 
prompting more X-rays190. In agreement with this observation, hMPV infection was 
diagnosed more frequently in children with lower RTI than in children with upper RTI in two 
studies18,159.  
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Table 1: Detection of hMPV in studies conducted on samples obtained in different study groups 
and different seasons. 
Study1 study period Country2 Remark3 study 
group 
number hMPV 
positive 
Peak age peak period 
Hospital         
18 Dec 01- Apr 02 CAN b All ages; RTI 862 20 (2.3%) 35% <5 yr 
46% >65 yr 
Feb - 02 
190 Aug 01 - Mar 02 HK c <18 yr; ARTI 587 32 (5.5%) 3 - 72 mo Resp. Season 
258 Okt 00 - Mar 02 NL c all ages; RTI 681 47 (7%) 4 - 6 mo Dec - Jan 02 
260 Jan 02 - May 02 DEU d <2 yr; RTI 63 11 (17.5%)  Jan - Apr 02 
159 Jan 00 - May 02 ITA c* <2 years; 
ARTI 
  7.8 ± 5.5 mo   Jan - Jun 
 2000    19 7 (37%)   
 2001    41 3 ( 7 %)   
 2002    30 13 (43%)   
19 Dec 01- Apr 02 CAN e <3 yr; ARTI 208 12 (5.8%) 3 - 5 mo Mar - Apr 02 
    <3 yr; healthy 51 0   
261 Nov 00 - Feb 01 
Nov 01 - Feb 02 
SPA b <3 years; 
ARTI 
    
    neg for other 147 6 (4.1%) 7 - 20 mo ND 
    pos for other 100 0   
75 Nov 01- Feb 02 USA a <5 yr; RTI 296 19 (6.4%) 8.7 mo Jan - Feb 02 
90 Nov 01- Feb 02 FRA b children; RTI 337 26 (6.6%) 3 mo -12 yr Dec - Jan 02 
77 Nov 99 - Apr 00 
Nov 00 - Apr 01 
USA e fit elderly >65 
yr RTI 
233 4 (1.7%)  Feb 00 and 01 
 
    high risk 
adults 
RTI 
238 7 (2.9%)   
    healthy<40 
yrs 
RTI 
167 11 (6.6%)   
    nursing 
homes 
RTI 
37 2 (5.5%)   
    hospitalised 
RTI 
309 20 (6.5%)   
    asymptomatic 217 44 (4.5%)   
general 
community 
        
19 Jan 02 - Jun 02 CAN f RTI 1505 36 (2.9%) 67% <2yr Mar - May 02 
239 Okt 00 - Mar 01 UK e ILI 405 9 (1.3%) 0 >65 yr Dec - 00 
273 2001 NL c ARI/ILI 448 13 (2.9%) 4 - 74 yr ND 
    Healthy 397 0   
 
1.See references for study groups. 
2.CAN: Canada; HK: Hong Kong; NL: The Netherlands; DEU: Germany; ITA: Italy; SPA: Spain; 
USA: United States of America; FRA: France; UK: United Kingdom. 
3.a; samples negative for other viruses were tested, no documentation on other viruses in that period. 
b; samples negative for other viruses were tested, but other viruses are also documented. c; samples 
were tested for other viruses also (* but not differentiated in report). d; samples only tested for RSV 
and hMPV. e; samples tested for hMPV, RSV and influenza virus. f; no information. ND= not defined. 
Resp.season indicates winter season in modern climate zones and late spring to summer in the (sub) 
tropics. 
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                                             Studygroup1 
  
18 
n=6 
15-65 yr 
 
18 
n=12 
<5 yr 
 
18 
n=10 
>65 yr 
 
190 
n=32 
<18 yr 
 
258 
n=25 
8-22 mo 
 
19 
n=12 
<3 yr 
 
75  
n=19 
<5 yr 
 
90 
n=19  
children 
         
Cough 83 75 100 90 72 100 69 - 
Fever 83 92 80 100 61 67 63 16 
Rhinorrhea - - - - - 92 69 - 
Hypoxia - - - - 47 - 31 - 
Wheeze  50   24 83 50 - 
Dyspnoea 50 83 70 - 28 - - - 
Retractions - - - - 60 92 - - 
Diarrhea - - - 6 - 8 - 10 
Vomiting - - - - - 25 - - 
Hoarseness - - - 6 - - - - 
Truncal rash - - - 13 - - - - 
Sore throat 50 - - - - - - - 
Lacrymation - - - - - 25 - - 
Febrile seizures - - - 16 - - - - 
Feeding difficulties - - - - 36 - - - 
Hyperventilation - - - - 42 - - - 
Cyanosis - - - - 8 - - - 
Otitis media - 25 - - - 50 - 21 
Lymphopenia - - - 0 - - - - 
Rhinitis - - - - 80 - - - 
Rhinopharyngitis - - - - - - - 5 
Pharyngitis - - - - - 0 - - 
Laryngitis - - - - - - - 5 
Tachycardia - - - - 23 - - - 
Conjunctivitis - - - - - - - 5 
Asthma - - - 23 - - 11 21 
Pneumonititis 50 67 40 - - 17 - - 
Bronchiolitis - 58 60 10 - 67 47 62 
Bronchitis/ 
Bronchospasm 
- - 60 - - 0 - 5 
Influenza like illness 50 - - - - 0 - - 
Upper RTI - - - - - - 16 - 
Other - - - - - 8 21 - 
Pneumonia - - - 36 - -  - - 
 
Table 2: Clinical symptoms, signs and laboratory findings reported for hMPV infection in different 
studies. 
1. See references for study groups. 
Numbers are given as percentages of the study group.  
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hMPV infection in the elderly and immunocompromised individuals 
Although the data presented above may suggest that hMPV tends to cause slightly milder 
disease than RSV, the virus may cause severe problems in patients with underlying disease 
and in fragile elderly. In three patients with acute lymphoblastic leukemia who suffered from 
RTI and subsequently died (a 7-month old girl191, a 33-year-old woman30 and a child 
younger than 5 years18), hMPV was the sole pathogen detected. Although there was no 
pathological examination in these cases, no other pathogens were identified, suggesting that 
hMPV infection was the cause of death. In contrast, a 5-year-old child diagnosed with acute 
lymphoblastic leukemia and infected with hMPV recovered uneventfully190. Our study 
revealed that hMPV-positive patients above the age of 5 (n = 13) had underlying disease and 
thus presented with more severe clinical signs than generally observed in the younger 
population258. In a study among young and elderly adults, hMPV caused more severe disease 
in fragile elderly than in healthy elderly or young adults77. Whereas young children have 
been studied in detail, studies on elderly and immunocompromised individuals thus far have 
been relatively weak. However, they may reveal an impact for hMPV similar to those for 
RSV and influenza virus infections78. 
 
Association of hMPV with asthma 
The role of viral respiratory tract infections in acute and chronic asthma has been a subject of 
much debate and research. Viruses such as RSV and rhinoviruses in particular have been 
suggested as the principal trigger of asthma exacerbation in older children and adults38,188. 
Several studies indicated a possible association between hMPV infection and 
asthma60,75,90,190,258. In children with asthma, hMPV was found more frequently than RSV, 
and asthma exacerbation accounted for a larger proportion of wheezing in hMPV-infected 
children than in RSV-infected children190,258. A study of children hospitalised with acute 
expiratory wheezing demonstrated hMPV in 8% of the 132 children tested, suggesting that 
hMPV is a causative agent of acute wheezing in young children120. In contrast other studies 
have found asthma to be more frequently associated with rhinoviruses than with hMPV 206 
(T. Jarti, et al., personal communication). Studies aiming at the identification of an 
association between RSV and/or hMPV and asthma are problematic because asthma is a 
difficult clinical diagnosis in children younger than 2 years of age, the most susceptible 
population for both hMPV and RSV. Nevertheless, these preliminary results on the 
association between asthma and hMPV infections warrant further research. 
 
Co-infection of hMPV and other respiratory viruses 
Many respiratory viruses share seasonality and susceptible populations; therefore, it is not 
surprising that coinfections are detected at a rate of 1% to 3% in various sample sets. 
However, it is uncertain whether coinfections predispose for more severe disease 148. 
Greenshill, et al. reported a high frequency of coinfections by hMPV and RSV101; 90% of 
RSV-infected infants with severe bronchiolitis were coinfected with hMPV, suggesting that 
coinfection with hMPV and RSV may predispose for severe disease. In contrast other studies 
that reported coinfections of hMPV with RSV or influenza virus did not report more severe 
disease in those patients. Care should be taken with the diagnosis of coinfections. Sensitive 
RT-PCR assays may enable the detection of viral genomes during two consecutive 
infections, which may be mistaken for double infections. Based on the detection of hMPV in 
severe acute respiratory syndrome (SARS) patients in different parts of the world, hMPV has 
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also been suggested to play a role in SARS198. However, a novel coronavirus was isolated 
from far more SARS patients studied66,138 and was thus identified as the primary causative 
agent86,139,189. In addition studies in macaques have revealed that hMPV did not cause the 
lesions associated with SARS, whereas the SARS coronavirus did. This same study showed 
that in cynomolgus macaques, the disease caused by the SARS corona virus was not 
enhanced upon subsequent inoculation with hMPV86,139. Further research may identify a role 
of secondary pathogens in SARS patients. 
 
 
Classification of hMPV 
 
Based on gene constellation and sequence homology with avian pneumovirus (APV), hMPV 
has been tentatively classified as the first human virus within the genus Metapneumovirus, 
subfamily Pneumovirinae259. RSV is a member of the other genus in the subfamily 
Pneumovirinae, the Pneumovirus genus. The separation between the two genera is based 
primarily on the difference in gene constellation151,204,282. High amino acid sequence identity 
(56% to 87%) is shared between hMPV and APV in all but two genes (G and SH), and < 
50% identity is shared with RSV259. 
 
For APV two subgroups, circulating mainly in Europe, have been identified: APV A and B, 
based on sequence variation of the attachment protein G, and differences in antigenicity39,130. 
In 1999, a new type –APV C- has been identified in the United States based on genetic and 
antigenic differences51,222,248. For most of the genes (N, P, M, F, M2) and intergenic regions, 
hMPV shares the highest sequence homology with APV C, in fact for those genes and 
regions hMPV and APV C are genetically more closely related to each other than both of 
them to either APV A and B259.  
The glycoprotein G and the small hydrophobic (SH) protein of hMPV did not reveal 
sequence homologies with those of RSV and APV A and B, and some similarity to, but also 
extensive sequence divergence with APV C5,249,283. Since new APV types, such as type D, 
are being detected it might be possible that hMPV is even closer related to other, undetected, 
APV types. Despite the close genetic relationship between APV C and hMPV antigenic 
relationships have not yet been described. Our own observation revealed that hMPV 
antibodies could be detected with commercially available ELISAs for the detection of APV 
antibodies, and APV can be detected in immune fluorescence assays using polyclonal hMPV 
antibodies. However, virus neutralisation assays have to reveal the true antigenic relationship 
between APV and hMPV. The close relationship between hMPV and APV C led to the 
hypothesis that either of the two viruses can cross infect, i.e. that hMPV might infect turkeys 
and/or APV C infects humans. Preliminary studies in which juvenile turkeys, chickens and 
cynomolgus macaques were inoculated with hMPV resulted in virus replication in the 
monkeys but not in the chickens and turkeys. The high sequence differences between the 
attachment proteins of hMPV and APV may form the basis of differences in host restriction.  
Serological assays demonstrated that the virus circulated in the human population for at least 
45 years. In addition, after identification of hMPV, many diagnostic laboratories tested 
samples collected over the last decades that were suspected of an unknown respiratory virus, 
retrospectively and hMPV was detected in samples dating 25 years ago60. These results 
indicate that hMPV is not a newly emerging virus, but a newly detected virus. 
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Heterogeneity of hMPV 
 
When hMPV was first described as the causative agent of RTI in children, at least two 
genetic lineages of hMPV were identified256. Several groups have subsequently confirmed 
the presence of these lineages around the globe9,18,77,159,191,192,239,260. We recently showed that, 
based on phylogenetic analysis of sequences obtained for part of the fusion protein (n = 83) 
and the complete attachment protein (n = 32), each of these lineages can be divided in two 
sublineages (Figure 2)257. Where the fusion protein revealed approximately 95% amino acid 
sequence identity between viruses from the two lineages, the G protein shared only 30% 
identity. Sequences obtained for the complete genome of viruses from the two different 
lineages, revealed an overall 80-81% nucleotide sequence identity, with a 92-93% identity 
between strains belonging to the same main lineage. The G and SH proteins are the most 
divergent between the two main lineages, and the G protein is even more divergent than 
observed between human RSV A and B (unpublished data and15).  
 
 
 
C
hapter 9
117
Figure 2: 
Phylogenetic trees for the fusion (F) and attachment (G) genes of selected hMPV isolates. From each 
of the four genetic lineages (van den Hoogen, et al., 2004)257 four representative isolates were 
selected, and maximum likelihood trees were generated for the G gene (right) and 451 nucleotides in 
the F gene (left). Numbers in trees represent percentages amino acid identity between virus isolates. 
  
  
Virus neutralisation assays using lineage-specific ferret anti-sera in our study demonstrated a 
twelve- to a > 100-fold difference in virus neutralisation titers between viruses from the two 
main lineages. Classical virology studies have used a definition of a homologous-to-
heterologous virus neutralisation titer of more than 16 as a definition of serotypes.  On the 
basis of this definition, the antigenic differences and the high sequence divergence between 
the two main lineages, we defined two serotypes of hMPV. In accordance with both the RSV 
and APV nomenclature, we named these two main lineages serotype A and B, with each 
serotype divided into genetic sublineages 1 and 2257. In addition, virus neutralisation assays 
conducted with sera obtained 28 days post infection from Syrian golden hamsters 
demonstrated similar antigenic differences between viruses from the two main lineages 
(M.MacPhail, submitted). Although antigenic differences between sera collected from one 
animal species is sufficient for a technical description of serotypes, the relevance of these 
findings for infection of humans has still to be defined. 
The identification of two serotypes of hMPV has direct implications for the development of 
diagnostics assays (see below) and possibly also for the development of vaccines and other 
intervention strategies. 
 
 
Laboratory diagnosis of hMPV infections 
 
The identification of two serotypes of hMPV has implications for the development of both 
serological diagnostic tests and RT-PCR assays. Serological tests based on prototype viruses 
from one serotype were found to be less sensitive in detecting viruses belonging to the other 
serotype (Van den Hoogen, et al., unpublished data), indicating that mixtures of antigens 
should be used in developing diagnostic tests. For RT-PCR assays, it is important to design 
primers based on regions that are conserved between viruses of the various genetic lineages. 
 
Because hMPV was relatively difficult to isolate using standard procedures, hMPV has 
circulated unnoticed for some time. On the basis of antibody prevalence, it has circulated in 
the human population for at least 45 years and more likely longer. After the original isolation 
of hMPV on tMK cells, more cell lines have been explored for culturing hMPV and these 
days some laboratories use LLC-tMK2 or Vero cells successfully. Because virus isolation is 
time-consuming and sometimes difficult and serological tests have not yet been standardised, 
RT-PCR assays are usually the test of choice. 
 
Virus isolation 
Our own observations indicate that the different hMPV strains vary in growth kinetics and 
that cytopathic effects may be hard to observe. For instance, viruses closely genetically 
related to prototype strain NL/1/00 (serotype A) revealed cytopathic effects more clearly on 
tMK cells than viruses related to prototype strain NL/1/99 (serotype B). In search of a cell 
line similarly susceptible for both types, we generated a subclone of Vero cells. Vero cell 
clone 118 was permissive for infection with viruses from all four lineages, and cytopathic 
effects were easy to observe (Van den Hoogen, et al., unpublished data). This cell line is now 
used routinely for virus isolation in our laboratory, and similar subclones may be generated 
from other established cell lines to enhance detection of hMPV by virus isolation. 
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RT-PCR assays 
The design of RT-PCR assays for hMPV diagnostics should take in account the genetic 
variation between hMPV isolates. Thus far in conventional RT-PCR assays, only primers 
targeting the polymerase protein gene (L)256 and the fusion protein gene (F)191 have been 
demonstrated to detect viruses from both serotypes efficiently. Because conventional PCR is 
time consuming, real time PCR assays are preferable. The first reported primers and probes 
located in the nucleoprotein (N) or L genes54,154 for a LightCycler assay were developed 
based on sequences available for NL/1/00, the prototype virus for serotype A and similar 
viruses. Comparison of all nucleoprotein gene sequences available from Genbank and 
sequences obtained for 53 hMPV-positive specimens in our laboratory revealed that the N-
based primers154 probably have a lower sensitivity for serotype B viruses because of 
mismatches158. We were able to design primers and probes in the N gene for a real time PCR 
assay with a minimum number of mismatches for both serotypes. The newly designed assay 
was demonstrated to detect viruses belonging to the genetic sublineages described to date 
with equal specificity and sensitivity, and is now used in our laboratory for diagnosis of 
hMPV in samples from patients suffering from RTI158. Besides RT-PCR based diagnostics, 
isolation of hMPV from clinical specimens should be carried out since virus culture may 
allow the identification of hMPV lineages that have so far remained undetected. 
 
 
Development of antibody therapy and vaccination 
 
The clinical impact of hMPV has resulted in efforts to generate (live attenuated) hMPV 
vaccines as well as neutralising hMPV monoclonal antibodies by a number of research 
institutions worldwide. For the pneumoviruses, such as RSV, the F and G proteins are the 
main targets for the neutralising and protective antibody response, with F being one of the 
most conserved proteins and G the most variable6,123-125,184. For RSV, the immune response 
against the F protein is cross reactive between subgroup A and B, whereas the response 
against the G protein is subgroup specific6,125,184,240,242. Immunisation with individual F or G 
proteins in animals has shown that the F protein is broadly cross protective whereas the G 
protein provides a more group-specific protection (reviewed in 241). The circulation of two 
serotypes of hMPV has to be taken in account for the development of both therapeutics and 
vaccines as the effectiveness of the intervention may vary by serotype or genetic lineage. 
 
Antibody therapy 
For RSV the prophylactic use of a virus neutralising monoclonal antibody preparation 
directed against the F protein has been shown to decrease the severity of lower respiratory 
tract (LRT) diseases by both subgroups of the virus. In a similar way, the conserved F 
protein of hMPV could be a target for the development of monoclonal antibodies for 
treatment of hMPV-infected individuals. However, future experiments still have to elucidate 
the correlates of protection for hMPV. 
 
Vaccines 
Vaccine development for RSV has been the goal of multiple studies for the last 20 years. 
Several strategies have been used, although only inactivated, subunit and live attenuated 
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RSV vaccines have been evaluated in clinical trials to date68. The use of a formaline 
inactived RSV vaccine and the enhanced disease observed upon subsequent natural infection 
has been a major complication of RSV vaccine development, and has led to the exploration 
of different vaccine candidates134. Several candidate subunit vaccines based on the RSV-F 
and/or G proteins, the main targets for induction of neutralising antibodies, have been 
developed. These subunit products are not particularly immunogenic in young infants, 
however they are suitable for immunisation of previously infected patients who are at high-
risk of severe disease or the elderly (reviewed in 24,59).  
Several different strategies for the development of a live attenuated RSV vaccine were 
originally explored, including the creation of host range mutants, cold-passaged mutants, and 
temperature-sensitive mutants. Importantly, enhanced disease was not observed when infants 
who were immunised with these candidate vaccines were naturally infected with wild type 
RSV. To date, a second generation, genetically stable through multiple attenuating 
mutations, live attenuated RSV vaccine candidates are tested in clinical trials (reviewed 
in24,59,68). Recently, investigators have demonstrated the ability to recover infectious virus 
from cDNA clones of RSV44. These reverse genetics systems provide a powerful tool for the 
generation of vaccine candidates, including live-attenuated vaccines, because point-
mutations, deletions and insertions can be engineered to suit specific needs. The use of 
reverse genetics resulted in a variety of genetically designed RSV vaccine candidates that 
harbour mutations in essential RSV genes or deletions of nonessential RSV genes in an effort 
to attenuate virus replication without compromising immunogenicity47.  
 
hMPV vaccine development might encounter similar problems as RSV vaccine development 
(for instance enhanced disease upon wild type infection after inactivated virus vaccination). 
At present, live-attenuated virus vaccines receive the most attention, which can be achieved 
by the use of reverse genetics systems. Recently our laboratory has established a reverse 
genetics system for the rescue of both serotypes of hMPV (S.Herfst, submitted). With this 
establishment, recombinant hMPV strains can be constructed that harbour the surface 
glycoproteins of both serotype A and B isolates of hMPV, which may induce a broad 
antibody response in infected hosts. Using reverse genetics, one can also envisage creating 
chimeric viruses between hMPV and other human respiratory pathogens (RSV, PIV) to 
combat RTI in humans. Chimeric live-attenuated vaccines based on the hMPV genome, in 
which genes of RSV and or PIV are inserted, may be useful as multivalent vaccine 
candidates. Recently, a reciprocal vector in which an hMPV gene was inserted in a b/hPIV3 
vector has been described, and was found to induce protective antibody titers in a hamster 
model245. The rescue of RSV, PIV and RSV in reverse genetics systems allows the use of 
different backbones for creating chimeric viruses which might be advantageous for 
circumventing specific immune responses. 
Next to vaccine development, reverse genetics systems provide a powerful tool for studies of 
molecular biology, viral pathogenesis, and the host immune response. 
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Conclusion 
 
hMPV is a new member of the Metapneumovirus genus within the subfamily 
Pneumovirinae, family Paramyxoviridae. This proposed classification is based on a similar 
genomic constellation and sequences to APV, so far the sole member of the 
Metapneumovirus genus, which causes respiratory tract disease in chickens and turkeys. 
The failure to detect hMPV in healthy individuals in combination with the isolation of hMPV 
from patients suffering from RTI and the results obtained in experimentally infected 
macaques corroborates with the causal relationship between hMPV infection and RTI.  
hMPV accounts for a significant portion of RTI in hospitalised children, with high 
incidences during epidemics in the winter months in moderate climate zones and late spring-
early summer in the subtropics. Only RSV, and occasionally influenza virus, was detected 
more frequently in the studies that included surveys for other respiratory viruses. Very young 
children (< 2 years of age), people with underlying disease, the immunocompromised, and 
fragile elderly are most at risk from hMPV infections; thus the virus shares its susceptible 
population with RSV. Surveillance in the general community found approximately 3% of 
samples from individuals attending physicians for RTI positive for hMPV, and serological 
studies indicate that hMPV may cause a self-limiting “common cold” among adults. The 
spectrum of clinical symptoms observed in hMPV-infected individuals are comparable to 
those in RSV-infected individuals, ranging from common cold-like symptoms in the general 
community to severe pneumonia in hospitalised patients. So far, RSV and hMPV infections 
cannot be discriminated on the bases of clinical signs.  
At this moment, at least two circulating serotypes of hMPV have been identified, and this 
variability must be taken into account in the development of diagnostic tests and possibly in 
the development of intervention strategies and vaccines.  
 
Future perspectives 
  
It will be important to conduct a wide range of prospective and retrospective studies to obtain 
a better understanding of the clinical impact of hMPV infections in different populations, the 
full spectrum of hMPV associated diseases and risk factors that may be associated with 
severe hMPV disease. In addition, the preliminary results on the association between asthma 
and hMPV infections, the role of hMPV in SARS, and the possible consequences of co-
infection of hMPV and RSV (or other respiratory viruses) on the severity of disease warrant 
further research. To conduct these epidemiological studies it is important to develop 
diagnostic assays to detect both serotypes of hMPV with equal specificity and sensitivity. 
The implications and relevance of the identification of two serotypes of hMPV has to be 
further elucidated, with an emphasis on the impact on intervention strategies. The 
development of vaccines and therapeutics demands the use of well-defined animal models, 
for which only preliminary results are known to date. 
 
Within the genus Metapneumovirus, new viruses have been identified, such as APV C and D 
and both types of hMPV. It would be interesting to investigate the ancestral relationships of 
APV and hMPV and whether the two serotypes of hMPV are the result of independent 
introductions in the human population. It can not be ruled out that new viruses belonging to 
this genus will be identified in humans and animals. 
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Epidemiological studies for the detection of aetiologic agents of respiratory tract illnesses 
detect a causative agent in 50-85% of the specimens, primarily depending on the skills of the 
laboratory involved. Studies so far have shown that hMPV accounts for a high proportion of 
these unidentified samples. It is highly likely, that other agents are responsible for a 
proportion of the remaining unidentified samples. The detection of hMPV has shown that 
virus isolation on a broad range of cells (such as tertiary monkey kidney cells, not routinely 
used in most laboratories) and for a longer period than standard, allows the detection of 
viruses, which cannot easily be detected with techniques currently used in diagnostic 
laboratories. The combination of classical virological techniques and the use of state of the 
art techniques, such as molecular techniques, might identify new pathogens.  Molecular 
techniques may include the use of degenerate primer sets in PCR assays to identify new 
members of a known virus family, or for instance the random amplification PCR (RAP PCR) 
technique described in this thesis. Genomics tools (such as, the recently described DNA 
microarray-based platform for novel virus identification265) might identify virus specific 
proteins or genome sequences directly. Alternatively these tools may allow identification of 
specific host gene expression profiles associated with viral infection.
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 Summary 
 
 
Acute respiratory tract infections are responsible for considerable morbidity and mortality, 
and costs attributable to acute respiratory tract illnesses (RTI) are an important burden on 
national health care budgets. A variety of viruses, bacteria and fungi are associated with RTI. 
Chapter 1 provides background information on the most important viral causes of RTI in 
humans.  
We have isolated a previously undiscovered paramyxovirus from samples obtained from 
children with RTI (chapter 2). The newly discovered paramyxovirus was identified as a 
tentative new member of the Metapneumovirus genus within the subfamily Pneumovirinae 
based on virological data, sequence homology and gene constellation. Previously, avian 
pneumovirus was the sole member of this recently assigned genus, hence the provisional 
name for the newly discovered virus: human metapneumovirus (hMPV). The clinical 
symptoms of the children from whom the virus was isolated were similar to those caused by 
human RSV infection, ranging from mild upper RTI to severe bronchiolitis and pneumonia. 
Serological studies showed that by the age of five years, virtually all children in The 
Netherlands have been exposed to hMPV and that the virus has been circulating in humans 
for at least 45 years. Analysis of the complete genomic sequence of hMPV confirmed the 
classification of this new paramyxovirus in the genus Metapneumovirus of the subfamily 
Pneumovirinae (chapter 3). The overall percentage amino acid sequence identity between 
APV and hMPV ORFs was 56 to 88 %. Some nucleotide sequence identity was also found 
between the noncoding regions of the APV and hMPV genomes.  
In chapter 4, analyses of a large number of hMPV sequences obtained for the fusion and 
attachment glycoprotein genes, revealed the presence of two main genetic lineages (A and 
B), each consisting of two sublineages (A1, A2, B1, B2). Virus neutralisation assays with 
ferret sera raised against viruses from the four sublineages revealed a 12 to 128 fold higher 
homologous than heterologous virus neutralisation titer for viruses belonging to the two main 
lineages A and B.  We thus conclude that two hMPV serotypes, each of which can be divided 
in two genetic lineages, are circulating in humans around the world.  
The dynamics and associated lesions of hMPV infection were studied in experimentally 
infected cynomolgus macaques (chapter 5). Viral excretion in the nose of these macaques 
peaked at 4 days post infection and decreased to zero by 10 days post infection. Viral 
replication was restricted to the respiratory tract and associated with minimal to mild, 
multifocal erosive and inflammatory changes in conducting airways, and increased numbers 
of macrophages in alveoli. Viral expression was seen mainly at the apical surface of ciliated 
epithelial cells throughout the respiratory tract, and less frequently in type 1 pneumocytes 
and alveolar macrophages. The animals demonstrated a subclinical or mild disease 
associated with hMPV infection, which corresponds to that in immunocompetent middle-age 
adults. The obtained results, in combination with isolation of the virus from humans with 
RTI and not from healthy individuals, established hMPV as an aetiologic agent of RTI. 
After identification and molecular characterisation of the virus, we performed retrospective 
analyses of the prevalence of and clinical symptoms associated with hMPV infection among 
patients in a university hospital in The Netherlands, during a 17-month period (chapter 6). 
hMPV was detected in 7% of samples obtained from patients with RTI and in only 2 patients 
without RTI. hMPV was the second-most-detected viral pathogen in these patients during the 
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winter seasons of 2000 and 2001 and was detected primarily in very young children and in 
immunocompromised individuals. In young children, the clinical symptoms associated with 
hMPV infection were similar to those associated with RSV infection, perhaps slightly 
milder. Whereas hMPV-infections were most frequently detected in children between 4 and 
6 months of age, hRSV infections were detected most frequently in children below 2 months 
of age. A potential link between hMPV infection and exacerbation of asthma was also 
described in chapter 6.  In agreement with this, 8% of 132 Finish children admitted for acute 
expiratory wheezing were found to be positive for hMPV (chapter 7). In chapter 6, most of 
the hMPV-positive patients between the ages 5 and 65 years either had an underlying disease 
or received immunotherapy. The relevance of hMPV infection in immunocompromised 
individuals is illustrated by the study described in chapter 8. Here, hMPV was detected as 
the sole pathogen in a hematopoietic stem cell transplant recipient with a fatal respiratory 
illness.   
After the initial discovery of hMPV, several surveys on the burden of disease of hMPV 
infection have been conducted in various study groups and with different diagnostic assays. 
We reviewed these surveys to establish the burden of disease of hMPV infection in chapter 
9. We concluded that hMPV infections occur worldwide and account for at least 5 to 7% of 
the RTI in hospitalised children, but that immunocompromised and elderly individuals are 
also at risk. Surveillance studies in the general community revealed that approximately 3% 
of samples from individuals attending physicians for RTI were positive for hMPV, and 
serological studies indicate that hMPV may cause a self-limiting “common cold” among 
adults.  
 
Future perspectives 
It will be important to conduct a wide range of prospective and retrospective studies to obtain 
a better understanding of the clinical impact of hMPV infections in different populations, the 
full spectrum of hMPV diseases and risk factors that may be associated with severe hMPV 
disease. The implications and relevance of the identification of two serotypes of hMPV has 
to be further elucidated, with an emphasis on the impact on intervention strategies. The 
development of vaccines and therapeutics demands the use of well-defined animal models, 
for which only preliminary results are known to date.  
Epidemiological studies for the detection of aetiologic agents of RTI detect a causative agent 
in 50-85% of the specimens, and studies so far have shown that hMPV accounts for a high 
proportion of these unidentified samples. It is highly likely that other agents are responsible 
for a proportion of the remaining unidentified samples, which, with the aid of classical 
virological assays and state-of the art molecular techniques, can be identified in the future. 
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Nederlandse samenvatting 
 
Luchtweginfecties (LWI) zijn verantwoordelijk voor aanzienlijke ziekte- en sterftecijfers. Ze 
vormen een belangrijke uitgavenpost op het budget van het ministerie van VWS. LWI 
kunnen worden veroorzaakt door een groot aantal verschillende pathogenen, zoals virussen, 
bacteriën en schimmels. Hoofdstuk 1 geeft een overzicht van de belangrijkste virale 
luchtweginfecties bij de mens. 
Wij hebben een onbekend virus geïsoleerd uit monsters die werden verkregen van kinderen 
met LWI. Dit is beschreven in hoofdstuk 2. Met behulp van klassieke virologische 
experimenten hebben we aangetoond dat dit virus tot de familie der Paramyxoviridae 
behoort. De virusfamilie Paramyxoviridae is onderverdeeld in twee subfamilies, de 
Paramyxovirinae en de Pneumovirinae. Deze laatste subfamilie is vervolgens ingedeeld in 
twee genera, het genus Pneumovirus en het genus Metapneumovirus.  
Het respiratoir syncytieel virus (RSV), het prototype virus van het genus Pneumovirus, is 
over de hele wereld de belangrijkste veroorzaker van lagere LWI bij baby’s en peuters. Het 
aviaire pneumovirus (APV), veroorzaker van hogere LWI bij kalkoenen, was tot de 
ontdekking van het nieuwe virus het enige lid van het genus Metapneumovirus. Van het 
ontdekte paramyxovirus is op basis van virologische data en de organisatie van het virale 
genoom vastgesteld dat het een lid van het genus Metapneumovirus is. Daarom hebben wij 
het de naam ‘humaan metapneumovirus’ (hMPV) gegeven. Onderzoek naar de aanwezigheid 
van antistoffen tegen hMPV toonde aan dat kinderen vóór het bereiken van de 5-jarige 
leeftijd bijna allemaal in aanraking zijn geweest met hMPV, en dat het virus al minstens 45 
jaar onder mensen circuleert. 
De analyse van het complete genoom van hMPV is beschreven in hoofdstuk 3. De resultaten 
van deze analyse bevestigen de classificatie van het virus als een nieuw lid van het genus 
Metapneumovirus. De leesramen in de genomen van APV en hMPV waren 56 tot 88 % 
identiek. Ook in de niet-coderende delen van het genoom werden op nucleotideniveau grote 
overeenkomsten gevonden. 
Hoofdstuk 4 beschrijft de genetische verscheidenheid van hMPV aan de hand van analyses 
van sequenties van het fusie-eiwit en het aanhechtingseiwit van een groot aantal isolaten. De 
hMPV-isolaten werden ingedeeld in twee hoofdgroepen (A en B), waarna elke hoofdgroep 
verder werd verdeeld in twee subgroepen (A1, A2, B1 en B2). Alleen tussen virussen van de 
twee hoofdgroepen werden vervolgens grote antigene verschillen waargenomen. Op basis 
van de genetische verschillen en de verschillen in antigene reactiviteit hebben wij twee 
hMPV-serotypen gedefinieerd.  
De dynamiek en de gevolgen van een hMPV-infectie zijn bestudeerd in experimenteel 
geïnfecteerde Java-apen (hoofdstuk 5). Deze apen werden pathologisch en virologisch 
onderzocht. Dit onderzoek heeft aangetoond dat hMPV een respiratoir pathogeen is, dat de 
virusreplicatie van korte duur is, en dat deze voornamelijk plaatsvindt in trilhaar-
epitheelcellen. Het subklinische of milde ziektebeeld dat werd waargenomen bij deze apen is 
vergelijkbaar met het hMPV-gerelateerde ziektebeeld in immuuncompetente volwassenen 
van gemiddelde leeftijd. In combinatie met het feit dat het virus wel werd geïsoleerd bij 
mensen met LWI maar niet bij gezonde mensen, vormen de verkregen resultaten het bewijs 
dat hMPV een veroorzaker is van LWI.  
Na identificatie en moleculaire karakterisering van het virus, is onderzoek verricht naar de 
prevalentie en klinische symptomen die in verband worden gebracht met hMPV-infecties. 
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Dit staat beschreven in hoofdstuk 6. Voor dit onderzoek zijn monsters getest die zijn 
verzameld van ziekenhuispatiënten die werden opgenomen voor LWI maar ook voor andere 
klachten. In 7% van de monsters die werden afgenomen van patiënten met LWI werd hMPV 
aangetoond, terwijl maar 2 van de patiënten zonder LWI hMPV-positief waren. hMPV was 
het op één na vaakst waargenomen virale pathogeen gedurende de winterseizoenen van 2000 
en 2001. Het werd voornamelijk aangetroffen bij zeer jonge kinderen en individuen met een 
verzwakt immuunsysteem. De meeste hMPV-positieve patiënten tussen de 5 en 65 jaar 
hadden een onderliggende ziekte of werden met immuunsuppressieve middelen behandeld. 
Bij jonge kinderen met een hMPV-infectie waren de symptomen vergelijkbaar met die bij 
kinderen met een RSV-infectie, hoewel het ziektebeeld van een hMPV-infectie iets milder 
was. hMPV werd meestal waargenomen bij kinderen van 4 tot 6 maanden oud, terwijl RSV 
vooral werd waargenomen bij kinderen van 0 tot 2 maanden oud. 
Hoofdstuk 7 levert verdere aanwijzingen voor het een verband tussen hMPV-infectie en 
astma dat al werd beschreven in hoofdstuk 6. In dit Finse onderzoek was 8% van de 
monsters, afgenomen van 132 kinderen met astmaverschijnselen, hMPV-positief. De 
relevantie van hMPV-infecties in individuen met een verzwakt immuun systeem wordt ook 
aangetoond in een studie beschreven in hoofdstuk 8. In dit onderzoek bij een 
beenmergtransplantatiepatiënte met een ziekte van de hogere luchtwegen, met fatale afloop, 
werd hMPV als enig pathogeen waargenomen  
Na de ontdekking van hMPV hebben een groot aantal onderzoeksgroepen over de hele 
wereld onderzoek gestart naar het klinische belang van hMPV. Hoofdstuk 9 bevat een  van 
deze studies. Hieruit concluderen wij dat hMPV wereldwijd circuleert en minimaal 5 tot 7% 
van de acute LWI bij in het ziekenhuis opgenomen kinderen veroorzaakt. Tevens bleek dat 
individuen met een verzwakt immuunsysteem en ouderen ook tot de risicogroepen behoren. 
Van patiënten met LWI die hun huisarts bezochten bleek ongeveer 3% met hMPV 
geïnfecteerd te zijn. Serologische onderzoeken hebben aangetoond dat hMPV-infecties ook 
een gewone verkoudheid kunnen veroorzaken bij volwassenen, zonder dat deze medische 
zorg nodig hebben. 
 
 
Toekomstperspectief 
Het is wenselijk dat er uitgebreide prospectieve en retrospectieve onderzoeken naar hMPV-
infecties worden verricht. Hiermee kan het klinische belang van hMPV-infecties in 
verschillende populaties verder worden aangetoond. Tevens moeten alle ziekten en 
risicofactoren worden geïdentificeerd die in verband kunnen worden gebracht met ernstige 
hMPV-infecties. De implicaties en de relevantie van de identificatie van twee verschillende 
hMPV-serotypes zullen verder onderzocht moeten worden. Bij dit toekomstige onderzoek zal 
de nadruk moeten liggen op het belang voor interventiestrategieën. Voor het ontwikkelen van 
vaccins en therapeutische middelen zijn goed gedefinieerde proefdiermodellen nodig. 
Momenteel zijn hiervoor slechts beperkte resultaten beschikbaar. 
Met de identificatie van hMPV is het nu mogelijk om in monsters van patiënten met LWI, 
waarin voorheen geen pathogeen gedetecteerd kon worden,  een oorzaak voor de ziekte aan 
te wijzen. De verwachting is dat met een combinatie van klassiek virologische en moderne 
moleculaire technieken nog meer respiratoire pathogenen zullen worden gevonden, zodat in 
een groter percentage van de monsters van patiënten met LWI een oorzaak kan worden 
aangewezen. 
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